

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Cost-effectiveness of fecal calprotectin used in primary care in the diagnosis of inflammatory bowel disease

|                               |  |
|-------------------------------|--|
| Journal:                      | <i>BMJ Open</i>  |
| Manuscript ID                 | bmjopen-2018-027043  |
| Article Type:                 | Research   |
| Date Submitted by the Author: | 02-Oct-2018  |
| Complete List of Authors:     | Zhang, Wei; St. Paul's hospital, Centre for Health Evaluation & Outcome Sciences; University of British Columbia, School of Population and Public Health<br>Wong, Chiew; University of Sheffield<br>Chavannes, Mallory; University of British Columbia; University of Southern California<br>Mohammadi, Tima; Centre for Health Evaluation and Outcome Sciences<br>Rosenfeld, Greg; University of British Columbia, Department of Medicine, Division of Gastroenterology |
| Keywords:                     | Fecal calprotectin, Inflammatory bowel disease < GASTROENTEROLOGY, cost-effectiveness  |
|                               |  |

SCHOLARONE™  
Manuscripts

# Cost-effectiveness of fecal calprotectin used in primary care in the diagnosis of inflammatory bowel disease

Wei Zhang, PhD<sup>1,2</sup>; Chiew Hsia Wong, MSc<sup>3</sup>; Mallory Chavannes, MD<sup>4,5</sup>; Tima Mohammadi, MA, MSc<sup>2</sup>; Greg Rosenfeld, MD<sup>4</sup>

1. School of Population and Public Health, University of British Columbia
2. Centre for Health Evaluation and Outcome Sciences, St. Paul's Hospital
3. School of Health and Related Research, University of Sheffield
4. Department of Medicine, Division of Gastroenterology, University of British Columbia
5. Department of Pediatric, Division of Gastroenterology, Hepatology and Nutrition, Children Hospital of Los Angeles, University of Southern California.

## Correspondence:

**Wei Zhang**, PhD

Centre for Health Evaluation and Outcome Sciences, St. Paul's Hospital

588-1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6

Tel: +1-604-806-9343

Email: [wzhang@cheos.ubc.ca](mailto:wzhang@cheos.ubc.ca)

**Word count:** Abstract [274]; Manuscript [3706]

**Tables and figures:** Tables [2]; Figures [4]

**Keywords:** Fecal calprotectin; inflammatory bowel disease; cost-effectiveness

## ABSTRACT

**Objective:** Inflammatory bowel disease (IBD) is a chronic, autoimmune, gastrointestinal disorder. Canada has one of the highest prevalence and incidence rates of IBD in the world. Diagnosis is challenging due to the similarity of symptoms to functional gastrointestinal disorders. Fecal calprotectin (FC) is a biomarker for active mucosal inflammation and has proven effective in the diagnosis of IBD. Our study objective was to assess the cost-effectiveness of adding a FC test compared with standard practice (blood test) in primary care among adult patients presenting with gastrointestinal symptoms.

**Design:** We constructed a decision analytic tree with a one-year time horizon. The cut-off level of 100µg/g was used for FC testing. Probabilistic analyses were conducted for the base case and all scenarios.

**Setting:** Canadian health sector perspective.

**Population:** A hypothetical cohort of adult patients presenting with gastrointestinal symptoms in the primary care setting

**Interventions:** FC test compared with blood test

**Main outcome measures:** Costs, quality-adjusted life years (QALYs), incremental cost-effectiveness ratio (ICER) of FC test expressed as cost per QALY gained compared with blood test, and time to IBD diagnosis.

**Results:** FC testing costs more (\$295.1 vs. \$273.9) than standard practice but yielded little higher QALY (0.751 vs. 0.750). The ICER of FC test was \$20,323 per QALY. Probabilistic analysis demonstrated that at a willingness-to-pay threshold of \$50,000 per QALY, there was 81.3% probability of FC test being cost-effective. The use of FC test in primary care reduced the

1  
2  
3 time to IBD diagnosis by 40.0 days (95% Confidence Interval: 16.3-65.3 days), compared with  
4  
5 blood testing alone.  
6

7 **Conclusions:** Screening adult patients in primary care by FC test at the cut-off level of 100µg/g  
8  
9 is cost-effective in Canada.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## ARTICLE SUMMARY

### Strengths and limitations of this study

- This paper presents a cost-effectiveness analysis (CEA) comparing a fecal calprotectin test to blood test in diagnosis of inflammatory bowel disease (IBD) in the primary care setting.
- This was the first CEA of FC test in the Canadian context and one of few CEAs of FC test in the primary care setting in literature.
- We also compared the average time to IBD diagnosis between using FC test and blood test in primary care and estimated the reduced time to IBD diagnosis by using FC test.
- The analysis was from the Canadian health sector perspective and did not consider costs (e.g., productivity losses) from a societal perspective.

## INTRODUCTION

Inflammatory bowel disease (IBD), of which the two main subtypes are Crohn's Disease (CD) and ulcerative colitis (UC), is characterized by mucosal inflammation and ulceration of the gastrointestinal tract. During the course of the disease, patients often present with symptoms such as diarrhea, abdominal pain, and fatigue, which significantly impact the quality of life of IBD patients.<sup>1</sup> Canada has one of the highest reported prevalence and incidence rates of IBD in the world.<sup>2</sup> The prevalence of IBD in Canada was estimated at 0.67% [129,000 individuals with CD and 104,000 with UC] in 2012, with approximately 10,200 incidents occurring annually.<sup>3</sup> The corresponding economic costs of IBD were estimated at \$2.8 billion.<sup>3</sup>

In order to distinguish IBD from functional gut disorders that often share similar symptoms, the conventional diagnostic pathway in primary care includes initial blood tests, such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), which are used to determine whether patients should be referred to gastroenterologists for further investigation including imaging studies and/or endoscopy.<sup>4</sup> However, these blood tests lack accuracy. They may not only delay IBD diagnosis in the case of false negatives, but also lead to unnecessary endoscopies in the case of false positives.<sup>5,6</sup> Due to limited resources, endoscopy is not readily accessible in many areas of Canada and unnecessary endoscopies can have further impacts on health care resources and costs.

Recently, the detection of fecal calprotectin (FC), the most extensively studied fecal marker of IBD, has been shown to be an accurate and useful screening tool for identifying patients who need further investigation through endoscopy.<sup>5-8</sup> The majority of studies that assessed the

1  
2  
3 accuracy of FC testing to date have been in the secondary care setting.<sup>5-7</sup> A recent prospective  
4  
5 primary care cohort study conducted in the United Kingdom (UK) demonstrated that FC testing  
6  
7 using the cut-off of 100 µg/g accurately distinguishes IBD from functional gut disorder in  
8  
9 primary care and reduces secondary care referrals as well as diagnostic health care costs.<sup>9</sup> Waugh  
10  
11 *et al.* have also shown that FC testing is cost-effective for distinguishing between IBD and non-  
12  
13 IBD in adults in primary care in the UK.<sup>6,10</sup> The National Institute for Health and Care  
14  
15 Excellence (NICE) in the UK therefore recommends FC testing as an option to help clinicians  
16  
17 distinguish between IBD and non-IBD in adults with recent onset of gastrointestinal symptoms.<sup>10</sup>  
18  
19 In Canada, however, FC tests are currently only covered by provincial health plans in Alberta  
20  
21 and Quebec, as well as some extended health insurance plans.<sup>11</sup> There is still no cost-  
22  
23 effectiveness evidence within primary care in Canada. The objective of this study, therefore, is to  
24  
25 determine the cost-effectiveness of FC testing in the diagnosis of adult cases of IBD in primary  
26  
27 care from the Canadian health care sector perspective.  
28  
29  
30  
31  
32  
33  
34

## 35 MATERIALS AND METHODS

### 36 Decision model

37  
38 A decision analytic model was built to estimate the cost-effectiveness of using FC test as  
39  
40 compared to the current practice using blood test, in the screening for IBD in the primary care  
41  
42 setting. The patient population in the model was a hypothetical cohort of adult patients aged 19  
43  
44 to 64 years old, presenting with gastrointestinal symptoms suggestive of IBD in a primary care  
45  
46 setting. No patients were involved in this study. A decision tree was developed in Microsoft  
47  
48 Excel where the hypothetical cohort of adult patients underwent certain pathways. The  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 associated cost and effectiveness of each pathway was captured in the model and the expected  
4 cost and effectiveness was estimated.  
5  
6  
7  
8  
9

10 Effectiveness was measured using quality-adjusted life years (QALYs). The time horizon for the  
11 cost-effectiveness analysis was one year as this was a reasonable length of time for a patient to  
12 reach a confirmed diagnosis of either IBD or non-IBD. Due to the brief time horizon,  
13  
14 discounting was not applied to either costs or benefits in this analysis. Time to IBD diagnosis  
15 was also estimated from the model. The analysis perspective was the Canadian health sector.  
16  
17  
18  
19  
20  
21  
22  
23

24 The clinical pathways of patients presenting with gastrointestinal symptoms in primary care were  
25 established from published literature<sup>6,12-14</sup> as well as input by two gastroenterologists from St.  
26 Paul's Hospital, Vancouver. Established clinical pathways were consistent with the best-practice  
27 clinical care pathway for management of irritable bowel syndrome (IBS) in primary care as  
28 outlined by the Canadian Association of Gastroenterology<sup>15</sup> and local primary care guidelines on  
29 the use of FC by the NICE, UK.<sup>16</sup>  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

40 Figure 1 illustrates the current practice using the standard blood test whereas Figure 2 depicts the  
41 proposed strategy of adding FC test as a diagnostic support tool for general practitioners (GPs).  
42 Under the current practice (Figure 1), based on results of the blood investigation (ESR and CRP),  
43 a GP will make a decision on whether to refer patients to specialist care or not. Patients with  
44 abnormal blood results will be referred to gastroenterology for specialist assessment. The  
45 specialist may then order an endoscopy as necessary to confirm IBD diagnosis or follow-up with  
46 patients unlikely to have IBD and monitor their symptoms accordingly. If symptoms are still  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 persistent after 3 months (assumed and same as Waugh *et al.*<sup>6</sup>), an endoscopy may be ordered at  
4 the specialist follow-up visit to confirm diagnosis of IBD. Under the proposed strategy of adding  
5 FC test (Figure 2), patients with positive results of FC test will be referred to specialist care and  
6 an endoscopy will be ordered for them at the specialist visit to confirm diagnosis of IBD.  
7  
8  
9  
10  
11  
12

13  
14 Patients with normal blood results or negative FC test results will be followed-up by the GP and  
15 receive lifestyle and dietary advice with appropriate medication to treat symptoms for 3 months  
16 (assumed) (Figure 3). Those with symptoms inadequately controlled will receive more intensive  
17 management (different medication) from their GP for another 4 weeks (assumed). If symptoms  
18 are still persistent, further assessment by a gastroenterologist and endoscopy will be performed.  
19  
20  
21  
22  
23  
24  
25  
26  
27

### 28 **Model parameters**

29  
30 The model parameters (Table 1) were obtained from literature or based on assumptions. The  
31 parameters include sensitivity and specificity for FC testing at the 100 µg/g cut-off and ≥15mm/h  
32 for ESR and ≥5mg/l for CPR blood testing; prevalence of IBD in primary care; the ratio of UC  
33 and CD; non-IBD patients with negative test results; costs; utilities; and waiting time.  
34  
35  
36  
37  
38  
39  
40  
41

### 42 *Sensitivity and specificity*

43  
44 The 100 µg/g cut-off was proposed for FC testing in this analysis. As mentioned above, the  
45 majority of studies measuring FC testing accuracy were conducted in the secondary care  
46 setting. As such, we used the sensitivity and specificity of FC testing at the 100 µg/g cut-off  
47 from the recent UK study conducted with the prospective primary cohort.<sup>9</sup> For blood testing,  
48 we chose the cut-offs of ≥15mm/h for ESR and ≥5mg/l for CRP. Three studies using these  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 ESR and CRP cut-offs were identified from a published systematic review.<sup>5</sup> Following this, a  
4 meta-analysis was conducted to synthesize the logit-transformation of sensitivity and  
5  
6 specificity.  
7  
8  
9

### 10 11 12 *Prevalence of IBD in primary care*

13  
14 Very few studies have estimated the prevalence of IBD in primary care,<sup>6,9,17-19</sup> with most  
15 estimates originating from UK studies. To be consistent with the sensitivity and specificity  
16 estimates used in our model, we used the prevalence of IBD (=6.8%) in primary care from the  
17 same study.<sup>9</sup> Among IBD cases, 45% were UC and 55% were CD.<sup>3</sup>  
18  
19  
20  
21  
22  
23  
24  
25

### 26 *Non-IBD patients with negative test results*

27  
28 Previous studies estimated a 50% or 60% probability of non-IBD patients still having  
29 persistent symptoms after the initial management by GPs, estimates were based on expert  
30 opinion.<sup>12-14</sup> In our study, we applied the 47% probability used in the cost-effectiveness  
31 analysis conducted by Waugh *et al.*<sup>6</sup> We also assumed that 15% of these who have persistent  
32 symptoms after initial management by GP (based on expert advice) would subsequently  
33 experience uncontrolled symptoms after further intensive management by GPs, be referred to  
34 a specialist, and undergo endoscopy.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

### 46 *Costs*

47  
48 Only the diagnosis related costs, including the costs for diagnostic testing (FC, endoscopy, and  
49 pathology) and physician and gastroenterologist visits, were considered. All costs were  
50 reported in 2017 Canadian dollars. Cost data were obtained from the British Columbia  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Ministry of Health Medical Services Commission Payment Schedule (July 1, 2017 version)<sup>20</sup>  
4 which is comparable with other provinces in Canada; literature review for colonoscopy cost in  
5 Canada adjusted to 2017 cost using total health care implicit price index;<sup>21</sup> and literature  
6 review and a local gastroenterology clinic for FC testing cost.<sup>6,14</sup> Costs of managing  
7 complications associated with colonoscopy such as bleeding and perforation were not  
8 considered in this analysis due to the unavailability of data.  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18

### 19 *Utilities*

20  
21 Our utility estimates for IBS were taken from a study conducted among 257 patients in the  
22 United States (US) using EuroQol-5D.<sup>22</sup> The utilities of 0.78 for IBS patients with adequate  
23 relief of symptoms or 0.73 for those with persistent symptoms were applied to non-IBD patients  
24 in our analysis.<sup>22</sup> A weighted IBS utility of 0.76 was calculated based on the proportion (47%  
25 assumed above) of non-IBD patients with persistent symptoms and the remaining 53% with  
26 adequately controlled symptoms. In our model, patients with adequately controlled symptoms  
27 started with a weighted utility of 0.76 until the time of diagnosis, wherein a weighted utility of  
28 0.78 (utility for adequately controlled) was applied for the rest of the one-year time horizon.  
29 Patients with persistent symptoms started with 0.73 (utility for persistent symptoms) until the  
30 time of diagnosis followed by 0.78 if symptoms were eventually controlled or 0.76 if they had to  
31 undergo endoscopy.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48

49 Similar to Waugh *et al.*<sup>6</sup>, our utility estimates of IBD were taken from a study conducted among  
50 225 CD patients and 219 UC patients in Germany using the EuroQol-5D.<sup>23</sup> This study had a  
51 reasonably large sample size and reported utility estimates for active disease compared with  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 remission for both UC and CD. The utility estimates of 0.71 for active UC and 0.61 for active  
4  
5 CD were chosen to represent the utility of IBD patients when they visited GP for the first time.  
6  
7 We assumed that their utilities would then decrease by a certain amount every month due to  
8  
9 disease progression until diagnosis was made, at which point the utility value at the time of  
10  
11 diagnosis would be maintained throughout the rest of the one-year time horizon. Following the  
12  
13 method of Waugh *et al.* by taking the utility difference between active disease and remission and  
14  
15 dividing it by twelve, we derived a monthly utility decrement of 0.0167 for UC and 0.023 for  
16  
17 CD.<sup>6</sup>  
18  
19  
20  
21  
22  
23

#### 24 *Waiting time*

25  
26 The median time an IBD patient was first referred to specialist until consultation by a specialist  
27  
28 was 72 days (95% confidence interval (CI) 52-121) and the median time from the first specialist  
29  
30 consultation to endoscopy was 44 days (95% CI: 27-100) in Canada.<sup>24</sup> The median time for non-  
31  
32 IBD patients from the first referral to specialist consultation was 126 days (95% CI: 103-141).<sup>24</sup>  
33  
34 Other wait times were assumed to be fixed according to the guidelines.  
35  
36  
37  
38  
39

#### 40 **Analyses**

41  
42 All costs were reported in 2017 Canadian dollars. We performed probabilistic analyses to  
43  
44 estimate means and 95% CI of total costs, QALYs, and incremental cost-effectiveness ratios  
45  
46 (ICERs) to reflect the underlying parameter uncertainty. Additionally, the time to the diagnosis  
47  
48 of IBD among IBD patients was calculated. A total of 5,000 Monte Carlo simulations were  
49  
50 generated from the parameter probability distributions. The base-case results were presented as  
51  
52 the cost-effectiveness acceptability curve, which demonstrates the probability of the FC testing  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 strategy being cost-effective compared to the standard care across a range of willingness-to-pay  
4 thresholds. To explore the sensitivity of results to specific parameter uncertainty, alternative  
5 assumptions and sources of data, we conducted a series of scenario analyses.  
6  
7  
8  
9  
10

## 11 RESULTS

### 12 Base case

13  
14  
15 For the base case, the probabilistic analysis based on 5,000 Monte Carlo simulations showed that  
16 the FC testing strategy was about \$21 more expensive than the standard practice using blood test  
17 (\$295.12 vs. \$273.93) but yielded a slightly higher QALY (0.751 vs. 0.750, respectively) (Table  
18 2). Thus, the ICER was \$20,323.35 per QALY gained. The time to diagnosis for IBD patients  
19 was 39.96 days (95% CI: 16.34-65.29) shorter under the FC testing strategy (192.39 days (95%  
20 CI: 143.10-239.74) than standard practice (232.36 days (95% CI: 186.02-277.92)). There was an  
21 81.3% probability that the FC testing strategy was cost-effective at the willingness-to-pay  
22 threshold of \$50,000/QALY (Figure 4).  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

### 38 Scenario analyses

39 We conducted a series of scenario analyses (Table 2). 1) IBD prevalence was varied from 5% to  
40 20% in 5% increments. 2) FC testing accuracy was changed using alternative data source. The  
41 meta-analysis results of sensitivity and specificity at the cut-off of 50 µg/g (conducted and used  
42 by Waugh *et al.*<sup>6</sup>) were used in the model. The estimated mean for both sensitivity and  
43 specificity were higher than the inputs we applied in the base case. 3) We increased the  
44 proportion of patients with abnormal blood test for whom an endoscopy was ordered in the initial  
45 gastroenterologist consultation from 83% to 100%. 4) We changed the proportion of non-IBD  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 patients with symptoms after further intensive management by GPs that needed further  
4 investigation by specialist and endoscopy from 5% (same as Waugh *et al.*<sup>6</sup> and Whitehead *et*  
5 *al.*<sup>12</sup>) to 25% with 5% increments. 5) Different FC test costs and an increase or decrease in other  
6 costs by 20% were implemented. 6) We changed the source of utility decrement estimates from  
7 Stark *et al.*<sup>23</sup> to that of Gregor *et al.*<sup>25</sup> and Poole *et al.*<sup>26</sup> 7) Time taken to the first follow-up by GP  
8 and time taken to follow-up by a specialist were changed from 1 month to 4 months with 1-  
9 month increments.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20

21 Our analyses showed that the cost-effectiveness of FC testing strategy was sensitive to the  
22 prevalence of IBD among the patients presenting with gastrointestinal symptoms in primary care,  
23 the FC cost, and the value of utility decrements. When the prevalence increased to 20%, the  
24 probability of FC testing strategy being cost-effective would increase to 96.7% at the threshold  
25 of \$50,000/QALY. The price threshold at which FC testing strategy became cost-effective was  
26 \$70. At \$70, the probability of FC testing being cost-effective was 47.4% at the willingness-to-  
27 pay threshold of \$50,000/QALY. When applying a much lower utility monthly decrement  
28 especially for CD (from 0.023 to 0.006 for CD and from 0.017 to 0.014 for UC), the probability  
29 of FC testing strategy was 68.6% at the threshold of \$50,000/QALY.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

## 44 **DISCUSSION**

45  
46 Based on cost-effectiveness models built in previous studies,<sup>6,12-14</sup> current practice guidelines in  
47 Canada,<sup>15</sup> and clinical expertise from gastroenterologists, we constructed a decision analytic  
48 model to evaluate the cost-effectiveness of adding FC testing to current practice compared with  
49 the current practice of blood test only in the diagnosis of adult IBD patients in the Canadian  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 primary care setting. To our knowledge, this is the first cost-effectiveness analysis of FC testing  
4  
5 in primary care in Canada. Our base-case analysis suggested that the FC test was cost-effective.  
6  
7 Probabilistic analysis showed that at a willingness-to-pay threshold of \$50,000 per QALY, there  
8  
9 was an 81.3% chance of the FC testing strategy being cost-effective. Scenario analysis  
10  
11 demonstrated that the cost-effectiveness was most sensitive towards prevalence of IBD, monthly  
12  
13 utility decrement of IBD, and cost of FC test.  
14  
15

16  
17  
18  
19 A 6.8% prevalence of IBD was applied in our base case analysis. This estimate was based on a  
20  
21 prospective UK primary care cohort,<sup>9</sup> the prevalence was very similar to the one used in the cost-  
22  
23 effectiveness analysis conducted by Waugh *et al.*<sup>6</sup> Unfortunately, Canadian estimates were not  
24  
25 found in published literature. Thus, we conducted scenario analysis by varying the prevalence  
26  
27 from 5% to 20%. Although the cost-effectiveness of the FC testing strategy was highly sensitive  
28  
29 to the prevalence of IBD in the adult patient population presented in the primary care setting, our  
30  
31 study has shown it is still cost-effective when the prevalence is as low as 5%.  
32  
33  
34  
35

36  
37  
38 The ICER of the FC testing strategy compared with blood testing increased when the monthly  
39  
40 utility decrement for IBD was lower. This finding is consistent with the assumption made in the  
41  
42 calculation of QALYs for IBD patients. A delay in diagnosis would cause patients to reach a  
43  
44 lower utility value before diagnosis. Therefore, a higher utility decrement for IBD increased the  
45  
46 difference in QALYs gained between the two strategies and caused a decrease in ICER and vice  
47  
48 versa.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 We used the current FC test cost, \$40, in our base case, which was consistent with the cost used  
4  
5 in previous cost-effectiveness analyses conducted in the UK and US.<sup>6,14</sup> When the cost of FC  
6  
7 testing was under \$70, the FC testing strategy had the potential to be cost-effective. The wider  
8  
9 implementation of FC testing across Canada may drive the cost down. Laboratory-based FC  
10  
11 testing has been shown to be cost-effective when conducted in batches.<sup>6,10</sup>  
12  
13  
14  
15

16  
17 One of the strengths of our study is that we used the FC testing accuracy in primary care<sup>9</sup>  
18  
19 instead of the secondary care setting. The test accuracy in the secondary care setting was found  
20  
21 to be higher than that of primary care setting. According to the most recent meta-analysis  
22  
23 conducted by Waugh *et al.*,<sup>6</sup> all of studies included were for secondary setting and the  
24  
25 synthesized sensitivity (0.93) and specificity (0.94) of FC testing at the 50µg/g cut-off were both  
26  
27 higher than the estimates (0.86 and 0.90) for the 100µg/g cut-off we used for the primary care  
28  
29 setting.  
30  
31  
32  
33  
34

35  
36 Additionally, we estimated the benefit of using FC testing in primary care in terms of reducing  
37  
38 the time to IBD diagnosis (by about 40 days). The average times to IBD diagnosis among IBD  
39  
40 patients were 192.4 days with FC testing and 232.4 days for standard practice. The time to  
41  
42 diagnosis under the standard practice was reasonably consistent with a Canadian study that  
43  
44 reported the mean time to diagnosis for CD and UC to be 255.5 and 202.3 days, respectively.<sup>27</sup>  
45  
46 Delayed diagnosis is a common problem in IBD. A study involving 1,591 IBD patients from the  
47  
48 Swiss IBD cohort reported a diagnostic delay of 9 and 4 months for CD and UC.<sup>28</sup> The delay was  
49  
50 due to similarities in symptoms among patients with mild IBD and those with IBS. A literature  
51  
52 review on natural history studies of CD reported that at time of diagnosis, one third of patients  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 already had intestinal complications such as ileitis, colitis, or ileocolitis.<sup>29</sup> In UC, an early  
4 diagnosis and identification of patients with a high risk of developing complicated disease, is  
5 crucial for choosing appropriate treatment and prevention of colectomies.<sup>30</sup> The FC testing  
6 strategy has the potential to speed up diagnosis and reduce the wait time for a specialist and  
7 endoscopy by avoiding the unnecessary referrals.  
8  
9  
10  
11  
12  
13  
14  
15  
16

17 Our study has several limitations. First, there was a lack of data for certain parameter inputs of  
18 the model. For example, costs and utility decrements of complications associated with  
19 colonoscopy such as bleeding and perforation could not be identified and were therefore not  
20 considered in this analysis. In Canada, the pooled rates of colonoscopy-related bleeding,  
21 perforation, and mortality were 1.64/1000, 0.85/1000, and 0.074/1000, respectively.<sup>31</sup> While the  
22 rates of complications associated with colonoscopy may be low, the impact on the overall costs  
23 and outcomes may be significant if the time horizon of the analysis was longer, especially when  
24 deaths occur. As the number of colonoscopies were expected to be reduced by FC testing, we  
25 took a more conservative approach by not considering the impact of the complications associated  
26 with colonoscopies. Data on the utility decrement of IBD due to delayed diagnosis was also  
27 unavailable. Therefore, we adopted the approach used in Waugh *et al.*,<sup>6</sup> assuming the annual  
28 utility decrement of IBD due to delayed diagnosis as the difference between active disease and  
29 remission of UC. While our CEA was limited to costs from a health sector perspective,  
30 considering costs from a societal perspective, e.g., productivity losses due to colposcopy, would  
31 further make FC testing more cost effective.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Secondly, some modelling assumptions we made may have simplified actual clinical practice.  
4  
5 For instance, the modelling assumed that patients with FC levels above 100µg/g have positive  
6  
7 test results and patients with FC levels below 100µg/g have negative test results. Subsequently,  
8  
9 every patient who tests positive is referred to secondary care and will receive endoscopy. The  
10  
11 modelling does not consider indeterminate results of FC testing and assumes that FC testing is  
12  
13 only carried out once and is not repeated in the diagnosis pathway. In actual practice, patients  
14  
15 whose initial FC test results were found to be within an indeterminate range, for example  
16  
17 between 100µg/g to 250µg/g, may be subjected to a second FC test and only be referred to a  
18  
19 specialist if the result of the second FC test still yielded a result above 100µg/g. Literature  
20  
21 showed that over 10% of patients had results which fell in this 'grey zone'.<sup>16</sup> Retesting patients  
22  
23 with indeterminate results will essentially increase the cost of the FC testing strategy. However,  
24  
25 the impact of retesting on the overall costs will depend on the proportion of patients who fall  
26  
27 back to FC levels below 100µg/g and would not need to be referred unnecessarily, avoiding the  
28  
29 costs of specialist consultations and colonoscopies.  
30  
31  
32  
33  
34  
35  
36  
37

38 Additionally, our modelling assumed 100% patient uptake for every diagnostic test, blood test,  
39  
40 FC test, and endoscopy. Given the invasive nature and set of complications associated with  
41  
42 colonoscopies, patients may refuse this diagnostic test. The FC test may also not be widely  
43  
44 accepted, with a variable uptake rate between primary and secondary care. Some patients might  
45  
46 decline to produce a sample of feces for their GP, but may possibly be willing to do so for a  
47  
48 gastroenterologist if the alternative is colonoscopy. Recently, a home-based FC kit has been  
49  
50 made available, allowing patients to measure the concentration of FC directly using a rapid  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 immunochromatographic assay captured by a smartphone's camera. The availability of this kit  
4  
5 may increase the uptake and patient adherence of FC testing.<sup>32</sup>  
6  
7  
8  
9

10 Future research can be conducted to estimate the cost-effectiveness of FC test for distinguishing  
11  
12 between IBD and non-IBD in the paediatrics population when the important model parameters  
13  
14 are available. Furthermore, there has also been growing interest in the use of FC test in a few  
15  
16 areas of IBD management. For example, FC test might be used to monitor disease progression,  
17  
18 predict relapse and monitor response to treatment.<sup>33</sup> As such, an economic model which links the  
19  
20 diagnostic outcomes of this analysis to the management of IBD in terms of treatment and  
21  
22 monitoring can be considered in the future.  
23  
24  
25  
26  
27

28 In conclusion, using FC at the 100µg/g cut-off in primary care in the diagnosis of IBD can be a  
29  
30 cost-effective strategy and can speed up IBD diagnosis in adults who present with  
31  
32 gastrointestinal symptoms in Canada.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Author Statement:**

WZ and GR designed the study. All authors contributed to the cost-effectiveness model: CHW initiated the model, MC, TM and GR contributed their expertise in the model building and parameter determination, and WZ modified and finalized the model. WZ and CHW drafted the manuscript and all authors significantly contributed to and reviewed the final manuscript. All authors agree to be accountable for all aspects of the work.

**Funding:** This work was supported by the Future Leaders in Inflammatory Bowel Disease (FLIBD) Grant.

**Competing interests:** None declared.

**Ethics approval:** Not applicable. A hypothetical cohort of adult patients has been simulated.

**Data sharing statement:** There is no additional unpublished data from the study.

## REFERENCES

1. Irvine EJ. Quality of life of patients with ulcerative colitis: past, present, and future. *Inflamm. Bowel Dis.* 2008;14:554–565.
2. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. *Lancet Lond. Engl.* 2018;390:2769–2778.
3. Rocchi A, Benchimol EI, Bernstein CN, et al. Inflammatory bowel disease: a Canadian burden of illness review. *Can. J. Gastroenterol. J. Can. Gastroenterol.* 2012;26:811–817.
4. Walsham NE, Sherwood RA. Fecal calprotectin in inflammatory bowel disease. *Clin. Exp. Gastroenterol.* 2016;9:21–29.
5. Jellema P, Windt D a. WM van der, Schellevis FG, et al. Systematic review: accuracy of symptom-based criteria for diagnosis of irritable bowel syndrome in primary care. *Aliment. Pharmacol. Ther.* 2009;30:695–706.
6. Waugh N, Cummins E, Royle P, et al. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation. *Health Technol. Assess. Winch. Engl.* 2013;17:xv–xix, 1–211.
7. Rhee PF van, Vijver EV de, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. *BMJ.* 2010;341:c3369.
8. Rosenfeld G, Greenup A-J, Round A, et al. FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease. *World J. Gastroenterol.* 2016;22:8211–8218.
9. Walker GJ, Moore L, Heerasing N, et al. Faecal calprotectin effectively excludes inflammatory bowel disease in 789 symptomatic young adults with/without alarm

- 1  
2  
3 symptoms: a prospective UK primary care cohort study. *Aliment. Pharmacol. Ther.*  
4  
5 2018;47:1103–1116.  
6  
7  
8 10. NICE. Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel |  
9  
10 Guidance and guidelines. Available at: <https://www.nice.org.uk/guidance/dg11> [Accessed  
11  
12 January 18, 2018].  
13  
14  
15 11. GIS. Fecal Calprotectin Test. *Gastrointest. Soc.* Available at:  
16  
17 <https://www.badgut.org/information-centre/a-z-digestive-topics/fecal-calprotectin-test/>  
18  
19 [Accessed January 18, 2018].  
20  
21  
22 12. Whitehead S, Hutton J. *Economic report: Value of calprotectin in screening out irritable*  
23  
24 *bowel syndrome*. York, UK: Centre for Evidence-based Purchasing; 2010.  
25  
26  
27 13. Dubinsky MC, Johanson JF, Seidman EG, et al. Suspected inflammatory bowel disease--the  
28  
29 clinical and economic impact of competing diagnostic strategies. *Am. J. Gastroenterol.*  
30  
31 2002;97:2333–2342.  
32  
33  
34 14. Yang Z, Clark N, Park KT. Effectiveness and cost-effectiveness of measuring fecal  
35  
36 calprotectin in diagnosis of inflammatory bowel disease in adults and children. *Clin.*  
37  
38 *Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc.* 2014;12:253-262.e2.  
39  
40  
41 15. Canadian Association of Gastroenterology. Enhanced primary care pathway: IBS. 2016.  
42  
43 Available at: <https://www.cag->  
44  
45 [acg.org/images/publications/IBS\\_Enhanced\\_Primary\\_Care\\_Pathway\\_July\\_2016.pdf](https://www.cag-acg.org/images/publications/IBS_Enhanced_Primary_Care_Pathway_July_2016.pdf).  
46  
47  
48 16. Turvill J. Local Primary Care Guidelines: Use of Faecal Calprotectin in the Assessment of  
49  
50 Patients with Lower Gastrointestinal Symptoms. 2014. Available at:  
51  
52 [https://www.nice.org.uk/guidance/dg11/resources/primary-care-guidelines--york-teaching-](https://www.nice.org.uk/guidance/dg11/resources/primary-care-guidelines--york-teaching-hospital-pdf-4535195223)  
53  
54 [hospital-pdf-4535195223](https://www.nice.org.uk/guidance/dg11/resources/primary-care-guidelines--york-teaching-hospital-pdf-4535195223).  
55  
56  
57  
58  
59  
60

17. Pavlidis P, Chedgy FJ, Tibble JA. Diagnostic accuracy and clinical application of faecal calprotectin in adult patients presenting with gastrointestinal symptoms in primary care. *Scand. J. Gastroenterol.* 2013;48:1048–1054.
18. Thompson WG, Heaton KW, Smyth GT, et al. Irritable bowel syndrome in general practice: prevalence, characteristics, and referral. *Gut.* 2000;46:78–82.
19. Kok L, Elias SG, Witteman BJM, et al. Diagnostic accuracy of point-of-care fecal calprotectin and immunochemical occult blood tests for diagnosis of organic bowel disease in primary care: the Cost-Effectiveness of a Decision Rule for Abdominal Complaints in Primary Care (CEDAR) study. *Clin. Chem.* 2012;58:989–998.
20. British Columbia Ministry of Health. MEDICAL SERVICES COMMISSION PAYMENT SCHEDULE. 2017. Available at: <https://www2.gov.bc.ca/assets/gov/health/practitioner-pro/medical-services-plan/msc-payment-schedule-july-2017.pdf>.
21. Canadian Institute for Health Information. National Health Expenditure Trends. 2018. Available at: <https://www.cihi.ca/en/national-health-expenditure-trends> [Accessed January 23, 2018].
22. Spiegel B, Harris L, Lucak S, et al. Developing valid and reliable health utilities in irritable bowel syndrome: results from the IBS PROOF Cohort. *Am. J. Gastroenterol.* 2009;104:1984–1991.
23. Stark RG, Reitmeir P, Leidl R, et al. Validity, reliability, and responsiveness of the EQ-5D in inflammatory bowel disease in Germany. *Inflamm. Bowel Dis.* 2010;16:42–51.
24. Leddin D, Armstrong D, Borgaonkar M, et al. The 2012 SAGE wait times program: Survey of Access to GastroEnterology in Canada. *Can. J. Gastroenterol.* 2013;27:83–89.



- 1  
2  
3 25. Gregor JC, McDonald JW, Klar N, et al. An evaluation of utility measurement in Crohn's  
4 disease. *Inflamm. Bowel Dis.* 1997;3:265–276.  
5  
6
- 7  
8 26. Poole CD, Connolly MP, Nielsen SK, et al. A comparison of physician-rated disease  
9 severity and patient reported outcomes in mild to moderately active ulcerative colitis. *J.*  
10 *Crohns Colitis.* 2010;4:275–282.  
11  
12
- 13  
14 27. Benchimol EI, Manuel DG, Mojaverian N, et al. Health Services Utilization, Specialist  
15 Care, and Time to Diagnosis with Inflammatory Bowel Disease in Immigrants to Ontario,  
16 Canada: A Population-Based Cohort Study. *Inflamm. Bowel Dis.* 2016;22:2482–2490.  
17  
18
- 19  
20 28. Vavricka SR, Spigaglia SM, Rogler G, et al. Systematic evaluation of risk factors for  
21 diagnostic delay in inflammatory bowel disease. *Inflamm. Bowel Dis.* 2012;18:496–505.  
22  
23
- 24  
25 29. Peyrin-Biroulet L, Loftus EV, Colombel J-F, et al. The natural history of adult Crohn's  
26 disease in population-based cohorts. *Am. J. Gastroenterol.* 2010;105:289–297.  
27  
28
- 29  
30 30. Monstad I, Hovde Ø, Solberg IC, et al. Clinical course and prognosis in ulcerative colitis:  
31 results from population-based and observational studies. *Ann. Gastroenterol. Q. Publ. Hell.*  
32 *Soc. Gastroenterol.* 2014;27:95–104.  
33  
34
- 35  
36 31. Rabeneck L, Paszat LF, Hilsden RJ, et al. Bleeding and perforation after outpatient  
37 colonoscopy and their risk factors in usual clinical practice. *Gastroenterology.*  
38 2008;135:1899–1906, 1906.e1.  
39  
40
- 41  
42 32. Bello C, Roseth A, Guardiola J, et al. Usability of a home-based test for the measurement of  
43 fecal calprotectin in asymptomatic IBD patients. *Dig. Liver Dis. Off. J. Ital. Soc.*  
44 *Gastroenterol. Ital. Assoc. Study Liver.* 2017;49:991–996.  
45  
46
- 47  
48 33. Ikhtaire S, Shajib MS, Reinisch W, et al. Fecal calprotectin: its scope and utility in the  
49 management of inflammatory bowel disease. *J. Gastroenterol.* 2016;51:434–446.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 34. Sharara N, Adam V, Crott R, et al. The costs of colonoscopy in a Canadian hospital using a  
4 microcosting approach. *Can. J. Gastroenterol.* 2008;22:565–570.  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1. Model input parameters**

| Parameter  | Estimate | Distribution                 | Distribution parameters                    | Data source  |
|--|----------|------------------------------|--|--|
| IBD prevalence, %  | 6.8      | Beta                         | Alpha = 50<br>Beta = 689                   | Walker et al. <sup>9</sup>   |
| UC proportion, %   | 44.6     | Fixed                        |  | Rocchi et al. <sup>3</sup>   |
| <b>Test accuracy</b>   |          |                              |  |  |
| Sensitivity  |          |                              |  |  |
| Blood test   | 0.649    | Normal, logit transformation | Logit estimate = 0.613<br>Logit SE = 0.199 | Meta-analysis based on Jellema et al. <sup>5</sup>                         |
| FC test, at 100µg/g cut-off  | 0.860    | Beta                         | Alpha = 43<br>Beta = 7                     | Walker et al. <sup>9</sup>   |
| Specificity  |          |                              |  |  |
| Blood test   | 0.866    | Normal, logit transformation | Logit estimate = 1.867<br>Logit SE = 0.196 | Meta-analysis based on Jellema et al. <sup>5</sup>                         |
| FC test, at 100µg/g cut-off  | 0.901    | Beta                         | Alpha = 621<br>Beta = 68                   | Walker et al. <sup>9</sup>   |
| <b>Model probabilities, %</b>  |          |                              |  |  |
| Proportion of patients with abnormal blood test with endoscopy ordered in the initial gastroenterologist consultation                              | 88.3     | Beta                         | Alpha = 7.520<br>Beta = 0.993              | Expert opinion   |
| Proportion of non-IBD patients with persistent symptoms after the initial management by GPs  | 47.0     | Log-normal                   | 95% CI: 33-57                              | Waugh et al. <sup>6</sup>  |
| Proportion of non-IBD patients with symptoms after further intensive management by GPs that need further investigation by specialist and endoscopy | 15.0     | Fixed                        |  | Expert opinion   |
| <b>Cost estimates (\$)</b>   |          |                              |  |  |
| Colonoscopy, with biopsy   | 427.70   | Fixed                        |  | Sharara et al. <sup>34</sup>   |
| Surgical pathology   | 85.52    | Fixed                        |  | BC MSC payment schedule <sup>20</sup>                                      |
| FC test  | 40.00    | Fixed                        |  | Local clinic cost, Waugh et al. <sup>6</sup> and Yang et al. <sup>14</sup> |
| Initial GP visit   | 68.64    | Fixed                        |  | BC MSC payment schedule <sup>20</sup>                                      |
| Follow-up GP visit   | 30.92    | Fixed                        |  | BC MSC payment schedule <sup>20</sup>                                      |
| Initial gastroenterologist consultation  | 160.25   | Fixed                        |  | BC MSC payment   |

| Parameter  | Estimate | Distribution | Distribution parameters   | Data source  |
|--|----------|--------------|---|--|
| Follow-up gastroenterologist consultation  | 97.39    | Fixed        |   | schedule <sup>20</sup><br>BC MSC payment<br>schedule <sup>20</sup> |
| <b>Utilities</b>   |          |              |   |  |
| <b>IBD</b>   |          |              |   |  |
| Active UC  | 0.71     | Beta         | Alpha = 3.802<br>Beta = 1.553   | Stark et al. <sup>23</sup>   |
| Active CD  | 0.61     | Beta         | Alpha = 1.116<br>Beta = 0.713   | Stark et al. <sup>23</sup>   |
| Monthly utility decrement for UC   | 0.017    | Beta         | Alpha = 1.601<br>Beta = 94.443  | Stark et al. <sup>23</sup>   |
| Monthly utility decrement for CD   | 0.023    | Beta         | Alpha = 1.647<br>Beta = 68.958  | Stark et al. <sup>23</sup>   |
| <b>Non-IBD</b>   |          |              |   |  |
| a) With adequately controlled symptoms   | 0.78     | Beta         | Alpha = 5.367<br>Beta = 1.514   | Spiegel et al. <sup>22</sup>                                       |
| b) With persistent symptoms  | 0.73     |              | Calculated from a/c   | Spiegel et al. <sup>22</sup>                                       |
| c) Fixed ratio for utility of adequately controlled over persistent symptoms                   |          | Fixed        | 1.068   |  |
| Weighted IBS utility   | 0.76     |              | Calculated from a), b) and<br>Proportion of non-IBD<br>patients with persistent<br>symptoms above |  |
| <b>Wait time</b>   |          |              |   |  |
| Time taken to undergo blood test and/or FC test after presenting with symptoms in primary care | 7 days   | Fixed        |   | Expert opinion   |
| Time taken to obtain results of blood test and FC test   | 7 days   | Fixed        |   | Expert opinion   |
| Time taken to follow-up by GP first time   | 3 months | Fixed        |   | Expert opinion   |
| Time taken to follow-up by GP second time  | 4 weeks  | Fixed        |   | Expert opinion   |
| Time taken to a specialist consultation for IBD patients                                       | 86.50    | Normal       | SE=17.602   | Leddin et al. <sup>24</sup>  |
| Time taken to a specialist consultation for non-IBD patients                                   | 122.00   | Normal       | SE=9.694  | Leddin et al. <sup>24</sup>  |
| Time taken to endoscopy after seeing a specialist  | 63.50    | Normal       | SE=18.622   | Leddin et al. <sup>24</sup>  |
| Time taken to follow-up by a specialist  | 3 months | Fixed        |   | Expert opinion   |

IBD: inflammatory bowel disease; UC: ulcerative colitis; CD: Crohn's disease; FC: fecal calprotectin; GP: general practitioner; IBS: irritable bowel

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

| <b>Parameter</b>   | <b>Estimate</b> | <b>Distribution</b> | <b>Distribution parameters</b> | <b>Data source</b> |
|--|-----------------|---------------------|--------------------------------|--------------------|
| syndrome; SE: standard error; MSC: Medical Services Commission |                 |                     |                                |                    |

For peer review only

Table 2. Results of base-case analysis

| Scenario   | FC testing strategy       |                        | Standard practice<br>(blood test) |                        | Incremental<br>Cost       | Incremental<br>QALY       | ICER<br>(\$/QALY) | Probability of<br>FC being<br>cost-effective* |
|--|---------------------------|------------------------|-----------------------------------|------------------------|---------------------------|---------------------------|-------------------|---|
|  | Cost, \$                  | QALY                   | Cost, \$                          | QALY                   |                           |                           |                   |   |
| <b>Base-case</b>   | 295.12<br>(274.49,317.53) | 0.751<br>(0.431,0.939) | 273.93<br>(245.40,306.05)         | 0.750<br>(0.430,0.938) | 21.19 (-<br>7.50,46.57)   | 0.001<br>(0.0003,0.002)   | 20,323.35         | 81.3%   |
| <b>Scenario Analysis</b>   |                           |                        |                                   |                        |                           |                           |                   |   |
| <b>IBD prevalence, %</b>   |                           |                        |                                   |                        |                           |                           |                   |   |
| 5  | 286.17<br>(268.43,306.09) | 0.757<br>(0.427,0.943) | 264.65<br>(238.41,294.96)         | 0.756<br>(0.426,0.942) | 21.52 (-<br>7.75,46.72)   | 0.001<br>(0.0002,0.002)   | 24,440.81         | 75.5%   |
| 10   | 312.60<br>(295.98,331.11) | 0.743<br>(0.434,0.928) | 291.21<br>(267.12,319.28)         | 0.742<br>(0.433,0.927) | 21.39 (-<br>5.67,45.80)   | 0.001<br>(0.0004,0.003)   | 15,594.08         | 89.3%   |
| 15   | 339.26<br>(323.00,357.86) | 0.740<br>(0.448,0.916) | 318.14<br>(294.04,345.63)         | 0.738<br>(0.447,0.915) | 21.12 (-<br>5.02,43.94)   | 0.002<br>(0.0004,0.005)   | 11,515.23         | 93.8%   |
| 20   | 365.81<br>(350.40,383.68) | 0.728<br>(0.442,0.907) | 344.93<br>(322.74,371.08)         | 0.725<br>(0.440,0.904) | 20.88 (-<br>3.94,41.96)   | 0.002<br>(0.0006,0.006)   | 8,843.74          | 96.7%   |
| <b>FC test accuracy at 50 µg/g cut-off (Waugh et al.<sup>6</sup>)</b>  |                           |                        |                                   |                        |                           |                           |                   |   |
| Sensitivity=0.93<br>(CI: 0.83-0.97)  | 285.81<br>(240.29,392.06) | 0.753<br>(0.424,0.939) | 274.25<br>(246.24,306.17)         | 0.752<br>(0.423,0.938) | 11.55 (-<br>38.38,120.29) | 0.001 (-<br>0.0006,0.003) | 8,535.62          | 82.1%   |
| Specificity=0.94<br>(CI 0.73-0.99)   |                           |                        |                                   |                        |                           |                           |                   |   |
| <b>Proportion of patients with abnormal blood test with endoscopy ordered in the initial gastroenterologist consultation, %</b>                      |                           |                        |                                   |                        |                           |                           |                   |   |
| 100  | 295.38<br>(274.60,317.32) | 0.751<br>(0.430,0.938) | 276.23<br>(248.77,307.54)         | 0.750<br>(0.429,0.937) | 19.15 (-<br>10.31,44.69)  | 0.001<br>(0.0002,0.002)   | 22,007.50         | 76.9%   |
| <b>Proportion of non-IBD patients with symptoms after further intensive management by GPs that need investigation by specialist and endoscopy, %</b> |                           |                        |                                   |                        |                           |                           |                   |   |
| 5  | 268.69<br>(251.37,286.92) | 0.754<br>(0.444,0.940) | 248.96<br>(222.27,278.72)         | 0.753<br>(0.444,0.939) | 19.73 (-<br>10.67,46.48)  | 0.001<br>(0.0003,0.003)   | 17,988.04         | 83.5%   |
| 10   | 281.84<br>(263.26,301.20) | 0.754<br>(0.447,0.938) | 261.12<br>(234.23,290.74)         | 0.753<br>(0.446,0.937) | 20.72 (-<br>8.35,46.16)   | 0.001<br>(0.0002,0.002)   | 19,504.34         | 82.4%   |
| 20   | 308.68<br>(286.39,332.03) | 0.751<br>(0.426,0.938) | 286.82<br>(257.72,318.88)         | 0.750<br>(0.426,0.938) | 21.85 (-<br>5.70,45.83)   | 0.001<br>(0.0002,0.002)   | 21,405.41         | 81.2%   |
| 25   | 322.23<br>(297.17,350.17) | 0.749<br>(0.423,0.937) | 300.26<br>(268.29,334.99)         | 0.748<br>(0.422,0.936) | 21.97 (-<br>5.25,45.94)   | 0.001<br>(0.0003,0.002)   | 22,040.22         | 79.5%   |
| <b>Cost of FC, \$</b>  |                           |                        |                                   |                        |                           |                           |                   |   |
| 50   | 305.42<br>(284.54,327.76) | 0.751<br>(0.428,0.941) | 274.12<br>(246.34,305.69)         | 0.750<br>(0.428,0.940) | 31.29<br>(2.93,55.78)     | 0.001<br>(0.0003,0.002)   | 29,789.72         | 71.7%   |
| 60   | 315.60                    | 0.751                  | 274.19                            | 0.750                  | 41.40                     | 0.001                     | 39,243.50         | 59.8%   |

| Scenario   | FC testing strategy |               | Standard practice<br>(blood test) |               | Incremental<br>Cost | Incremental<br>QALY | ICER<br>(\$/QALY) | Probability of<br>FC being<br>cost-effective* |
|--|---------------------|---------------|-----------------------------------|---------------|---------------------|---------------------|-------------------|---|
|  | Cost, \$            | QALY          | Cost, \$                          | QALY          |                     |                     |                   |   |
| 70   | (295.76,337.54)     | (0.430,0.936) | (246.49,305.45)                   | (0.430,0.936) | (13.49,66.07)       | (0.0002,0.002)      | 48,712.48         | 47.4%   |
|  | 325.29              | 0.753         | 274.15                            | 0.751         | 51.14               | 0.001               |                   |   |
|  | (305.29,347.98)     | (0.428,0.938) | (246.63,305.86)                   | (0.427,0.936) | (22.70,75.99)       | (0.0002,0.002)      |                   |   |
| <b>All cost estimates except FC test cost, \$</b>  |                     |               |                                   |               |                     |                     |                   |   |
| +20%   | 346.68              | 0.752         | 329.42                            | 0.751         | 17.26 (-            | 0.001               | 16,191.86         | 83.4%   |
|  | (321.97,372.92)     | (0.430,0.940) | (295.89,367.82)                   | (0.429,0.939) | 16.39,48.03)        | (0.0003,0.002)      |                   |   |
| -20%   | 244.18              | 0.752         | 219.14                            | 0.751         | 25.04               | 0.001               | 23,509.13         | 79.8%   |
|  | (227.92,262.28)     | (0.433,0.936) | (196.94,244.50)                   | (0.432,0.935) | (2.13,44.91)        | (0.0003,0.003)      |                   |   |
| <b>Utility decrement</b>   |                     |               |                                   |               |                     |                     |                   |   |
| CD = 0.006<br>(Gregor et al. <sup>25</sup> )   | 295.11              | 0.755         | 274.24                            | 0.755         | 20.87 (-            | 0.001               | 30,136.89         | 68.6%   |
| UC = 0.014<br>(Poole et al. <sup>26</sup> )  | (274.59,316.66)     | (0.427,0.941) | (246.79,304.96)                   | (0.427,0.940) | 6.50,45.47)         | (0.0002,0.001)      |                   |   |
| <b>Time taken to follow-up by GP first time</b>  |                     |               |                                   |               |                     |                     |                   |   |
| 1 month  | 294.97              | 0.756         | 274.09                            | 0.755         | 20.89 (-            | 0.001               | 18,830.57         | 81.9%   |
|  | (274.80,316.36)     | (0.422,0.945) | (245.92,306.40)                   | (0.421,0.944) | 8.13,46.10)         | (0.0002,0.002)      |                   |   |
| 2 months   | 295.36              | 0.758         | 274.07                            | 0.757         | 21.29 (-            | 0.001               | 19,650.08         | 81.7%   |
|  | (274.91,317.69)     | (0.437,0.943) | (246.25,306.46)                   | (0.436,0.942) | 7.90,45.83)         | (0.0002,0.002)      |                   |   |
| 4 months   | 295.28              | 0.749         | 274.03                            | 0.748         | 21.25 (-            | 0.001               | 21,451.73         | 80.8%   |
|  | (275.08,317.76)     | (0.442,0.940) | (245.76,304.35)                   | (0.441,0.939) | 6.75,45.57)         | (0.0002,0.002)      |                   |   |
| <b>Time taken to follow-up by a specialist</b>   |                     |               |                                   |               |                     |                     |                   |   |
| 1 month  | 295.47              | 0.747         | 274.37                            | 0.746         | 21.10 (-            | 0.001               | 23,213.73         | 76.1%   |
|  | (275.10,317.87)     | (0.425,0.937) | (246.13,305.91)                   | (0.424,0.936) | 7.54,46.45)         | (0.0002,0.002)      |                   |   |
| 2 months   | 295.35              | 0.757         | 274.19                            | 0.756         | 21.16 (-            | 0.001               | 21,587.69         | 79.6%   |
|  | (275.19,318.36)     | (0.435,0.939) | (247.23,305.55)                   | (0.434,0.937) | 7.75,45.96)         | (0.0002,0.002)      |                   |   |
| 4 months   | 295.49              | 0.751         | 274.42                            | 0.750         | 21.07 (-            | 0.001               | 18,991.77         | 83.4%   |
|  | (274.69,317.09)     | (0.430,0.940) | (246.23,305.94)                   | (0.429,0.939) | 7.51,46.49)         | (0.0003,0.003)      |                   |   |
| 95% confidence intervals (CI) in brackets  |                     |               |                                   |               |                     |                     |                   |   |
| IBD: inflammatory bowel disease; FC: fecal calprotectin; GP: general practitioner; CD: Crohn's disease; UC: ulcerative colitis; QALY: quality-adjusted life year; ICER: incremental cost-effectiveness ratio |                     |               |                                   |               |                     |                     |                   |   |
| *at \$50,000/QALY threshold  |                     |               |                                   |               |                     |                     |                   |   |

1  
2  
3 **Figure 1. Overview of the model structure for standard practice using blood test**  
4

5 IBD: inflammatory bowel disease; GP: general practitioner  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



1  
2  
3 **Figure 2. Overview of the model structure for fecal calprotectin testing strategy**  
4

5 FC: fecal calprotectin IBD: inflammatory bowel disease; GP: general practitioner  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1  
2  
3 **Figure 3. Overview of the decision branch for normal blood test or negative fecal**  
4  
5 **calprotectin test results**  
6

7  
8 FC: fecal calprotectin IBD: inflammatory bowel disease; GP: general practitioner  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Figure 4. Cost-effectiveness acceptability curve**

For peer review only




Figure 1

279x361mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 2

279x361mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 3

279x361mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 4  
279x361mm (300 x 300 DPI)

# Reporting checklist for economic evaluation of health interventions

Based on the CHEERS guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the CHEERS reporting guidelines, and cite them as:

Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.

|                                 |                    | Reporting Item   | Page Number          |
|---------------------------------|--------------------|--|----------------------|
| Title                           | <a href="#">#1</a> | Identify the study as an economic evaluation or use more specific terms such as "cost-effectiveness analysis", and describe the interventions compared.                                | P1                   |
| Abstract                        | <a href="#">#2</a> | Provide a structured summary of objectives, perspective, setting, methods (including study design and inputs), results (including base case and uncertainty analyses), and conclusions | P2-P3                |
| Background and objectives       | <a href="#">#3</a> | Provide an explicit statement of the broader context for the study. Present the study question and its relevance for health policy or practice decisions                               | P5-P6                |
| Target population and subgroups | <a href="#">#4</a> | Describe characteristics of the base case population and subgroups analysed, including why they were chosen.   | Last paragraph on P6 |



|    |  |                      |   |                                      |
|----|--|----------------------|---|--------------------------------------|
| 1  | Setting and location                                   | <a href="#">#5</a>   | State relevant aspects of the system(s) in which the decision(s) need(s) to be made.  | P6                                   |
| 2  |  |                      |   |                                      |
| 3  |  |                      |   |                                      |
| 4  | Study perspective                                      | <a href="#">#6</a>   | Describe the perspective of the study and relate this to the costs being evaluated.   | P6                                   |
| 5  |  |                      |   |                                      |
| 6  |  |                      |   |                                      |
| 7  |  |                      |   |                                      |
| 8  | Comparators  | <a href="#">#7</a>   | Describe the interventions or strategies being compared and state why they were chosen.   | P6                                   |
| 9  |  |                      |   |                                      |
| 10 |  |                      |   |                                      |
| 11 |  |                      |   |                                      |
| 12 | Time horizon   | <a href="#">#8</a>   | State the time horizon(s) over which costs and consequences are being evaluated and say why appropriate.  | 2 <sup>nd</sup> paragraph on P7      |
| 13 |  |                      |   |                                      |
| 14 |  |                      |   |                                      |
| 15 |  |                      |   |                                      |
| 16 |  |                      |   |                                      |
| 17 | Discount rate  | <a href="#">#9</a>   | Report the choice of discount rate(s) used for costs and outcomes and say why appropriate   | N/A, 2 <sup>nd</sup> paragraph on P7 |
| 18 |  |                      |   |                                      |
| 19 |  |                      |   |                                      |
| 20 |  |                      |   |                                      |
| 21 |  |                      |   |                                      |
| 22 |  |                      |   |                                      |
| 23 | Choice of health outcomes                              | <a href="#">#10</a>  | Describe what outcomes were used as the measure(s) of benefit in the evaluation and their relevance for the type of analysis performed  | P7-P8                                |
| 24 |  |                      |   |                                      |
| 25 |  |                      |   |                                      |
| 26 |  |                      |   |                                      |
| 27 |  |                      |   |                                      |
| 28 | Measurement of effectiveness                           | <a href="#">#11a</a> | Single study-based estimates: Describe fully the design features of the single effectiveness study and why the single study was a sufficient source of clinical effectiveness data  | P8                                   |
| 29 |  |                      |   |                                      |
| 30 |  |                      |   |                                      |
| 31 |  |                      |   |                                      |
| 32 |  |                      |   |                                      |
| 33 |  |                      |   |                                      |
| 34 |  |                      |   |                                      |
| 35 | Measurement of effectiveness                           | <a href="#">#11b</a> | Synthesis-based estimates: Describe fully the methods used for identification of included studies and synthesis of clinical effectiveness data  | P8-9                                 |
| 36 |  |                      |   |                                      |
| 37 |  |                      |   |                                      |
| 38 |  |                      |   |                                      |
| 39 |  |                      |   |                                      |
| 40 | Measurement and valuation of preference based outcomes | <a href="#">#12</a>  | If applicable, describe the population and methods used to elicit preferences for outcomes.   | P10-P11                              |
| 41 |  |                      |   |                                      |
| 42 |  |                      |   |                                      |
| 43 |  |                      |   |                                      |
| 44 |  |                      |   |                                      |
| 45 |  |                      |   |                                      |
| 46 |  |                      |   |                                      |
| 47 |  | <a href="#">#13a</a> | Single study-based economic evaluation: Describe approaches used to estimate resource use associated with the alternative interventions. Describe primary or secondary research methods for valuing each resource item in terms of its unit cost. Describe any adjustments made to approximate to opportunity costs | N/A                                  |
| 48 |  |                      |   |                                      |
| 49 |  |                      |   |                                      |
| 50 |  |                      |   |                                      |
| 51 |  |                      |   |                                      |
| 52 |  |                      |   |                                      |
| 53 |  |                      |   |                                      |
| 54 |  |                      |   |                                      |
| 55 |  |                      |   |                                      |
| 56 |  |                      |   |                                      |
| 57 | Estimating resources and costs                         | <a href="#">#13b</a> | Model-based economic evaluation: Describe approaches and data sources used to estimate  | P9-P10                               |
| 58 |  |                      |   |                                      |
| 59 |  |                      |   |                                      |
| 60 |  |                      |   |                                      |

resource use associated with model health states.

Describe primary or secondary research methods for valuing each resource item in terms of its unit cost.

Describe any adjustments made to approximate to opportunity costs.

|    |                                      |                      |   |
|----|--------------------------------------|----------------------|---|
| 1  |                                      |                      |   |
| 2  |                                      |                      |   |
| 3  |                                      |                      |   |
| 4  |                                      |                      |   |
| 5  |                                      |                      |   |
| 6  |                                      |                      |   |
| 7  |                                      |                      |   |
| 8  |                                      |                      |   |
| 9  | Currency, price date, and conversion | <a href="#">#14</a>  | Report the dates of the estimated resource quantities and unit costs. Describe methods for adjusting estimated unit costs to the year of reported costs if necessary. Describe methods for converting costs into a common currency base and the exchange rate.  |
| 10 |                                      |                      | P9-P10  |
| 11 |                                      |                      |   |
| 12 |                                      |                      |   |
| 13 |                                      |                      |   |
| 14 |                                      |                      |   |
| 15 |                                      |                      |   |
| 16 |                                      |                      |   |
| 17 | Choice of model                      | <a href="#">#15</a>  | Describe and give reasons for the specific type of decision analytical model used. Providing a figure to show model structure is strongly recommended.  |
| 18 |                                      |                      | P6-8 and  |
| 19 |                                      |                      | Figures 1-3   |
| 20 |                                      |                      |   |
| 21 |                                      |                      |   |
| 22 | Assumptions                          | <a href="#">#16</a>  | Describe all structural or other assumptions underpinning the decision-analytical model.  |
| 23 |                                      |                      | P6-11   |
| 24 |                                      |                      |   |
| 25 |                                      |                      |   |
| 26 | Analytical methods                   | <a href="#">#17</a>  | Describe all analytical methods supporting the evaluation. This could include methods for dealing with skewed, missing, or censored data; extrapolation methods; methods for pooling data; approaches to validate or make adjustments (such as half cycle corrections) to a model; and methods for handling population heterogeneity and uncertainty. |
| 27 |                                      |                      | P11-P12   |
| 28 |                                      |                      |   |
| 29 |                                      |                      |   |
| 30 |                                      |                      |   |
| 31 |                                      |                      |   |
| 32 |                                      |                      |   |
| 33 |                                      |                      |   |
| 34 |                                      |                      |   |
| 35 |                                      |                      |   |
| 36 |                                      |                      |   |
| 37 | Study parameters                     | <a href="#">#18</a>  | Report the values, ranges, references, and, if used, probability distributions for all parameters. Report reasons or sources for distributions used to represent uncertainty where appropriate. Providing a table to show the input values is strongly recommended.   |
| 38 |                                      |                      | Table 1   |
| 39 |                                      |                      |   |
| 40 |                                      |                      |   |
| 41 |                                      |                      |   |
| 42 |                                      |                      |   |
| 43 |                                      |                      |   |
| 44 |                                      |                      |   |
| 45 | Incremental costs and outcomes       | <a href="#">#19</a>  | For each intervention, report mean values for the main categories of estimated costs and outcomes of interest, as well as mean differences between the comparator groups. If applicable, report incremental cost-effectiveness ratios.  |
| 46 |                                      |                      | P12 and   |
| 47 |                                      |                      | Table 2   |
| 48 |                                      |                      |   |
| 49 |                                      |                      |   |
| 50 |                                      |                      |   |
| 51 |                                      |                      |   |
| 52 |                                      |                      |   |
| 53 |                                      |                      |   |
| 54 | Characterising uncertainty           | <a href="#">#20a</a> | Single study-based economic evaluation: Describe the effects of sampling uncertainty for the estimated incremental cost and incremental effectiveness parameters, together with the impact of methodological  |
| 55 |                                      |                      | N/A   |
| 56 |                                      |                      |   |
| 57 |                                      |                      |   |
| 58 |                                      |                      |   |
| 59 |                                      |                      |   |
| 60 |                                      |                      |   |

assumptions (such as discount rate, study perspective).

|    |                       |                      |   |
|----|-----------------------|----------------------|---|
| 1  |                       |                      |   |
| 2  |                       |                      |   |
| 3  |                       | <a href="#">#20b</a> | Model-based economic evaluation: Describe the effects P12-P13 |
| 4  |                       |                      | on the results of uncertainty for all input parameters,       |
| 5  |                       |                      | and uncertainty related to the structure of the model         |
| 6  |                       |                      | and assumptions.  |
| 7  |                       |                      |   |
| 8  |                       |                      |   |
| 9  | Characterising        | <a href="#">#21</a>  | If applicable, report differences in costs, outcomes, or N/A  |
| 10 | heterogeneity         |                      | cost effectiveness that can be explained by variations        |
| 11 |                       |                      | between subgroups of patients with different baseline         |
| 12 |                       |                      | characteristics or other observed variability in effects      |
| 13 |                       |                      | that are not reducible by more information.                   |
| 14 |                       |                      |   |
| 15 |                       |                      |   |
| 16 |                       |                      |   |
| 17 | Study findings,       | <a href="#">#22</a>  | Summarise key study findings and describe how they P13-18     |
| 18 | limitations,          |                      | support the conclusions reached. Discuss limitations          |
| 19 | generalisability, and |                      | and the generalisability of the findings and how the          |
| 20 | current knowledge     |                      | findings fit with current knowledge.                          |
| 21 |                       |                      |   |
| 22 |                       |                      |   |
| 23 |                       |                      |   |
| 24 | Source of funding     | <a href="#">#23</a>  | Describe how the study was funded and the role of the P19     |
| 25 |                       |                      | funder in the identification, design, conduct, and            |
| 26 |                       |                      | reporting of the analysis. Describe other non-monetary        |
| 27 |                       |                      | sources of support  |
| 28 |                       |                      |   |
| 29 |                       |                      |   |
| 30 |                       |                      |   |
| 31 | Conflict of interest  | <a href="#">#24</a>  | Describe any potential for conflict of interest of study P19  |
| 32 |                       |                      | contributors in accordance with journal policy. In the        |
| 33 |                       |                      | absence of a journal policy, we recommend authors             |
| 34 |                       |                      | comply with International Committee of Medical Journal        |
| 35 |                       |                      | Editors recommendations                                       |
| 36 |                       |                      |   |
| 37 |                       |                      |   |
| 38 |                       |                      |   |

The CHEERS checklist is distributed under the terms of the Creative Commons Attribution License CC-BY-NC. This checklist can be completed online using <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)

# BMJ Open

## Cost-effectiveness of fecal calprotectin used in primary care in the diagnosis of inflammatory bowel disease

|                                 |  |
|---------------------------------|--|
| Journal:                        | <i>BMJ Open</i>  |
| Manuscript ID                   | bmjopen-2018-027043.R1   |
| Article Type:                   | Research   |
| Date Submitted by the Author:   | 20-Dec-2018  |
| Complete List of Authors:       | Zhang, Wei; St. Paul's hospital, Centre for Health Evaluation & Outcome Sciences; University of British Columbia, School of Population and Public Health<br>Wong, Chiew; University of Sheffield<br>Chavannes, Mallory; University of British Columbia; University of Southern California<br>Mohammadi, Tima; Centre for Health Evaluation and Outcome Sciences<br>Rosenfeld, Greg; University of British Columbia, Department of Medicine, Division of Gastroenterology |
| <b>Primary Subject Heading</b>: | Health economics   |
| Secondary Subject Heading:      | General practice / Family practice, Gastroenterology and hepatology, Public health   |
| Keywords:                       | Fecal calprotectin, Inflammatory bowel disease < GASTROENTEROLOGY, cost-effectiveness  |
|                                 |  |

SCHOLARONE™  
Manuscripts

# Cost-effectiveness of fecal calprotectin used in primary care in the diagnosis of inflammatory bowel disease

Wei Zhang, PhD<sup>1,2</sup>; Chiew Hsia Wong, MSc<sup>3</sup>; Mallory Chavannes, MD<sup>4,5</sup>; Tima Mohammadi, MA, MSc<sup>2</sup>; Greg Rosenfeld, MD<sup>4</sup>

1. School of Population and Public Health, University of British Columbia
2. Centre for Health Evaluation and Outcome Sciences, St. Paul's Hospital
3. School of Health and Related Research, University of Sheffield
4. Department of Medicine, Division of Gastroenterology, University of British Columbia
5. Department of Pediatric, Division of Gastroenterology, Hepatology and Nutrition, Children Hospital of Los Angeles, University of Southern California.

## Correspondence:

**Wei Zhang**, PhD

Centre for Health Evaluation and Outcome Sciences, St. Paul's Hospital

588-1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6

Tel: +1-604-806-9343

Email: [wzhang@cheos.ubc.ca](mailto:wzhang@cheos.ubc.ca)

**Word count:** Abstract [287]; Manuscript [4431]

**Tables and figures:** Tables [2]; Figures [4]

**Keywords:** Fecal calprotectin; inflammatory bowel disease; cost-effectiveness

## ABSTRACT

**Objective:** Inflammatory bowel disease (IBD) is a chronic, autoimmune, gastrointestinal disorder. Canada has one of the highest prevalence and incidence rates of IBD in the world. Diagnosis is challenging due to the similarity of symptoms to functional gastrointestinal disorders. Fecal calprotectin (FC) is a biomarker for active mucosal inflammation and has proven effective in the diagnosis of IBD. Our study objective was to assess the cost-effectiveness of adding a FC test compared with standard practice (blood test) in primary care among adult patients presenting with gastrointestinal symptoms.

**Design:** We constructed a decision analytic tree with a one-year time horizon. The cut-off level of 100µg/g was used for FC testing. Probabilistic analyses were conducted for the base case and all scenarios.

**Setting:** Canadian health sector perspective.

**Population:** A hypothetical cohort of adult patients presenting with gastrointestinal symptoms in the primary care setting

**Interventions:** FC test compared with blood test

**Main outcome measures:** Costs, quality-adjusted life years (QALYs), incremental cost-effectiveness ratio (ICER) of FC test expressed as cost per QALY gained compared with blood test, and time to IBD diagnosis.

**Results:** FC testing is expected to cost more (\$295.1 vs. \$273.9) than standard practice but yield little higher QALY (0.751 vs. 0.750). The ICER of FC test was \$20,323 per QALY. Probabilistic analysis demonstrated that at a willingness-to-pay threshold of \$50,000 per QALY, there was 81.3% probability of FC test being cost-effective. The use of FC test in primary care reduced the

1  
2  
3 time to IBD diagnosis by 40.0 days (95% Confidence Interval: 16.3-65.3 days), compared with  
4  
5 blood testing alone.  
6

7  
8 **Conclusions:** Based on this analysis of short-term outcomes, screening adult patients in primary  
9  
10 care using FC test at a cut-off level of 100µg/g is expected to be cost-effective in Canada.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## ARTICLE SUMMARY

### Strengths and limitations of this study

- This paper presents a cost-effectiveness analysis (CEA) comparing a fecal calprotectin test to blood test in diagnosis of inflammatory bowel disease (IBD) in the primary care setting.
- This was the first CEA of FC test in the Canadian context and one of few CEAs of FC test in the primary care setting in literature.
- We also compared the average time to IBD diagnosis between using FC test and blood test in primary care and estimated the reduced time to IBD diagnosis by using FC test.
- The analysis was from the Canadian health sector perspective and did not consider costs (e.g., productivity losses) from a societal perspective.
- The main limitation was the short-term time horizon of the analysis and thus there is outstanding uncertainty over the long-term impact of FC testing in this setting.



## INTRODUCTION

Inflammatory bowel disease (IBD), of which the two main subtypes are Crohn's Disease (CD) and ulcerative colitis (UC), is characterized by mucosal inflammation and ulceration of the gastrointestinal tract. During the course of the disease, patients often present with symptoms such as diarrhea, abdominal pain, and fatigue, which significantly impact the quality of life of IBD patients.<sup>1</sup> Canada has one of the highest reported prevalence and incidence rates of IBD in the world.<sup>2</sup> The prevalence of IBD in Canada was estimated at 0.67% [129,000 individuals with CD and 104,000 with UC] in 2012, with approximately 10,200 incidents occurring annually.<sup>3</sup> The corresponding annual economic costs of IBD were estimated at \$2.8 billion.<sup>3</sup>

IBD shares similar presenting symptoms with functional gut disorders. One of the most common functional gut disorders is difficult to distinguish from IBD is Irritable Bowel Syndrome (IBS), which affects around 11% of the population in Canada and globally. IBS usually requires symptomatic management in primary care and causes no serious consequences permanent damage. However, IBD have serious complications and may lead to surgical resections of the bowel and therefore requires specialist care management. In order to distinguish IBD from functional gut disorders, the conventional diagnostic pathway in primary care includes initial blood tests, such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), which are used to determine whether patients should be referred to gastroenterologists for further investigation including imaging studies and/or endoscopy.<sup>4</sup> However, these blood tests lack accuracy. They may not only delay IBD diagnosis in the case of false negatives, but also lead to unnecessary endoscopies in the case of false positives.<sup>5,6</sup> Due to limited resources, endoscopy is

1  
2  
3 not readily accessible in many areas of Canada and unnecessary endoscopies can have further  
4  
5 impacts on health care resources and costs.  
6  
7

8  
9  
10 Recently, the detection of fecal calprotectin (FC), the most extensively studied fecal marker of  
11  
12 IBD, has been shown to be an accurate and useful screening tool for identifying patients who  
13  
14 need further investigation through endoscopy.<sup>5-8</sup> The majority of studies that assessed the  
15  
16 accuracy of FC testing to date have been in the secondary care setting.<sup>5-7</sup> A recent prospective  
17  
18 primary care cohort study conducted in the United Kingdom (UK) demonstrated that FC testing  
19  
20 using the cut-off of 100µg/g accurately distinguishes IBD from functional gut disorder in  
21  
22 primary care and reduces secondary care referrals as well as diagnostic health care costs.<sup>9</sup> Waugh  
23  
24 *et al.* have also shown that FC testing is cost-effective for distinguishing between IBD and non-  
25  
26 IBD in adults in primary care in the UK.<sup>6,10</sup> The National Institute for Health and Care  
27  
28 Excellence (NICE) in the UK therefore recommends FC testing as an option to help clinicians  
29  
30 distinguish between IBD and non-IBD in adults with recent onset of gastrointestinal symptoms.<sup>10</sup>  
31  
32 A consensus document has subsequently been published to support the implementation of NICE  
33  
34 recommendation.<sup>11</sup> More recently, Turvill *et al.* have also demonstrated repeating FC testing  
35  
36 among those with first FC testing  $\geq 100\mu\text{g/g}$  in primary care is cost-saving compared with  
37  
38 CRP/ESR testing or a single FC testing at cut-off of 50µg/g.<sup>12</sup>  
39  
40  
41  
42  
43  
44  
45  
46

47 In Canada, however, FC tests are currently only covered by provincial health plans in Alberta  
48  
49 and Quebec, as well as some extended health insurance plans.<sup>13</sup> There is still no cost-  
50  
51 effectiveness evidence within primary care in Canada. The objective of this study, therefore, is to  
52  
53  
54  
55  
56  
57  
58  
59  
60

determine the cost-effectiveness of FC testing in the diagnosis of adult cases of IBD in primary care from the Canadian health care sector perspective.

## MATERIALS AND METHODS

### Comparison groups

A higher 100µg/g cut-off in primary care has been advocated and demonstrated to increase the positive predictive power of the test and counter the high false positive rate observed at the lower 50µg/g cut-off.<sup>9,11,12,14</sup> Therefore, we chose the 100µg/g cut-off for FC testing in primary care setting. Ideally, we would have the current primary care practice as our control group. However, there was not good data sources for the sensitivity and specificity of the primary care practice. Waugh et al.<sup>6</sup> used a very high sensitivity (=1) and specificity (=0.788) for the primary care practice. Turvill et al. considered it unlikely that general practitioners (GPs) were more accurate at referring patients based on symptomatology than based on ESR/CRP testing alone.<sup>12</sup> Thus, we chose CRP/ESR as the comparison group, which is consistent with previous CEAs by Whitehead and Hutton<sup>15</sup> and Turvill et al.<sup>12</sup>. This implies that patients with a normal CRP/ESR would not be referred initially but if they have ongoing symptoms, they would subsequently be referred.

### Decision model

A decision analytic model was built to estimate the cost-effectiveness of using FC test as compared to the current practice using blood test, in the screening for IBD in the primary care setting. The patient population in the model was a hypothetical cohort of adult patients aged 19 to 64 years old, who present with gastrointestinal symptoms suggestive of IBD in a primary care setting but are not suspected of having cancer that needs for urgent referral. A decision tree was

1  
2  
3 developed in Microsoft Excel where the hypothetical cohort of adult patients underwent certain  
4 pathways. The associated cost and effectiveness of each pathway was captured in the model and  
5  
6 the expected cost and effectiveness was estimated.  
7  
8  
9

10  
11 Effectiveness was measured using quality-adjusted life years (QALYs). The time horizon for the  
12 cost-effectiveness analysis was one year as this was a reasonable length of time for a patient to  
13 reach a confirmed diagnosis of either IBD or non-IBD. We did not consider the longer time  
14 horizon mainly due to the limited direct data and evidence to enable us to estimate the long term  
15 impact and the possibility of adding more uncertainties and assumptions in terms of  
16 management/treatment pathway for IBD and non-IBD. Due to the brief time horizon, discounting  
17 was not applied to either costs or benefits in this analysis. Time to IBD diagnosis was also  
18 estimated from the model. The analysis perspective was the Canadian health sector.  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32

33 The clinical pathways of patients presenting with gastrointestinal symptoms in primary care were  
34 established from published literature<sup>6,12,15-17</sup> as well as input by two gastroenterologists from St.  
35 Paul's Hospital, Vancouver. Established clinical pathways were consistent with the best-practice  
36 clinical care pathway for management of IBS in primary care as outlined by the Canadian  
37 Association of Gastroenterology<sup>18</sup> and local primary care guidelines on the use of FC in UK.<sup>11,14</sup>  
38  
39  
40  
41  
42  
43  
44  
45  
46

47 Figure 1 illustrates the current practice using the standard blood test whereas Figure 2 depicts the  
48 proposed strategy of adding FC test as a diagnostic support tool for general practitioners (GPs).  
49 Under the current practice (Figure 1), based on results of the blood investigation (ESR and CRP),  
50 a GP will make a decision on whether to refer patients to specialist care or not. Patients with  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 abnormal blood results will be referred to gastroenterology for specialist assessment. The  
4  
5 specialist may then order an endoscopy as necessary to confirm IBD diagnosis or follow-up with  
6  
7 patients unlikely to have IBD and monitor their symptoms accordingly. If symptoms are still  
8  
9 persistent after 3 months (assumed and same as Waugh *et al.*<sup>6</sup>), an endoscopy may be ordered at  
10  
11 the specialist follow-up visit to confirm diagnosis of IBD. Under the proposed strategy of adding  
12  
13 FC test (Figure 2), patients with positive results of FC test will be referred to specialist care and  
14  
15 an endoscopy will be ordered for them at the specialist visit to confirm diagnosis of IBD.  
16  
17  
18  
19  
20

21 Patients with normal blood results or negative FC test results will be followed-up by the GP and  
22  
23 receive lifestyle and dietary advice with appropriate medication to treat symptoms for 3 months  
24  
25 (assumed) (Figure 3). Those with symptoms inadequately controlled will receive more intensive  
26  
27 management (different medication) from their GP for another 4 weeks (assumed). If symptoms  
28  
29 are still persistent, further assessment by a gastroenterologist and endoscopy will be performed.  
30  
31  
32  
33  
34

### 35 **Model parameters**

36  
37 The model parameters (Table 1) were obtained from literature or based on assumptions. The  
38  
39 parameters include sensitivity and specificity for FC testing at the 100 $\mu$ g/g cut-off and  $\geq 15$ mm/h  
40  
41 for ESR and  $\geq 5$ mg/l for CRP blood testing; prevalence of IBD in primary care; the ratio of UC  
42  
43 and CD; non-IBD patients with negative test results; costs; utilities; and waiting time.  
44  
45  
46  
47  
48

#### 49 *Sensitivity and specificity*

50  
51 As mentioned above, the majority of studies measuring FC testing accuracy were conducted in  
52  
53 the secondary care setting. As such, we used the sensitivity and specificity of FC testing at the  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 100µg/g cut-off from the recent UK study conducted with the prospective primary cohort.<sup>9</sup> For  
4  
5 blood testing, we chose the cut-offs of  $\geq 15$ mm/h for ESR and  $\geq 5$ mg/l for CRP. Three studies  
6  
7 using these ESR and CRP cut-offs were identified from a published systematic review.<sup>5,19–21</sup>  
8  
9  
10 Following this, a meta-analysis was conducted to synthesize the logit-transformation of  
11  
12 sensitivity and specificity and the details can be found in the Supplementary file.  
13  
14  
15

### 16 17 *Prevalence of IBD in primary care*

18  
19 Very few studies have estimated the prevalence of IBD in primary care,<sup>6,9,22–24</sup> with most  
20  
21 estimates originating from UK studies. To be consistent with the sensitivity and specificity  
22  
23 estimates used in our model, we used the prevalence of IBD (=6.8%) in primary care from the  
24  
25 same study.<sup>9</sup> Among IBD cases, 45% were UC and 55% were CD.<sup>3</sup>  
26  
27  
28  
29

### 30 31 *Non-IBD patients with negative test results*

32  
33 Previous studies estimated a 50% or 60% probability of non-IBD patients still having  
34  
35 persistent symptoms after the initial management by GPs, estimates were based on expert  
36  
37 opinion.<sup>15–17</sup> In our study, we applied the 47% probability used in the cost-effectiveness  
38  
39 analysis conducted by Waugh *et al.*<sup>6</sup> We also assumed that 15% of these who have persistent  
40  
41 symptoms after initial management by GP (based on expert advice) would subsequently  
42  
43 experience uncontrolled symptoms after further intensive management by GPs, be referred to  
44  
45 a specialist, and undergo endoscopy.  
46  
47  
48  
49  
50

### 51 52 *Costs*

1  
2  
3 Only the diagnosis related costs, including the costs for diagnostic testing (FC, endoscopy, and  
4 pathology) and physician and gastroenterologist visits, were considered. All costs were  
5 reported in 2017 Canadian dollars. Cost data were obtained from the British Columbia  
6 Ministry of Health Medical Services Commission Payment Schedule (July 1, 2017 version)<sup>25</sup>  
7 which is comparable with other provinces in Canada; literature review for colonoscopy cost in  
8 Canada<sup>26</sup> adjusted to 2017 cost using total health care implicit price index;<sup>27</sup> and literature  
9 review and a local gastroenterology clinic for FC testing cost.<sup>6,17</sup> Costs of managing  
10 complications associated with colonoscopy such as bleeding and perforation were not  
11 considered in this analysis due to the unavailability of data.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

### 26 *Utilities*

27  
28 Our utility estimates for IBS were taken from a study conducted among 257 patients in the  
29 United States (US) using EuroQol-5D.<sup>28</sup> The utilities of 0.78 for IBS patients with adequate  
30 relief of symptoms or 0.73 for those with persistent symptoms were applied to non-IBD patients  
31 in our analysis.<sup>28</sup> A weighted IBS utility of 0.76 was calculated based on the proportion (47%  
32 assumed above) of non-IBD patients with persistent symptoms and the remaining 53% with  
33 adequately controlled symptoms. In our model, patients with adequately controlled symptoms  
34 started with a weighted utility of 0.76 until the time of diagnosis, wherein a weighted utility of  
35 0.78 (utility for adequately controlled) was applied for the rest of the one-year time horizon.  
36  
37 Patients with persistent symptoms started with 0.73 (utility for persistent symptoms) until the  
38 time of diagnosis followed by 0.78 if symptoms were eventually controlled or 0.76 if they had to  
39 undergo endoscopy.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Similar to Waugh *et al.*<sup>6</sup>, our utility estimates of IBD were taken from a study conducted among  
4 225 CD patients and 219 UC patients in Germany using the EuroQol-5D.<sup>29</sup> This study had a  
5 reasonably large sample size and reported utility estimates for active disease compared with  
6 remission for both UC and CD. The utility estimates of 0.71 for active UC and 0.61 for active  
7 CD were chosen to represent the utility of IBD patients when they visited GP for the first time.  
8 We assumed that their utilities would then decrease by a certain amount every month due to  
9 disease progression until diagnosis was made, at which point the utility value at the time of  
10 diagnosis would be maintained throughout the rest of the one-year time horizon. Following the  
11 method of Waugh *et al.* by taking the utility difference between active disease and remission and  
12 dividing it by twelve, we derived a monthly utility decrement of 0.0167 for UC and 0.023 for  
13 CD.<sup>6</sup>  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

### 31 *Waiting time*

32  
33 The median time an IBD patient was first referred to specialist until consultation by a specialist  
34 was 72 days (95% confidence interval (CI) 52-121) and the median time from the first specialist  
35 consultation to endoscopy was 44 days (95% CI: 27-100) in Canada.<sup>30</sup> The median time for non-  
36 IBD patients from the first referral to specialist consultation was 126 days (95% CI: 103-141).<sup>30</sup>  
37  
38 Other wait times were assumed to be fixed according to the guidelines.  
39  
40  
41  
42  
43  
44  
45  
46

### 47 **Analyses**

48  
49 All costs were reported in 2017 Canadian dollars. We performed probabilistic analyses to  
50 estimate means and 95% CI of total costs, QALYs, and incremental cost-effectiveness ratios  
51 (ICERs) to reflect the underlying parameter uncertainty. Additionally, the time to the diagnosis  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 of IBD among IBD patients was calculated. A total of 5,000 Monte Carlo simulations were  
4  
5 generated from the parameter probability distributions. The base-case results were presented in a  
6  
7 cost-effectiveness plane (Supplementary file) and as the cost-effectiveness acceptability curve,  
8  
9 which demonstrates the probability of the FC testing strategy being cost-effective compared to  
10  
11 the standard care across a range of willingness-to-pay thresholds.  
12  
13  
14

15  
16  
17 To explore the sensitivity of results to specific parameter uncertainty, alternative assumptions  
18  
19 and sources of data, we also conducted a series of scenario analyses. 1) IBD prevalence was  
20  
21 varied from 5% to 20% in 5% increments. 2) FC testing accuracy was changed using an  
22  
23 alternative data source. The sensitivity and specificity for repeating FC testing among the first  
24  
25 FC testing  $\geq 100\mu\text{g/g}$  in Turvill *et al.*<sup>12</sup> were used in the model. 3) The sensitivity and specificity  
26  
27 of the primary care practice in Waugh *et al.*<sup>6</sup> was used. 5) We increased the proportion of  
28  
29 patients with abnormal blood test for whom an endoscopy was ordered in the initial  
30  
31 gastroenterologist consultation from 83% to 100%. 6) We changed the proportion of non-IBD  
32  
33 patients with symptoms after further intensive management by GPs that needed further  
34  
35 investigation by specialist and endoscopy from 5% (same as Waugh *et al.*<sup>6</sup> and Whitehead and  
36  
37 Hutton.<sup>15</sup>) to 30% with 5% increments. 7) Different FC test costs and an increase or decrease in  
38  
39 other costs by 20% were implemented. 8) We changed the source of utility decrement estimates  
40  
41 from Stark *et al.*<sup>29</sup> to that of Gregor *et al.*<sup>31</sup> and Poole *et al.*<sup>32</sup> 9) Time taken to the first follow-up  
42  
43 by GP and time taken to follow-up by a specialist were changed from 1 month to 4 months with  
44  
45 1-month increments. 10) We applied our model to a patient population without gastrointestinal  
46  
47 alarm symptoms described by Walker *et al.*<sup>9</sup>  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Patient and public involvement

Patients and/or public were not involved in our study. A hypothetical cohort of adult patients has been simulated.

## RESULTS

### Base case

For the base case, the probabilistic analysis based on 5,000 Monte Carlo simulations showed that the FC testing strategy was about \$21 more expensive on average than the standard practice using blood test (\$295.12 vs. \$273.93) but yielded a slightly higher QALY (0.751 vs. 0.750, respectively) (Table 2). Thus, the ICER was \$20,323.35 per QALY gained. The time to diagnosis for IBD patients was 39.96 days (95% CI: 16.34-65.29) shorter under the FC testing strategy (192.39 days (95% CI: 143.10-239.74) than standard practice (232.36 days (95% CI: 186.02-277.92)). There was an 81.3% probability that the FC testing strategy was cost-effective at the willingness-to-pay threshold of \$50,000/QALY (Figure 4).

### Scenario analyses

Our analyses showed that the cost-effectiveness of FC testing strategy was sensitive to the prevalence of IBD among the patients presenting with gastrointestinal symptoms in primary care, the FC cost, and the value of utility decrements (Table 2). When the prevalence increased to 20%, the probability of FC testing strategy being cost-effective would increase to 96.7% at the threshold of \$50,000/QALY. The price threshold at which FC testing strategy became cost-effective was \$70. At \$70, the probability of FC testing being cost-effective was 47.4% at the willingness-to-pay threshold of \$50,000/QALY. When applying a much lower utility monthly

1  
2  
3 decrement especially for CD (from 0.023 to 0.006 for CD and from 0.017 to 0.014 for UC), the  
4 probability of FC testing strategy was 68.6% at the threshold of \$50,000/QALY.  
5  
6  
7  
8  
9

## 10 **DISCUSSION**

11  
12 Based on cost-effectiveness models built in previous studies,<sup>6,15-17</sup> current practice guidelines in  
13 Canada,<sup>18</sup> and clinical expertise from gastroenterologists, we constructed a decision analytic  
14 model to evaluate the cost-effectiveness of adding FC testing to current practice compared with  
15 the current practice of blood test only in the diagnosis of adult IBD patients in the Canadian  
16 primary care setting. To our knowledge, this is the first cost-effectiveness analysis of FC testing  
17 in primary care in Canada. Our base-case analysis suggested that the FC test was cost-effective.  
18 Probabilistic analysis showed that at a willingness-to-pay threshold of \$50,000 per QALY, there  
19 was an 81.3% chance of the FC testing strategy being cost-effective. Scenario analysis  
20 demonstrated that the cost-effectiveness was most sensitive towards prevalence of IBD, monthly  
21 utility decrement of IBD, and cost of FC test.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

38 A 6.8% prevalence of IBD was applied in our base case analysis. This estimate was based on a  
39 prospective UK primary care cohort of patients aged between 18 and 46 years old.<sup>9</sup> The  
40 prevalence was very similar to the one used in the cost-effectiveness analysis conducted by  
41 Waugh *et al.*<sup>6</sup> Among our model population (aged 19-64 years old), the prevalence would be  
42 likely to be higher. Unfortunately, Canadian estimates were not found in published literature.  
43  
44  
45  
46  
47  
48  
49 Thus, we conducted scenario analysis by varying the prevalence from 5% to 20%. Although the  
50 cost-effectiveness of the FC testing strategy was highly sensitive to the prevalence of IBD in the  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 adult patient population presented in the primary care setting, our study has shown it is still cost-  
4  
5 effective when the prevalence is as low as 5%.  
6  
7

8  
9  
10 The ICER of the FC testing strategy compared with blood testing increased when the monthly  
11  
12 utility decrement for IBD was lower. This finding is consistent with the assumption made in the  
13  
14 calculation of QALYs for IBD patients. A delay in diagnosis would cause patients to reach a  
15  
16 lower utility value before diagnosis. Therefore, a higher utility decrement for IBD increased the  
17  
18 difference in QALYs gained between the two strategies and caused a decrease in ICER and vice  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
versa.

We used the current FC test cost, \$40, in our base case, which was consistent with the cost used  
in previous cost-effectiveness analyses conducted in the UK and US.<sup>6,17</sup> When the cost of FC  
testing was under \$70, the FC testing strategy had the potential to be cost-effective. The wider  
implementation of FC testing across Canada may drive the cost down. Laboratory-based FC  
testing has been shown to be cost-effective when conducted in batches.<sup>6,10</sup>

One of the strengths of our study is that we used the FC testing accuracy in primary care<sup>9</sup>  
instead of the secondary care setting. The test accuracy in the secondary care setting was found  
to be higher than that of primary care setting. According to the most recent meta-analysis  
conducted by Waugh *et al.*,<sup>6</sup> all of studies included were for secondary setting and the  
synthesized sensitivity (0.93) and specificity (0.94) of FC testing at the 50µg/g cut-off were both  
higher than the estimates (0.86 and 0.90) for the 100µg/g cut-off we used for the primary care

1  
2  
3 setting. However, the sensitivity and specificity values of CRP/ESR in our study were derived  
4  
5 from secondary care sources<sup>19-21</sup> and thus might differ in primary care setting.  
6  
7

8  
9  
10 Additionally, we estimated the benefit of using FC testing in primary care in terms of reducing  
11  
12 the time to IBD diagnosis (by about 40 days). The average times to IBD diagnosis among IBD  
13  
14 patients were 192.4 days with FC testing and 232.4 days for standard practice. The time to  
15  
16 diagnosis under the standard practice was reasonably consistent with a Canadian study that  
17  
18 reported the mean time to diagnosis for CD and UC to be 255.5 and 202.3 days, respectively.<sup>33</sup>  
19  
20 Delayed diagnosis is a common problem in IBD. A study involving 1,591 IBD patients from the  
21  
22 Swiss IBD cohort reported a diagnostic delay of 9 and 4 months for CD and UC.<sup>34</sup> The delay was  
23  
24 due to similarities in symptoms among patients with mild IBD and those with IBS. A literature  
25  
26 review on natural history studies of CD reported that at time of diagnosis, one third of patients  
27  
28 already had intestinal complications such as ileitis, colitis, or ileocolitis.<sup>35</sup> In UC, an early  
29  
30 diagnosis and identification of patients with a high risk of developing complicated disease, is  
31  
32 crucial for choosing appropriate treatment and prevention of colectomies.<sup>36</sup> The FC testing  
33  
34 strategy has the potential to speed up diagnosis and reduce the wait time for a specialist and  
35  
36 endoscopy by avoiding the unnecessary referrals.  
37  
38  
39  
40  
41  
42  
43

44 Our study has several limitations. Firstly, there was a lack of data for certain parameter inputs of  
45  
46 the model. For example, costs and utility decrements of complications associated with  
47  
48 colonoscopy such as bleeding and perforation could not be identified and were therefore not  
49  
50 considered in this analysis. In Canada, the pooled rates of colonoscopy-related bleeding,  
51  
52 perforation, and mortality were 1.64/1000, 0.85/1000, and 0.074/1000, respectively.<sup>37</sup> While the  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 rates of complications associated with colonoscopy may be low, the impact on the overall costs  
4 and outcomes may be significant if the time horizon of the analysis was longer, especially when  
5 deaths occur. As the number of colonoscopies were expected to be reduced by FC testing, we  
6 took a more conservative approach by not considering the impact of the complications associated  
7 with colonoscopies. Data on the utility decrement of IBD due to delayed diagnosis was also  
8 unavailable. Therefore, we adopted the approach used in Waugh *et al.*,<sup>6</sup> assuming the annual  
9 utility decrement of IBD due to delayed diagnosis as the difference between active disease and  
10 remission of UC. While our CEA was limited to costs from a health sector perspective,  
11 considering costs from a societal perspective, e.g., productivity losses due to colonoscopy, would  
12 further make FC testing more cost effective.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27

28 Secondly, we did not consider a longer time horizon. In long term, because of the early  
29 diagnosis, we expect FC to generate more benefits, e.g., avoiding mortality/risk resulting from  
30 reduced unnecessary colonoscopies or bowel perforations/surgeries. Therefore, our study  
31 provides a relatively conservative cost-effectiveness results. Adopting a long-term horizon would  
32 produce more favourable results for FC and hence our finding that FC is cost-effective should  
33 hold in the long-run.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

45 Thirdly, some modelling assumptions we made may have simplified actual clinical practice. For  
46 instance, the modelling assumed that patients with FC levels above 100µg/g have positive test  
47 results and patients with FC levels below 100µg/g have negative test results. Subsequently, every  
48 patient who tests positive is referred to secondary care and will receive endoscopy. The  
49 modelling does not consider indeterminate results of FC testing and assumes that FC testing is  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 only carried out once and is not repeated in the diagnosis pathway. In actual practice, patients  
4 whose initial FC test results were found to be within an indeterminate range, for example  
5 between 100µg/g to 250µg/g, may be subjected to a second FC test and only be referred to a  
6 specialist if the result of the second FC test still yielded a result above 100µg/g. Literature  
7 showed that over 10% of patients had results which fell in this 'grey zone'.<sup>16</sup> Retesting patients  
8 with indeterminate results will essentially increase the cost of the FC testing strategy. However,  
9 the impact of retesting on the overall costs will depend on the proportion of patients who fall  
10 back to FC levels below 100µg/g and would not need to be referred unnecessarily, avoiding the  
11 costs of specialist consultations and colonoscopies. Turvill et al. recently compared such  
12 retesting FC strategy for the first FC test  $\geq 100\mu\text{g/g}$  with using CRP/ESR testing without FC  
13 testing in a UK primary care setting.<sup>12</sup> They found retesting FC strategy to be cost-saving, due to  
14 saving 100-150 unnecessary colonoscopies and 140-190 gastroenterology outpatient  
15 appointments, with the trade-off being 4 incorrectly diagnosed IBD patients. The utility of the  
16 second FC test is that it can cut out a high proportion of false positive test results, resulting in  
17 overall cost-savings. The future research should focus on these kinds of confirmatory testing  
18 strategies.

19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42 Additionally, our modelling assumed 100% patient uptake for every diagnostic test, blood test,  
43 FC test, and endoscopy. Given the invasive nature and set of complications associated with  
44 colonoscopies, patients may refuse this diagnostic test. The FC test may also not be widely  
45 accepted, with a variable uptake rate between primary and secondary care. Some patients might  
46 decline to produce a sample of feces for their GP, but may possibly be willing to do so for a  
47 gastroenterologist if the alternative is colonoscopy. Recently, a home-based FC kit has been  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 made available, allowing patients to measure the concentration of FC directly using a rapid  
4 immunochromatographic assay captured by a smartphone's camera. The availability of this kit  
5 may increase the uptake and patient adherence of FC testing.<sup>38</sup>  
6  
7  
8  
9

10  
11  
12 It is worth noticing that FC test accuracy might differ by populations with different age or in  
13 different settings. We used test sensitivity and specificity values from Walker et al.,<sup>9</sup> which  
14 focused on young adults between 18 and 46 years old in UK and might not be applicable to our  
15 model population aged 19-64 years old. In addition, different FC tests produced by different  
16 manufacturers and using different platforms, can produce significantly different test results (i.e.  
17 between-method bias).<sup>6</sup> This means that the sensitivity and specificity values adopted in our  
18 study (based on Walker et al.<sup>9</sup> using a specific ELISA test), may not hold for different  
19 laboratories with different pre-analytical and analytical operating procedures and/or using  
20 different test kits/methods. This is potentially a significant issue for home-based FC kits since  
21 the benefits of increased uptake of testing may be negated by issues with test imprecision and  
22 bias.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

40 Future research can be conducted to estimate the cost-effectiveness of FC test for distinguishing  
41 between IBD and non-IBD in the paediatrics population when the important model parameters  
42 are available. Furthermore, there has also been growing interest in the use of FC test in a few  
43 areas of IBD management. For example, FC test might be used to monitor disease progression,  
44 predict relapse and monitor response to treatment.<sup>39</sup> As such, an economic model which links the  
45 diagnostic outcomes of this analysis to the management of IBD in terms of treatment and  
46 monitoring can be considered in the future.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5 In conclusion, using FC at the 100µg/g cut-off in primary care in the diagnosis of IBD can be a  
6  
7  
8 cost-effective strategy and can speed up IBD diagnosis in adults who present with  
9  
10 gastrointestinal symptoms in Canada.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

**Author Statement:**

WZ and GR designed the study. All authors contributed to the cost-effectiveness model: CHW initiated the model, MC, TM and GR contributed their expertise in the model building and parameter determination, and WZ modified and finalized the model. WZ and CHW drafted the manuscript and all authors significantly contributed to and reviewed the final manuscript. All authors agree to be accountable for all aspects of the work.

**Funding:** This work was supported by the Future Leaders in Inflammatory Bowel Disease (FLIBD) Grant.

**Competing interests:** None declared.

**Ethics approval:** Not applicable. A hypothetical cohort of adult patients has been simulated.

**Data sharing statement:** There is no additional unpublished data from the study.

**Open access:** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

## REFERENCES

1. Irvine EJ. Quality of life of patients with ulcerative colitis: past, present, and future. *Inflamm. Bowel Dis.* 2008;14:554–565.
2. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. *Lancet Lond. Engl.* 2018;390:2769–2778.
3. Rocchi A, Benchimol EI, Bernstein CN, et al. Inflammatory bowel disease: a Canadian burden of illness review. *Can. J. Gastroenterol. J. Can. Gastroenterol.* 2012;26:811–817.
4. Walsham NE, Sherwood RA. Fecal calprotectin in inflammatory bowel disease. *Clin. Exp. Gastroenterol.* 2016;9:21–29.
5. Jellema P, Windt D a. WM van der, Schellevis FG, et al. Systematic review: accuracy of symptom-based criteria for diagnosis of irritable bowel syndrome in primary care. *Aliment. Pharmacol. Ther.* 2009;30:695–706.
6. Waugh N, Cummins E, Royle P, et al. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation. *Health Technol. Assess. Winch. Engl.* 2013;17:xv–xix, 1–211.
7. Rheenen PF van, Vijver EV de, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. *BMJ.* 2010;341:c3369.
8. Rosenfeld G, Greenup A-J, Round A, et al. FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease. *World J. Gastroenterol.* 2016;22:8211–8218.
9. Walker GJ, Moore L, Heerasing N, et al. Faecal calprotectin effectively excludes inflammatory bowel disease in 789 symptomatic young adults with/without alarm symptoms: a prospective UK primary care cohort study. *Aliment. Pharmacol. Ther.* 2018;47:1103–1116.

- 1  
2  
3 10. NICE. Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel |  
4 Guidance and guidelines. Available at: <https://www.nice.org.uk/guidance/dg11> [Accessed  
5  
6 January 18, 2018].  
7
- 8  
9  
10 11. NHS England. Faecal Calprotectin in Primary Care as a Decision Diagnostic for  
11 Inflammatory Bowel Disease and Irritable Bowel Syndrome. Available at: <https://www.pcc->  
12 [cic.org.uk/sites/default/files/articles/attachments/fcp\\_consensus\\_paper\\_2018\\_0.pdf](https://www.pcc-cic.org.uk/sites/default/files/articles/attachments/fcp_consensus_paper_2018_0.pdf) [Accessed  
13  
14 December 9, 2018].  
15  
16
- 17  
18  
19 12. Turvill J, Turnock D, Holmes H, et al. Evaluation of the clinical and cost-effectiveness of  
20 the York Faecal Calprotectin Care Pathway. *Frontline Gastroenterol.* 2018;9:285–294.  
21  
22
- 23  
24 13. GIS. Fecal Calprotectin Test. *Gastrointest. Soc.* Available at:  
25  
26 <https://www.badgut.org/information-centre/a-z-digestive-topics/fecal-calprotectin-test/>  
27  
28 [Accessed January 18, 2018].  
29
- 30  
31 14. Turvill J. Local Primary Care Guidelines: Use of Faecal Calprotectin in the Assessment  
32 of Patients with Lower Gastrointestinal Symptoms. 2014. Available at:  
33  
34 [https://www.nice.org.uk/guidance/dg11/resources/primary-care-guidelines--york-teaching-](https://www.nice.org.uk/guidance/dg11/resources/primary-care-guidelines--york-teaching-hospital-pdf-4535195223)  
35 [hospital-pdf-4535195223](https://www.nice.org.uk/guidance/dg11/resources/primary-care-guidelines--york-teaching-hospital-pdf-4535195223).  
36  
37
- 38  
39  
40 15. Whitehead S, Hutton J. *Economic report: Value of calprotectin in screening out irritable*  
41 *bowel syndrome*. York, UK: Centre for Evidence-based Purchasing; 2010.  
42  
43
- 44  
45 16. Dubinsky MC, Johanson JF, Seidman EG, et al. Suspected inflammatory bowel disease--  
46 the clinical and economic impact of competing diagnostic strategies. *Am. J. Gastroenterol.*  
47  
48 2002;97:2333–2342.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 17. Yang Z, Clark N, Park KT. Effectiveness and cost-effectiveness of measuring fecal  
4 calprotectin in diagnosis of inflammatory bowel disease in adults and children. *Clin.*  
5  
6 *Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc.* 2014;12:253-262.e2.  
7  
8  
9  
10 18. Canadian Association of Gastroenterology. Enhanced primary care pathway: IBS. 2016.  
11  
12 Available at: <https://www.cag->  
13  
14 [acg.org/images/publications/IBS\\_Enhanced\\_Primary\\_Care\\_Pathway\\_July\\_2016.pdf](https://www.cag-acg.org/images/publications/IBS_Enhanced_Primary_Care_Pathway_July_2016.pdf).  
15  
16  
17 19. Kaiser T, Langhorst J, Wittkowski H, et al. Faecal S100A12 as a non-invasive marker  
18 distinguishing inflammatory bowel disease from irritable bowel syndrome. *Gut.* 2007;56:1706–  
19  
20 1713.  
21  
22  
23  
24 20. Poullis AP, Zar S, Sundaram KK, et al. A new, highly sensitive assay for C-reactive  
25 protein can aid the differentiation of inflammatory bowel disorders from constipation- and  
26  
27 diarrhoea-predominant functional bowel disorders. *Eur. J. Gastroenterol. Hepatol.* 2002;14:409–  
28  
29 412.  
30  
31  
32  
33 21. Shine B, Berghouse L, Jones JE, et al. C-reactive protein as an aid in the differentiation  
34 of functional and inflammatory bowel disorders. *Clin. Chim. Acta Int. J. Clin. Chem.*  
35  
36 1985;148:105–109.  
37  
38  
39  
40 22. Pavlidis P, Chedgy FJ, Tibble JA. Diagnostic accuracy and clinical application of faecal  
41 calprotectin in adult patients presenting with gastrointestinal symptoms in primary care. *Scand.*  
42  
43 *J. Gastroenterol.* 2013;48:1048–1054.  
44  
45  
46  
47 23. Thompson WG, Heaton KW, Smyth GT, et al. Irritable bowel syndrome in general  
48 practice: prevalence, characteristics, and referral. *Gut.* 2000;46:78–82.  
49  
50  
51 24. Kok L, Elias SG, Wittman BJM, et al. Diagnostic accuracy of point-of-care fecal  
52 calprotectin and immunochemical occult blood tests for diagnosis of organic bowel disease in  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 primary care: the Cost-Effectiveness of a Decision Rule for Abdominal Complaints in Primary  
4 Care (CEDAR) study. *Clin. Chem.* 2012;58:989–998.
- 5  
6  
7  
8 25. British Columbia Ministry of Health. MEDICAL SERVICES COMMISSION  
9 PAYMENT SCHEDULE. 2017. Available at:  
10  
11  
12 <https://www2.gov.bc.ca/assets/gov/health/practitioner-pro/medical-services-plan/msc-payment->  
13  
14 [schedule-july-2017.pdf](https://www2.gov.bc.ca/assets/gov/health/practitioner-pro/medical-services-plan/msc-payment-schedule-july-2017.pdf).
- 15  
16  
17 26. Sharara N, Adam V, Crott R, et al. The costs of colonoscopy in a Canadian hospital using  
18 a microcosting approach. *Can. J. Gastroenterol.* 2008;22:565–570.
- 19  
20  
21 27. Canadian Institute for Health Information. National Health Expenditure Trends. 2018.  
22 Available at: <https://www.cihi.ca/en/national-health-expenditure-trends> [Accessed January 23,  
23  
24 2018].
- 25  
26  
27 28. Spiegel B, Harris L, Lucak S, et al. Developing valid and reliable health utilities in  
28 irritable bowel syndrome: results from the IBS PROOF Cohort. *Am. J. Gastroenterol.*  
29  
30 2009;104:1984–1991.
- 31  
32  
33 29. Stark RG, Reitmeir P, Leidl R, et al. Validity, reliability, and responsiveness of the EQ-  
34 5D in inflammatory bowel disease in Germany. *Inflamm. Bowel Dis.* 2010;16:42–51.
- 35  
36  
37 30. Leddin D, Armstrong D, Borgaonkar M, et al. The 2012 SAGE wait times program:  
38 Survey of Access to GastroEnterology in Canada. *Can. J. Gastroenterol.* 2013;27:83–89.
- 39  
40  
41 31. Gregor JC, McDonald JW, Klar N, et al. An evaluation of utility measurement in Crohn's  
42 disease. *Inflamm. Bowel Dis.* 1997;3:265–276.
- 43  
44  
45 32. Poole CD, Connolly MP, Nielsen SK, et al. A comparison of physician-rated disease  
46 severity and patient reported outcomes in mild to moderately active ulcerative colitis. *J. Crohns*  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 33. Benchimol EI, Manuel DG, Mojaverian N, et al. Health Services Utilization, Specialist  
4 Care, and Time to Diagnosis with Inflammatory Bowel Disease in Immigrants to Ontario,  
5 Canada: A Population-Based Cohort Study. *Inflamm. Bowel Dis.* 2016;22:2482–2490.  
6  
7  
8  
9  
10 34. Vavricka SR, Spigaglia SM, Rogler G, et al. Systematic evaluation of risk factors for  
11 diagnostic delay in inflammatory bowel disease. *Inflamm. Bowel Dis.* 2012;18:496–505.  
12  
13  
14 35. Peyrin-Biroulet L, Loftus EV, Colombel J-F, et al. The natural history of adult Crohn's  
15 disease in population-based cohorts. *Am. J. Gastroenterol.* 2010;105:289–297.  
16  
17  
18 36. Monstad I, Hovde Ø, Solberg IC, et al. Clinical course and prognosis in ulcerative colitis:  
19 results from population-based and observational studies. *Ann. Gastroenterol. Q. Publ. Hell. Soc.*  
20  
21  
22  
23  
24  
25  
26 37. Rabeneck L, Paszat LF, Hilsden RJ, et al. Bleeding and perforation after outpatient  
27 colonoscopy and their risk factors in usual clinical practice. *Gastroenterology.* 2008;135:1899–  
28  
29  
30  
31  
32 1906, 1906.e1.  
33 38. Bello C, Roseth A, Guardiola J, et al. Usability of a home-based test for the measurement  
34 of fecal calprotectin in asymptomatic IBD patients. *Dig. Liver Dis. Off. J. Ital. Soc.*  
35  
36  
37  
38  
39  
40 39. Ikhtaire S, Shajib MS, Reinisch W, et al. Fecal calprotectin: its scope and utility in the  
41 management of inflammatory bowel disease. *J. Gastroenterol.* 2016;51:434–446.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1. Model input parameters**

| Parameter  | Estimate | Distribution                 | Distribution parameters                    | Data source  |
|--|----------|------------------------------|--|--|
| IBD prevalence, %  | 6.8      | Beta                         | Alpha = 50<br>Beta = 689                   | Walker et al. <sup>9</sup>   |
| UC proportion, %   | 44.6     | Fixed                        |  | Rocchi et al. <sup>3</sup>   |
| <b>Test accuracy</b>   |          |                              |  |  |
| Sensitivity  |          |                              |  |  |
| Blood test   | 0.649    | Normal, logit transformation | Logit estimate = 0.613<br>Logit SE = 0.199 | Meta-analysis based on a systematic review of three studies <sup>5,19-21</sup> |
| FC test, at 100µg/g cut-off  | 0.860    | Beta                         | Alpha = 43<br>Beta = 7                     | Walker et al. <sup>9</sup>   |
| Specificity  |          |                              |  |  |
| Blood test   | 0.866    | Normal, logit transformation | Logit estimate = 1.867<br>Logit SE = 0.196 | Meta-analysis based on a systematic review of three studies <sup>5,19-21</sup> |
| FC test, at 100µg/g cut-off  | 0.901    | Beta                         | Alpha = 621<br>Beta = 68                   | Walker et al. <sup>9</sup>   |
| <b>Model probabilities, %</b>  |          |                              |  |  |
| Proportion of patients with abnormal blood test with endoscopy ordered in the initial gastroenterologist consultation                              | 88.3     | Beta                         | Alpha = 7.520<br>Beta = 0.993              | Expert opinion   |
| Proportion of non-IBD patients with persistent symptoms after the initial management by GPs  | 47.0     | Log-normal                   | 95% CI: 33-57                              | Waugh et al. <sup>6</sup>  |
| Proportion of non-IBD patients with symptoms after further intensive management by GPs that need further investigation by specialist and endoscopy | 15.0     | Fixed                        |  | Expert opinion   |
| <b>Cost estimates (\$)</b>   |          |                              |  |  |
| FC test  | 40.00    | Fixed                        |  | Local clinic cost, Waugh et al. <sup>6</sup> and Yang et al. <sup>17</sup>     |
| Initial GP visit   | 68.64    | Fixed                        |  | BC MSC payment schedule <sup>25</sup>  |
| Follow-up GP visit   | 30.92    | Fixed                        |  | BC MSC payment schedule <sup>25</sup>  |
| Initial gastroenterologist consultation  | 160.25   | Fixed                        |  | BC MSC payment schedule <sup>25</sup>  |



| Parameter  | Estimate | Distribution | Distribution parameters  | Data source                           |
|--|----------|--------------|--|---------------------------------------|
| Follow-up gastroenterologist consultation  | 97.39    | Fixed        |  | BC MSC payment schedule <sup>25</sup> |
| Surgical pathology   | 85.52    | Fixed        |  | BC MSC payment schedule <sup>25</sup> |
| Colonoscopy, with biopsy   | 427.70   | Fixed        |  | Sharara et al. <sup>26</sup>          |
| <b>Utilities</b>   |          |              |  |                                       |
| <b>Non-IBD</b>   |          |              |  |                                       |
| a) With adequately controlled symptoms   | 0.78     | Beta         | Alpha = 5.367<br>Beta = 1.514  | Spiegel et al. <sup>28</sup>          |
| b) With persistent symptoms  | 0.73     |              | Calculated from a/c  | Spiegel et al. <sup>28</sup>          |
| c) Fixed ratio for utility of adequately controlled over persistent symptoms                   |          | Fixed        | 1.068  |                                       |
| Weighted IBS utility   | 0.76     |              | Calculated from a), b) and Proportion of non-IBD patients with persistent symptoms above |                                       |
| <b>IBD</b>   |          |              |  |                                       |
| Active UC  | 0.71     | Beta         | Alpha = 3.802<br>Beta = 1.553  | Stark et al. <sup>29</sup>            |
| Active CD  | 0.61     | Beta         | Alpha = 1.116<br>Beta = 0.713  | Stark et al. <sup>29</sup>            |
| Monthly utility decrement for UC   | 0.017    | Beta         | Alpha = 1.601<br>Beta = 94.443   | Stark et al. <sup>29</sup>            |
| Monthly utility decrement for CD   | 0.023    | Beta         | Alpha = 1.647<br>Beta = 68.958   | Stark et al. <sup>29</sup>            |
| <b>Wait time</b>   |          |              |  |                                       |
| Time taken to undergo blood test and/or FC test after presenting with symptoms in primary care | 7 days   | Fixed        |  | Expert opinion                        |
| Time taken to obtain results of blood test and FC test   | 7 days   | Fixed        |  | Expert opinion                        |
| Time taken to follow-up by GP first time   | 3 months | Fixed        |  | Expert opinion                        |
| Time taken to follow-up by GP second time  | 4 weeks  | Fixed        |  | Expert opinion                        |
| Time taken to a specialist consultation for IBD patients                                       | 86.50    | Normal       | SE=17.602  | Leddin et al. <sup>30</sup>           |
| Time taken to a specialist consultation for non-IBD patients                                   | 122.00   | Normal       | SE=9.694   | Leddin et al. <sup>30</sup>           |
| Time taken to endoscopy after seeing a specialist  | 63.50    | Normal       | SE=18.622  | Leddin et al. <sup>30</sup>           |

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

| <b>Parameter</b>                        | <b>Estimate</b> | <b>Distribution</b> | <b>Distribution parameters</b> | <b>Data source</b> |
|---|-----------------|---------------------|--------------------------------|--------------------|
| Time taken to follow-up by a specialist | 3 months        | Fixed               |                                | Expert opinion     |

IBD: inflammatory bowel disease; UC: ulcerative colitis; CD: Crohn's disease; FC: fecal calprotectin; GP: general practitioner; IBS: irritable bowel syndrome; SE: standard error; MSC: Medical Services Commission

For peer review only

Table 2. Results of base-case analysis and scenario analyses

| Scenario   | FC testing strategy       |                        | Standard practice (blood test) |                        | Incremental Cost         | Incremental QALY        | ICER (\$/QALY) | Probability of FC being cost-effective* |
|--|---------------------------|------------------------|--------------------------------|------------------------|--------------------------|-------------------------|----------------|---|
|  | Cost, \$                  | QALY                   | Cost, \$                       | QALY                   |                          |                         |                |   |
| <b>Base-case</b>   | 295.12<br>(274.49,317.53) | 0.751<br>(0.431,0.939) | 273.93<br>(245.40,306.05)      | 0.750<br>(0.430,0.938) | 21.19 (-<br>7.50,46.57)  | 0.001<br>(0.0003,0.002) | 20,323.35      | 81.3%                                   |
| <b>Scenario Analyses</b>   |                           |                        |                                |                        |                          |                         |                |   |
| <b>IBD prevalence, %</b>   |                           |                        |                                |                        |                          |                         |                |   |
| 5  | 286.17<br>(268.43,306.09) | 0.757<br>(0.427,0.943) | 264.65<br>(238.41,294.96)      | 0.756<br>(0.426,0.942) | 21.52 (-<br>7.75,46.72)  | 0.001<br>(0.0002,0.002) | 24,440.81      | 75.5%                                   |
| 10   | 312.60<br>(295.98,331.11) | 0.743<br>(0.434,0.928) | 291.21<br>(267.12,319.28)      | 0.742<br>(0.433,0.927) | 21.39 (-<br>5.67,45.80)  | 0.001<br>(0.0004,0.003) | 15,594.08      | 89.3%                                   |
| 15   | 339.26<br>(323.00,357.86) | 0.740<br>(0.448,0.916) | 318.14<br>(294.04,345.63)      | 0.738<br>(0.447,0.915) | 21.12 (-<br>5.02,43.94)  | 0.002<br>(0.0004,0.005) | 11,515.23      | 93.8%                                   |
| 20   | 365.81<br>(350.40,383.68) | 0.728<br>(0.442,0.907) | 344.93<br>(322.74,371.08)      | 0.725<br>(0.440,0.904) | 20.88 (-<br>3.94,41.96)  | 0.002<br>(0.0006,0.006) | 8,843.74       | 96.7%                                   |
| <b>FC test accuracy (Turvill et al.<sup>12</sup>)</b>  |                           |                        |                                |                        |                          |                         |                |   |
| Sensitivity=0.94 (95% CI:<br>0.85-0.98)  | 285.36<br>(265.56,306.98) | 0.755<br>(0.431,0.939) | 274.16<br>(245.10,306.04)      | 0.754<br>(0.430,0.937) | 11.21 (-<br>16.20,35.83) | 0.001<br>(0.0005,0.003) | 8,012.69       | 96.5%                                   |
| Specificity=0.92 (95% CI<br>0.90-0.94)   |                           |                        |                                |                        |                          |                         |                |   |
| <b>Primary care practice accuracy (Waugh et al.<sup>6</sup>)</b>   |                           |                        |                                |                        |                          |                         |                |   |
| Sensitivity=1 (7/7)  | 295.55                    | 0.753                  | 312.85                         | 0.752                  | -17.30 (-                | 0.001 (-                | N/A            | 93.6%                                   |
| Specificity=0.79 (82/104)  | (275.41,317.36)           | (0.446,0.938)          | (270.56,359.49)                | (0.445,0.937)          | 62.90,22.76)             | 0.0001,0.002)           |                |   |
| <b>Proportion of patients with abnormal blood test with endoscopy ordered in the initial gastroenterologist consultation, %</b>                      |                           |                        |                                |                        |                          |                         |                |   |
| 100  | 295.38<br>(274.60,317.32) | 0.751<br>(0.430,0.938) | 276.23<br>(248.77,307.54)      | 0.750<br>(0.429,0.937) | 19.15 (-<br>10.31,44.69) | 0.001<br>(0.0002,0.002) | 22,007.50      | 76.9%                                   |
| <b>Proportion of non-IBD patients with symptoms after further intensive management by GPs that need investigation by specialist and endoscopy, %</b> |                           |                        |                                |                        |                          |                         |                |   |
| 5  | 268.69<br>(251.37,286.92) | 0.754<br>(0.444,0.940) | 248.96<br>(222.27,278.72)      | 0.753<br>(0.444,0.939) | 19.73 (-<br>10.67,46.48) | 0.001<br>(0.0003,0.003) | 17,988.04      | 83.5%                                   |
| 10   | 281.84<br>(263.26,301.20) | 0.754<br>(0.447,0.938) | 261.12<br>(234.23,290.74)      | 0.753<br>(0.446,0.937) | 20.72 (-<br>8.35,46.16)  | 0.001<br>(0.0002,0.002) | 19,504.34      | 82.4%                                   |
| 20   | 308.68<br>(286.39,332.03) | 0.751<br>(0.426,0.938) | 286.82<br>(257.72,318.88)      | 0.750<br>(0.426,0.938) | 21.85 (-<br>5.70,45.83)  | 0.001<br>(0.0002,0.002) | 21,405.41      | 81.2%                                   |
| 25   | 322.23<br>(297.17,350.17) | 0.749<br>(0.423,0.937) | 300.26<br>(268.29,334.99)      | 0.748<br>(0.422,0.936) | 21.97 (-<br>5.25,45.94)  | 0.001<br>(0.0003,0.002) | 22,040.22      | 79.5%                                   |

| Scenario  | FC testing strategy       |                        | Standard practice<br>(blood test) |                        | Incremental<br>Cost      | Incremental<br>QALY     | ICER<br>(\$/QALY) | Probability of<br>FC being<br>cost-effective* |
|---|---------------------------|------------------------|-----------------------------------|------------------------|--------------------------|-------------------------|-------------------|---|
|   | Cost, \$                  | QALY                   | Cost, \$                          | QALY                   |                          |                         |                   |   |
| 30  | 335.85<br>(308.40,366.80) | 0.750<br>(0.432,0.934) | 313.02<br>(280.31,348.54)         | 0.749<br>(0.431,0.933) | 22.84 (-<br>3.46,45.44)  | 0.001<br>(0.0002,0.002) | 23,221.90         | 78.8%   |
| <b>Cost of FC, \$</b>   |                           |                        |                                   |                        |                          |                         |                   |   |
| 20  | 275.24<br>(254.13,297.02) | 0.755<br>(0.446,0.940) | 273.98<br>(246.12,304.75)         | 0.754<br>(0.445,0.939) | 1.26 (-<br>27.32,25.62)  | 0.001<br>(0.0002,0.002) | 1,206.34          | 94.9%   |
| 30  | 285.21<br>(264.91,307.09) | 0.753<br>(0.436,0.940) | 274.13<br>(246.69,306.58)         | 0.752<br>(0.435,0.939) | 11.08 (-<br>17.29,36.28) | 0.001<br>(0.0003,0.002) | 10,567.51         | 89.8%   |
| 50  | 305.42<br>(284.54,327.76) | 0.751<br>(0.428,0.941) | 274.12<br>(246.34,305.69)         | 0.750<br>(0.428,0.940) | 31.29<br>(2.93,55.78)    | 0.001<br>(0.0003,0.002) | 29,789.72         | 71.7%   |
| 60  | 315.60<br>(295.76,337.54) | 0.751<br>(0.430,0.936) | 274.19<br>(246.49,305.45)         | 0.750<br>(0.430,0.936) | 41.40<br>(13.49,66.07)   | 0.001<br>(0.0002,0.002) | 39,243.50         | 59.8%   |
| 70  | 325.29<br>(305.29,347.98) | 0.753<br>(0.428,0.938) | 274.15<br>(246.63,305.86)         | 0.751<br>(0.427,0.936) | 51.14<br>(22.70,75.99)   | 0.001<br>(0.0002,0.002) | 48,712.48         | 47.4%   |
| <b>All cost estimates except FC test cost, \$</b>   |                           |                        |                                   |                        |                          |                         |                   |   |
| +20%  | 346.68<br>(321.97,372.92) | 0.752<br>(0.430,0.940) | 329.42<br>(295.89,367.82)         | 0.751<br>(0.429,0.939) | 17.26 (-<br>16.39,48.03) | 0.001<br>(0.0003,0.002) | 16,191.86         | 83.4%   |
| -20%  | 244.18<br>(227.92,262.28) | 0.752<br>(0.433,0.936) | 219.14<br>(196.94,244.50)         | 0.751<br>(0.432,0.935) | 25.04<br>(2.13,44.91)    | 0.001<br>(0.0003,0.003) | 23,509.13         | 79.8%   |
| <b>Utility decrement</b>  |                           |                        |                                   |                        |                          |                         |                   |   |
| CD = 0.006 (Gregor et al. <sup>31</sup> )   | 295.11                    | 0.755                  | 274.24                            | 0.755                  | 20.87 (-                 | 0.001                   | 30,136.89         | 68.6%   |
| UC = 0.014 (Poole et al. <sup>32</sup> )  | (274.59,316.66)           | (0.427,0.941)          | (246.79,304.96)                   | (0.427,0.940)          | 6.50,45.47)              | (0.0002,0.001)          |                   |   |
| <b>Time taken to follow-up by GP first time</b>   |                           |                        |                                   |                        |                          |                         |                   |   |
| 1 month   | 294.97<br>(274.80,316.36) | 0.756<br>(0.422,0.945) | 274.09<br>(245.92,306.40)         | 0.755<br>(0.421,0.944) | 20.89 (-<br>8.13,46.10)  | 0.001<br>(0.0002,0.002) | 18,830.57         | 81.9%   |
| 2 months  | 295.36<br>(274.91,317.69) | 0.758<br>(0.437,0.943) | 274.07<br>(246.25,306.46)         | 0.757<br>(0.436,0.942) | 21.29 (-<br>7.90,45.83)  | 0.001<br>(0.0002,0.002) | 19,650.08         | 81.7%   |
| 4 months  | 295.28<br>(275.08,317.76) | 0.749<br>(0.442,0.940) | 274.03<br>(245.76,304.35)         | 0.748<br>(0.441,0.939) | 21.25 (-<br>6.75,45.57)  | 0.001<br>(0.0002,0.002) | 21,451.73         | 80.8%   |
| <b>Time taken to follow-up by a specialist</b>  |                           |                        |                                   |                        |                          |                         |                   |   |
| 1 month   | 295.47<br>(275.10,317.87) | 0.747<br>(0.425,0.937) | 274.37<br>(246.13,305.91)         | 0.746<br>(0.424,0.936) | 21.10 (-<br>7.54,46.45)  | 0.001<br>(0.0002,0.002) | 23,213.73         | 76.1%   |
| 2 months  | 295.35<br>(275.19,318.36) | 0.757<br>(0.435,0.939) | 274.19<br>(247.23,305.55)         | 0.756<br>(0.434,0.937) | 21.16 (-<br>7.75,45.96)  | 0.001<br>(0.0002,0.002) | 21,587.69         | 79.6%   |
| 4 months  | 295.49<br>(274.69,317.09) | 0.751<br>(0.430,0.940) | 274.42<br>(246.23,305.94)         | 0.750<br>(0.429,0.939) | 21.07 (-<br>7.51,46.49)  | 0.001<br>(0.0003,0.003) | 18,991.77         | 83.4%   |
| <b>Patient population without gastrointestinal alarm symptoms (Walker et al.<sup>9</sup>)</b> |                           |                        |                                   |                        |                          |                         |                   |   |

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

| Scenario                     | FC testing strategy |               | Standard practice (blood test) |               | Incremental Cost | Incremental QALY | ICER (\$/QALY) | Probability of FC being cost-effective* |
|------------------------------|---------------------|---------------|--------------------------------|---------------|------------------|------------------|----------------|---|
|                              | Cost, \$            | QALY          | Cost, \$                       | QALY          |                  |                  |                |   |
| Prevalence = 4% (18/447)     | 276.29              | 0.760         | 258.90                         | 0.760         | 17.40 (-         | 0.001            | 21,608.85      | 75.6%                                   |
| Sensitivity = 0.84 (15/18)   | (253.94,299.86)     | (0.429,0.948) | (230.11,291.19)                | (0.429,0.947) | 13.70,44.78)     | (0.0002,0.002)   |                |   |
| Specificity = 0.91 (390/429) |                     |               |                                |               |                  |                  |                |   |

95% confidence intervals (CI) in brackets  
 IBD: inflammatory bowel disease; FC: fecal calprotectin; GP: general practitioner; CD: Crohn's disease; UC: ulcerative colitis; QALY: quality-adjusted life year; ICER: incremental cost-effectiveness ratio  
 \*at \$50,000/QALY threshold

For peer review only

1  
2  
3 **Figure 1. Overview of the model structure for standard practice using blood test**  
4

5 IBD: inflammatory bowel disease; GP: general practitioner  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1  
2  
3 **Figure 2. Overview of the model structure for fecal calprotectin testing strategy**  
4

5 FC: fecal calprotectin IBD: inflammatory bowel disease; GP: general practitioner  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1  
2  
3 **Figure 3. Overview of the decision branch for normal blood test or negative fecal**  
4  
5 **calprotectin test results**  
6

7  
8 FC: fecal calprotectin IBD: inflammatory bowel disease; GP: general practitioner  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Figure 4. Cost-effectiveness acceptability curve**

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1

279x361mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 2

215x279mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 3

279x361mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 4  
279x361mm (300 x 300 DPI)

## Supplementary File

### Meta-analysis for sensitivity and specificity of blood test

Jellema et al. conducted a high quality systematic review that summarized the evidence on the performance of different diagnostic tests including the blood tests (C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)) in patients with abdominal symptoms.<sup>1</sup> They identified four studies that investigated the diagnostic performance of CRP or ESR with different diagnostic cut-off points. The gastroenterologists (Drs. Rosenfeld and Chavannes) in our study selected the studies and the cut-off points that are most relevant to the clinical practice.


**Table 1. Diagnostic performance of studies with test cut-offs of CRP  $\geq 5\text{mg/l}$  and ESR  $\geq 15\text{mm/h}$**

| Study                                    | True Positives | False Positives | True Negatives | False Negatives |
|--|----------------|-----------------|----------------|-----------------|
| Kaiser <i>et al</i> , 2007 <sup>2</sup>  | 29             | 5               | 19             | 21              |
| Poullis <i>et al</i> , 2002 <sup>3</sup> | 11             | 16              | 143            | 9               |
| Shine <i>et al</i> , 1985 <sup>4</sup>   | 32             | 9               | 32             | 9               |

The numbers were directly obtained from Jellema et al.<sup>1</sup>

Subsequently, we have attempted to model these data using a bivariate analysis to take account of the correlation between the sensitivity and specificity based on Reitsma et al.<sup>5</sup> (model specification shown on page 988). However, the estimated covariance matrix was not full rank and might be unreliable, possibly due to our small sample size (only 3 studies). Therefore, we estimated the sensitivity and specificity independently (i.e., without accounting for the correlation between the sensitivity and specificity). The logit estimates for sensitivity and specificity were 0.613 (SE=0.199) and 1.867 (0.196), respectively.

### Cost-effectiveness plane for our base case



### References

1. Jellema P, Windt D a. WM van der, Schellevis FG, et al. Systematic review: accuracy of symptom-based criteria for diagnosis of irritable bowel syndrome in primary care. *Aliment. Pharmacol. Ther.* 2009;30:695–706.
2. Kaiser T, Langhorst J, Wittkowski H, et al. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. *Gut.* 2007;56:1706–1713.
3. Poullis AP, Zar S, Sundaram KK, et al. A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation- and

1  
2  
3 diarrhoea-predominant functional bowel disorders. *Eur J Gastroenterol Hepatol.*  
4  
5 2002;14:409–412.  
6

- 7  
8 4. Shine B, Berghouse L, Jones JE, et al. C-reactive protein as an aid in the differentiation of  
9  
10 functional and inflammatory bowel disorders. *Clin. Chim. Acta.* 1985;148:105–109.  
11  
12 5. Reitsma JB, Glas AS, Rutjes AWS, et al. Bivariate analysis of sensitivity and specificity  
13  
14 produces informative summary measures in diagnostic reviews. *J Clin Epidemiol.*  
15  
16 2005;58:982–990.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



# Reporting checklist for economic evaluation of health interventions

Based on the CHEERS guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the CHEERS reporting guidelines, and cite them as:

Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.

|       | Reporting Item   | Page Number |
|-------|--|-------------|
| Title | <a href="#">#1</a> Identify the study as an economic evaluation or use more specific terms such as “cost-effectiveness analysis”, and describe the interventions compared. | P1          |

|  |                                 |                    |  |                                      |
|--|---------------------------------|--------------------|--|--------------------------------------|
| 1<br>2<br>3<br>4<br>5<br>6<br>7<br>8<br>9<br>10          | Abstract                        | <a href="#">#2</a> | Provide a structured summary of objectives, perspective, setting, methods (including study design and inputs), results (including base case and uncertainty analyses), and conclusions | P2-P3                                |
| 11<br>12<br>13<br>14<br>15<br>16<br>17<br>18<br>19<br>20 | Background and objectives       | <a href="#">#3</a> | Provide an explicit statement of the broader context for the study. Present the study question and its relevance for health policy or practice decisions                               | P5-P7                                |
| 21<br>22<br>23<br>24<br>25<br>26<br>27                   | Target population and subgroups | <a href="#">#4</a> | Describe characteristics of the base case population and subgroups analysed, including why they were chosen.   | Last paragraph on P7                 |
| 28<br>29<br>30<br>31<br>32<br>33                         | Setting and location            | <a href="#">#5</a> | State relevant aspects of the system(s) in which the decision(s) need(s) to be made.   | P7                                   |
| 34<br>35<br>36<br>37<br>38                               | Study perspective               | <a href="#">#6</a> | Describe the perspective of the study and relate this to the costs being evaluated.  | P7                                   |
| 39<br>40<br>41<br>42<br>43<br>44                         | Comparators                     | <a href="#">#7</a> | Describe the interventions or strategies being compared and state why they were chosen.  | P7                                   |
| 45<br>46<br>47<br>48<br>49<br>50<br>51                   | Time horizon                    | <a href="#">#8</a> | State the time horizon(s) over which costs and consequences are being evaluated and say why appropriate.   | 2 <sup>nd</sup> paragraph on P8      |
| 52<br>53<br>54<br>55<br>56<br>57<br>58<br>59<br>60       | Discount rate                   | <a href="#">#9</a> | Report the choice of discount rate(s) used for costs and outcomes and say why appropriate  | N/A, 2 <sup>nd</sup> paragraph on P8 |

|    |                      |                      |   |               |
|----|----------------------|----------------------|---|---------------|
| 1  | Choice of health     | <a href="#">#10</a>  | Describe what outcomes were used as the             | P7-P8         |
| 2  |                      |                      |   |               |
| 3  | outcomes             |                      | measure(s) of benefit in the evaluation and their   |               |
| 4  |                      |                      |   |               |
| 5  |                      |                      | relevance for the type of analysis performed        |               |
| 6  |                      |                      |   |               |
| 7  |                      |                      |   |               |
| 8  |                      |                      |   |               |
| 9  | Measurement of       | <a href="#">#11a</a> | Single study-based estimates: Describe fully the    | P9-P10        |
| 10 |                      |                      |   |               |
| 11 | effectiveness        |                      | design features of the single effectiveness study   |               |
| 12 |                      |                      |   |               |
| 13 |                      |                      | and why the single study was a sufficient source    |               |
| 14 |                      |                      |   |               |
| 15 |                      |                      | of clinical effectiveness data                      |               |
| 16 |                      |                      |   |               |
| 17 |                      |                      |   |               |
| 18 |                      |                      |   |               |
| 19 | Measurement of       | <a href="#">#11b</a> | Synthesis-based estimates: Describe fully the       | P9-P10 and    |
| 20 |                      |                      |   |               |
| 21 | effectiveness        |                      | methods used for identification of included studies | supplementary |
| 22 |                      |                      |   |               |
| 23 |                      |                      | and synthesis of clinical effectiveness data        | file          |
| 24 |                      |                      |   |               |
| 25 |                      |                      |   |               |
| 26 | Measurement and      | <a href="#">#12</a>  | If applicable, describe the population and methods  | P11-P12       |
| 27 |                      |                      |   |               |
| 28 | valuation of         |                      | used to elicit preferences for outcomes.            |               |
| 29 |                      |                      |   |               |
| 30 | preference based     |                      |   |               |
| 31 |                      |                      |   |               |
| 32 | outcomes             |                      |   |               |
| 33 |                      |                      |   |               |
| 34 |                      |                      |   |               |
| 35 |                      |                      |   |               |
| 36 |                      | <a href="#">#13a</a> | Single study-based economic evaluation:             | N/A           |
| 37 |                      |                      |   |               |
| 38 |                      |                      | Describe approaches used to estimate resource       |               |
| 39 |                      |                      |   |               |
| 40 |                      |                      | use associated with the alternative interventions.  |               |
| 41 |                      |                      |   |               |
| 42 |                      |                      | Describe primary or secondary research methods      |               |
| 43 |                      |                      |   |               |
| 44 |                      |                      | for valuing each resource item in terms of its unit |               |
| 45 |                      |                      |   |               |
| 46 |                      |                      | cost. Describe any adjustments made to              |               |
| 47 |                      |                      |   |               |
| 48 |                      |                      | approximate to opportunity costs                    |               |
| 49 |                      |                      |   |               |
| 50 |                      |                      |   |               |
| 51 |                      |                      |   |               |
| 52 |                      |                      |   |               |
| 53 | Estimating resources | <a href="#">#13b</a> | Model-based economic evaluation: Describe           | P11           |
| 54 |                      |                      |   |               |
| 55 | and costs            |                      | approaches and data sources used to estimate        |               |
| 56 |                      |                      |   |               |
| 57 |                      |                      | resource use associated with model health states.   |               |
| 58 |                      |                      |   |               |
| 59 |                      |                      |   |               |
| 60 |                      |                      |   |               |

1 Describe primary or secondary research methods  
 2  
 3 for valuing each resource item in terms of its unit  
 4  
 5 cost. Describe any adjustments made to  
 6  
 7 approximate to opportunity costs.  
 8  
 9

|   |     |  |                             |
|---|-----|--|-----------------------------|
| 10 Currency, price date,<br>11 and conversion | #14 | 12 Report the dates of the estimated resource<br>13 quantities and unit costs. Describe methods for<br>14 adjusting estimated unit costs to the year of<br>15 reported costs if necessary. Describe methods for<br>16 converting costs into a common currency base<br>17 and the exchange rate.<br>18<br>19<br>20<br>21<br>22<br>23<br>24  | P11                         |
| 25 Choice of model                            | #15 | 26 Describe and give reasons for the specific type of<br>27 decision analytical model used. Providing a figure<br>28 to show model structure is strongly<br>29 recommended.<br>30<br>31<br>32<br>33<br>34  | P7-P9 and<br>35 Figures 1-3 |
| 36 Assumptions                                | #16 | 37 Describe all structural or other assumptions<br>38 underpinning the decision-analytical model.<br>39  | P7-P13                      |
| 40 Analytical methods                         | #17 | 41 Describe all analytical methods supporting the<br>42 evaluation. This could include methods for dealing<br>43 with skewed, missing, or censored data;<br>44 extrapolation methods; methods for pooling data;<br>45 approaches to validate or make adjustments<br>46 (such as half cycle corrections) to a model; and<br>47 methods for handling population heterogeneity<br>48 and uncertainty.<br>49<br>50<br>51<br>52<br>53<br>54<br>55<br>56<br>57<br>58<br>59<br>60 | P12-P13                     |

|    |                                   |                                    |   |                 |
|----|-----------------------------------|------------------------------------|---|-----------------|
| 1  | Study parameters                  | <a href="#">#18</a>                | Report the values, ranges, references, and, if      | Table 1         |
| 2  |                                   |                                    | used, probability distributions for all parameters. |                 |
| 3  |                                   |                                    | Report reasons or sources for distributions used    |                 |
| 4  |                                   |                                    | to represent uncertainty where appropriate.         |                 |
| 5  |                                   |                                    | Providing a table to show the input values is       |                 |
| 6  |                                   |                                    | strongly recommended.                               |                 |
| 7  |                                   |                                    |   |                 |
| 8  |                                   |                                    |   |                 |
| 9  |                                   |                                    |   |                 |
| 10 |                                   |                                    |   |                 |
| 11 |                                   |                                    |   |                 |
| 12 |                                   |                                    |   |                 |
| 13 |                                   |                                    |   |                 |
| 14 |                                   |                                    |   |                 |
| 15 | Incremental costs<br>and outcomes | <a href="#">#19</a>                | For each intervention, report mean values for the   | P14 and Table 2 |
| 16 |                                   |                                    | main categories of estimated costs and outcomes     |                 |
| 17 |                                   |                                    | of interest, as well as mean differences between    |                 |
| 18 |                                   |                                    | the comparator groups. If applicable, report        |                 |
| 19 |                                   |                                    | incremental cost-effectiveness ratios.              |                 |
| 20 |                                   |                                    |   |                 |
| 21 |                                   |                                    |   |                 |
| 22 |                                   |                                    |   |                 |
| 23 |                                   |                                    |   |                 |
| 24 |                                   |                                    |   |                 |
| 25 | Characterising<br>uncertainty     | <a href="#">#20a</a>               | Single study-based economic evaluation:             | N/A             |
| 26 |                                   |                                    | Describe the effects of sampling uncertainty for    |                 |
| 27 |                                   |                                    | the estimated incremental cost and incremental      |                 |
| 28 |                                   |                                    | effectiveness parameters, together with the         |                 |
| 29 |                                   |                                    | impact of methodological assumptions (such as       |                 |
| 30 |                                   | discount rate, study perspective). |   |                 |
| 31 |                                   | <a href="#">#20b</a>               | Model-based economic evaluation: Describe the       | P13-P15         |
| 32 |                                   |                                    | effects on the results of uncertainty for all input |                 |
| 33 |                                   |                                    | parameters, and uncertainty related to the          |                 |
| 34 |                                   |                                    | structure of the model and assumptions.             |                 |
| 35 |                                   |                                    |   |                 |
| 36 | Characterising<br>heterogeneity   | <a href="#">#21</a>                | If applicable, report differences in costs,         | N/A             |
| 37 |                                   |                                    | outcomes, or cost effectiveness that can be         |                 |
| 38 |                                   |                                    | explained by variations between subgroups of        |                 |
| 39 |                                   |                                    |   |                 |
| 40 |                                   |                                    |   |                 |
| 41 |                                   |                                    |   |                 |
| 42 |                                   |                                    |   |                 |

1 patients with different baseline characteristics or  
 2 other observed variability in effects that are not  
 3 reducible by more information.  
 4  
 5  
 6  
 7

|   |     |  |         |
|---|-----|--|---------|
| 8 Study findings,<br>9 limitations,<br>10 generalisability, and<br>11 current knowledge | #22 | Summarise key study findings and describe how<br>12 they support the conclusions reached. Discuss<br>13 limitations and the generalisability of the findings<br>14 and how the findings fit with current knowledge.  | P15-P20 |
| 15 Source of funding  | #23 | Describe how the study was funded and the role<br>16 of the funder in the identification, design, conduct,<br>17 and reporting of the analysis. Describe other non-<br>18 monetary sources of support  | P22     |
| 24 Conflict of interest   | #24 | Describe any potential for conflict of interest of<br>19 study contributors in accordance with journal<br>20 policy. In the absence of a journal policy, we<br>21 recommend authors comply with International<br>22 Committee of Medical Journal Editors<br>23 recommendations | P22     |

26  
 27  
 28  
 29  
 30  
 31  
 32  
 33  
 34  
 35  
 36  
 37  
 38  
 39  
 40  
 41  
 42 The CHEERS checklist is distributed under the terms of the Creative Commons Attribution License  
 43 CC-BY-NC. This checklist can be completed online using <https://www.goodreports.org/>, a tool made  
 44 by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)  
 45  
 46  
 47  
 48  
 49  
 50  
 51  
 52  
 53  
 54  
 55  
 56  
 57  
 58  
 59  
 60

# BMJ Open

## Cost-effectiveness of fecal calprotectin used in primary care in the diagnosis of inflammatory bowel disease

|                                 |  |
|---------------------------------|--|
| Journal:                        | <i>BMJ Open</i>  |
| Manuscript ID                   | bmjopen-2018-027043.R2   |
| Article Type:                   | Research   |
| Date Submitted by the Author:   | 04-Mar-2019  |
| Complete List of Authors:       | Zhang, Wei; St. Paul's hospital, Centre for Health Evaluation & Outcome Sciences; University of British Columbia, School of Population and Public Health<br>Wong, Chiew; University of Sheffield<br>Chavannes, Mallory; University of British Columbia; University of Southern California<br>Mohammadi, Tima; Centre for Health Evaluation and Outcome Sciences<br>Rosenfeld, Greg; University of British Columbia, Department of Medicine, Division of Gastroenterology |
| <b>Primary Subject Heading</b>: | Health economics   |
| Secondary Subject Heading:      | General practice / Family practice, Gastroenterology and hepatology, Public health   |
| Keywords:                       | Fecal calprotectin, Inflammatory bowel disease < GASTROENTEROLOGY, cost-effectiveness  |
|                                 |  |

SCHOLARONE™  
Manuscripts

# Cost-effectiveness of fecal calprotectin used in primary care in the diagnosis of inflammatory bowel disease

Wei Zhang, PhD<sup>1,2</sup>; Chiew Hsia Wong, MSc<sup>3</sup>; Mallory Chavannes, MD<sup>4,5</sup>; Tima Mohammadi, MA, MSc<sup>2</sup>; Greg Rosenfeld, MD<sup>4</sup>

1. School of Population and Public Health, University of British Columbia
2. Centre for Health Evaluation and Outcome Sciences, St. Paul's Hospital
3. School of Health and Related Research, University of Sheffield
4. Department of Medicine, Division of Gastroenterology, University of British Columbia
5. Department of Pediatric, Division of Gastroenterology, Hepatology and Nutrition, Children Hospital of Los Angeles, University of Southern California.

## Correspondence:

**Wei Zhang**, PhD

Centre for Health Evaluation and Outcome Sciences, St. Paul's Hospital

588-1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6

Tel: +1-604-806-9343

Email: [wzhang@cheos.ubc.ca](mailto:wzhang@cheos.ubc.ca)

**Word count:** Abstract [287]; Manuscript [4349]

**Tables and figures:** Tables [2]; Figures [4]

**Keywords:** Fecal calprotectin; inflammatory bowel disease; cost-effectiveness



## ABSTRACT

**Objective:** Inflammatory bowel disease (IBD) is a chronic, autoimmune, gastrointestinal disorder. Canada has one of the highest prevalence and incidence rates of IBD in the world. Diagnosis is challenging due to the similarity of symptoms to functional gastrointestinal disorders. Fecal calprotectin (FC) is a biomarker for active mucosal inflammation and has proven effective in the diagnosis of IBD. Our study objective was to assess the cost-effectiveness of adding a FC test compared with standard practice (blood test) in primary care among adult patients presenting with gastrointestinal symptoms.

**Design:** We constructed a decision analytic tree with a one-year time horizon. The cut-off level of 100µg/g was used for FC testing. Probabilistic analyses were conducted for the base case and all scenarios.

**Setting:** Canadian health sector perspective.

**Population:** A hypothetical cohort of adult patients presenting with gastrointestinal symptoms in the primary care setting

**Interventions:** FC test compared with blood test

**Main outcome measures:** Costs, quality-adjusted life years (QALYs), incremental cost-effectiveness ratio (ICER) of FC test expressed as cost per QALY gained compared with blood test, and time to IBD diagnosis.

**Results:** FC testing is expected to cost more (\$295.1 vs. \$273.9) than standard practice but yield little higher QALY (0.751 vs. 0.750). The ICER of FC test was \$20,323 per QALY. Probabilistic analysis demonstrated that at a willingness-to-pay threshold of \$50,000 per QALY, there was 81.3% probability of FC test being cost-effective. The use of FC test in primary care reduced the

1  
2  
3 time to IBD diagnosis by 40.0 days (95% Confidence Interval: 16.3-65.3 days), compared with  
4  
5 blood testing alone.  
6

7  
8 **Conclusions:** Based on this analysis of short-term outcomes, screening adult patients in primary  
9  
10 care using FC test at a cut-off level of 100µg/g is expected to be cost-effective in Canada.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## ARTICLE SUMMARY

### Strengths and limitations of this study

- This paper presents a cost-effectiveness analysis (CEA) comparing a fecal calprotectin test to blood test in diagnosis of inflammatory bowel disease (IBD) in the primary care setting.
- This was the first CEA of FC test in the Canadian context and one of few CEAs of FC test in the primary care setting in literature.
- We also compared the average time to IBD diagnosis between using FC test and blood test in primary care and estimated the reduced time to IBD diagnosis by using FC test.
- The analysis was from the Canadian health sector perspective and did not consider costs (e.g., productivity losses) from a societal perspective.
- The main limitation was the short-term time horizon of the analysis and thus there is outstanding uncertainty over the long-term impact of FC testing in this setting.

## INTRODUCTION

Inflammatory bowel disease (IBD), of which the two main subtypes are Crohn's Disease (CD) and ulcerative colitis (UC), is characterized by mucosal inflammation and ulceration of the gastrointestinal tract. During the course of the disease, patients often present with symptoms such as diarrhea, abdominal pain, and fatigue, which significantly impact the quality of life of IBD patients.<sup>1</sup> Canada has one of the highest reported prevalence and incidence rates of IBD in the world.<sup>2</sup> The prevalence of IBD in Canada was estimated at 0.67% [129,000 individuals with CD and 104,000 with UC] in 2012, with approximately 10,200 incidents occurring annually.<sup>3</sup> The corresponding annual economic costs of IBD were estimated at \$2.8 billion.<sup>3</sup>

IBD shares similar presenting symptoms with functional gut disorders. One of the most common function gut disorders that is difficult to distinguish from IBD is Irritable Bowel Syndrome (IBS), which affects around 11% of the population in Canada and globally.<sup>4</sup> While IBS can be safely managed within primary care setting, the risk of serious complications associated with IBD (such as bowel obstruction and toxic megacolon) necessitates specialist care management. In order to distinguish IBD from functional gut disorders, the conventional diagnostic pathway in primary care includes initial blood tests, such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), which are used to determine whether patients should be referred to gastroenterologists for further investigation including imaging studies and/or endoscopy.<sup>5</sup> However, these blood tests lack accuracy. They may not only delay IBD diagnosis in the case of false negatives, but also lead to unnecessary endoscopies in the case of false positives.<sup>6,7</sup> Due to limited resources, endoscopy is not readily accessible in many areas of Canada and unnecessary endoscopies can have further impacts on health care resources and costs.

1  
2  
3  
4  
5 Recently, the detection of fecal calprotectin (FC), the most extensively studied fecal marker of  
6  
7 IBD, has been shown to be an accurate and useful screening tool for identifying patients who  
8  
9 need further investigation through endoscopy.<sup>6-9</sup> The majority of studies that assessed the  
10  
11 accuracy of FC testing to date have been in the secondary care setting.<sup>6-8</sup> Based predominantly  
12  
13 on secondary care data using the standard cut-off of 50µg/g, Waugh *et al* have shown that FC  
14  
15 testing is cost-effective for distinguishing between IBD and non-IBD in adults in primary care in  
16  
17 the United Kingdom (UK).<sup>7,10</sup> The National Institute for Health and Care Excellence (NICE) in  
18  
19 the UK therefore recommends FC testing as an option to help clinicians distinguish between IBD  
20  
21 and non-IBD in adults with recent onset of gastrointestinal symptoms.<sup>10</sup> A recent prospective  
22  
23 primary care cohort study conducted in the UK demonstrated that FC testing using the cut-off of  
24  
25 100µg/g accurately distinguishes IBD from functional gut disorder in primary care and reduces  
26  
27 secondary care referrals as well as diagnostic health care costs.<sup>11</sup> More recently, Turvill *et al*  
28  
29 have also demonstrated that repeating FC testing among those with a first FC test  $\geq 100\mu\text{g/g}$  in  
30  
31 primary care is cost-saving compared with CRP/ESR testing or single FC testing using the  
32  
33 standard cut-off of 50µg/g.<sup>12</sup> NICE has subsequently endorsed this repeated testing algorithm,  
34  
35 using the higher 100µg/g cut-off, within a recent consensus document.<sup>13</sup>  
36  
37  
38  
39  
40  
41  
42  
43

44 In Canada, however, FC tests are currently only covered by provincial health plans in Alberta  
45  
46 and Quebec, as well as some extended health insurance plans.<sup>14</sup> There is still no cost-  
47  
48 effectiveness evidence within primary care in Canada. The objective of this study, therefore, is to  
49  
50 determine the cost-effectiveness of FC testing in the diagnosis of adult cases of IBD in primary  
51  
52 care from the Canadian health care sector perspective.  
53  
54  
55  
56  
57  
58  
59  
60

## MATERIALS AND METHODS

### Comparison groups

A higher 100µg/g cut-off in primary care has been advocated and demonstrated to increase the positive predictive power of the test and counter the high false positive rate observed at the lower 50µg/g cut-off.<sup>11-13,15</sup> Therefore, we chose the 100µg/g cut-off for FC testing in primary care setting as the intervention for our analysis. Referrals based on standard care CRP/ESR testing in primary care were used as the comparator. This assumes that patients with a normal CRP/ESR would not be referred initially but would subsequently be referred if they have ongoing symptoms. This is a simplification of real-world practice – clinicians are known, for example, to refer patients with normal CRP/ESR to secondary care. Nevertheless, there is currently a lack of reliable data on the accuracy of real-world primary care referral practices in the literature particularly in Canada. Thus, we based the comparator on CRP/ESR testing, in line with previous cost-effectiveness analyses.<sup>12,16</sup> An alternative estimate of primary care referral accuracy was based on the study of Waugh *et al*,<sup>7</sup> which estimated a high sensitivity (=1) and specificity (=0.788). Since the reliability of these estimates has been previously questioned,<sup>12</sup> they were used as a scenario analysis only.

### Decision model

A decision analytic model was built to estimate the cost-effectiveness of using FC test as compared to the current practice using blood test, in the screening for IBD in the primary care setting. The patient population in the model was a hypothetical cohort of adult patients aged 19 to 64 years old, who present with gastrointestinal symptoms suggestive of IBD in a primary care

1  
2  
3 setting but are not suspected of having cancer (which requires urgent specialist referral). A  
4  
5 decision tree was developed in Microsoft Excel where the hypothetical cohort of adult patients  
6  
7 underwent certain pathways. The associated cost and effectiveness of each pathway was captured  
8  
9 in the model and the expected cost and effectiveness was estimated.  
10  
11

12  
13  
14 Effectiveness was measured using quality-adjusted life years (QALYs). The time horizon for the  
15  
16 cost-effectiveness analysis was one year as this was a reasonable length of time for a patient to  
17  
18 reach a confirmed diagnosis of either IBD or non-IBD. Due to the brief time horizon,  
19  
20 discounting was not applied to either costs or benefits in this analysis. Time to IBD diagnosis  
21  
22 was also estimated from the model. The analysis perspective was the Canadian health sector.  
23  
24  
25

26  
27  
28 The clinical pathways of patients presenting with gastrointestinal symptoms in primary care were  
29  
30 established from published literature<sup>7,12,16-18</sup> as well as input by two gastroenterologists from St.  
31  
32 Paul's Hospital, Vancouver. Established clinical pathways were consistent with the best-practice  
33  
34 clinical care pathway for management of IBS in primary care as outlined by the Canadian  
35  
36 Association of Gastroenterology<sup>19</sup> and local primary care guidelines on the use of FC in the  
37  
38 UK.<sup>13,15</sup>  
39  
40  
41

42  
43  
44 Figure 1 illustrates the current practice using the standard blood test whereas Figure 2 depicts the  
45  
46 proposed strategy of adding FC test as a diagnostic support tool for general practitioners (GPs).  
47  
48 Under the current practice (Figure 1), based on results of the blood investigation (ESR and CRP),  
49  
50 a GP will make a decision on whether to refer patients to specialist care or not. Patients with  
51  
52 abnormal blood results will be referred to gastroenterology for specialist assessment. The  
53  
54  
55  
56  
57

1  
2  
3 specialist may then order an endoscopy as necessary to confirm IBD diagnosis or follow-up with  
4  
5 patients unlikely to have IBD and monitor their symptoms accordingly. If symptoms are still  
6  
7 persistent after 3 months (assumed and same as Waugh *et al*<sup>7</sup>), an endoscopy may be ordered at  
8  
9 the specialist follow-up visit to confirm diagnosis of IBD. Under the FC testing strategy (Figure  
10  
11 2), patients with positive FC test results will be referred to specialist care and an endoscopy will  
12  
13 be ordered for them at the specialist visit to confirm diagnosis of IBD.  
14  
15

16  
17  
18  
19 Patients with normal blood results or negative FC test results will be followed-up by the GP and  
20  
21 receive lifestyle and dietary advice with appropriate medication to treat symptoms for 3 months  
22  
23 (assumed) (Figure 3). Those with symptoms inadequately controlled will receive more intensive  
24  
25 management (different medication) from their GP for another 4 weeks (assumed). If symptoms  
26  
27 are still persistent, further assessment by a gastroenterologist and endoscopy will be performed.  
28  
29  
30

### 31 32 33 **Model parameters**

34  
35 The model parameters (Table 1) were obtained from literature or based on assumptions. The  
36  
37 parameters include sensitivity and specificity for FC testing at the 100µg/g cut-off and  $\geq 15$ mm/h  
38  
39 for ESR and  $\geq 5$ mg/l for CRP blood testing; prevalence of IBD in primary care; the ratio of UC  
40  
41 and CD; non-IBD patients with negative test results; costs; utilities; and waiting time.  
42  
43  
44

#### 45 46 47 *Sensitivity and specificity*

48  
49 As mentioned above, the majority of studies measuring FC testing accuracy were conducted in  
50  
51 the secondary care setting. As such, we used the sensitivity and specificity of FC testing at the  
52  
53 100µg/g cut-off from the recent UK study conducted with the prospective primary cohort.<sup>11</sup>  
54  
55  
56



1  
2  
3 For blood testing, we chose the cut-offs of  $\geq 15$  mm/h for ESR and  $\geq 5$  mg/l for CRP. Three  
4  
5 studies using these ESR and CRP cut-offs were identified from a published systematic  
6  
7 review.<sup>6,20–22</sup> Following this, a meta-analysis was conducted to synthesize the logit-  
8  
9 transformation of sensitivity and specificity and the details can be found in the Supplementary  
10  
11 file.  
12  
13

### 14 15 16 17 *Prevalence of IBD in primary care*

18  
19 Very few studies have estimated the prevalence of IBD in primary care,<sup>7,11,23–25</sup> with most  
20  
21 estimates originating from UK studies. To be consistent with the sensitivity and specificity  
22  
23 estimates used in our model, we used the prevalence of IBD (=6.8%) in primary care from the  
24  
25 same study.<sup>11</sup> Among IBD cases, 45% were UC and 55% were CD.<sup>3</sup>  
26  
27  
28  
29

### 30 31 *Non-IBD patients with negative test results*

32  
33 Based on expert opinions, previous studies estimated that the probability of non-IBD patients  
34  
35 still having persistent symptoms after the initial management by GPs was 50% or 60%.<sup>16–18</sup> In  
36  
37 our study, we applied the 47% probability used in the cost-effectiveness analysis conducted by  
38  
39 Waugh *et al.*<sup>7</sup> We also assumed that 15% of these who have persistent symptoms after initial  
40  
41 management by GP (based on expert advice) would subsequently experience uncontrolled  
42  
43 symptoms after further intensive management by GPs, be referred to a specialist, and undergo  
44  
45 endoscopy.  
46  
47  
48  
49

### 50 51 *Costs*

1  
2  
3 Only the diagnosis related costs, including the costs for diagnostic testing (FC, endoscopy, and  
4 pathology) and physician and gastroenterologist visits, were considered. All costs were  
5 reported in 2017 Canadian dollars. Cost data were obtained from the British Columbia  
6 Ministry of Health Medical Services Commission Payment Schedule (July 1, 2017 version)<sup>26</sup>  
7 which is comparable with other provinces in Canada; literature review for colonoscopy cost in  
8 Canada<sup>27</sup> adjusted to 2017 cost using total health care implicit price index;<sup>28</sup> and literature  
9 review and a local gastroenterology clinic for FC testing cost.<sup>7,18</sup> Costs of managing  
10 complications associated with colonoscopy such as bleeding and perforation were not  
11 considered in this analysis due to the unavailability of data.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

### 26 *Utilities*

27  
28 Our utility estimates for IBS were taken from a study conducted among 257 patients in the  
29 United States (US) using EuroQol-5D.<sup>29</sup> The utilities of 0.78 for IBS patients with adequate  
30 relief of symptoms or 0.73 for those with persistent symptoms were applied to non-IBD patients  
31 in our analysis.<sup>29</sup> A weighted IBS utility of 0.76 was calculated based on the proportion (47%  
32 assumed above) of non-IBD patients with persistent symptoms and the remaining 53% with  
33 adequately controlled symptoms. In our model, patients with adequately controlled symptoms  
34 started with a weighted utility of 0.76 until the time of diagnosis, wherein a weighted utility of  
35 0.78 (utility for adequately controlled) was applied for the rest of the one-year time horizon.  
36  
37 Patients with persistent symptoms started with 0.73 (utility for persistent symptoms) until the  
38 time of diagnosis followed by 0.78 if symptoms were eventually controlled or 0.76 if they had to  
39 undergo endoscopy.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Similar to Waugh *et al*,<sup>7</sup> our utility estimates of IBD were taken from a study conducted among  
4 225 CD patients and 219 UC patients in Germany using the EuroQol-5D.<sup>30</sup> This study had a  
5 reasonably large sample size and reported utility estimates for active disease compared with  
6 remission for both UC and CD. The utility estimates of 0.71 for active UC and 0.61 for active  
7 CD were chosen to represent the utility of IBD patients when they visited GP for the first time.  
8 We assumed that their utilities would then decrease by a certain amount every month due to  
9 disease progression until diagnosis was made, at which point the utility value at the time of  
10 diagnosis would be maintained throughout the rest of the one-year time horizon. Following the  
11 method of Waugh *et al* by taking the utility difference between active disease and remission and  
12 dividing it by twelve, we derived a monthly utility decrement of 0.0167 for UC and 0.023 for  
13 CD.<sup>7</sup>  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

### 31 *Waiting time*

32  
33 The median time an IBD patient was first referred to specialist until consultation by a specialist  
34 was 72 days (95% confidence interval (CI) 52-121) and the median time from the first specialist  
35 consultation to endoscopy was 44 days (95% CI: 27-100) in Canada.<sup>31</sup> The median time for non-  
36 IBD patients from the first referral to specialist consultation was 126 days (95% CI: 103-141).<sup>31</sup>  
37  
38 Other wait times were assumed to be fixed according to the guidelines.  
39  
40  
41  
42  
43  
44  
45  
46

### 47 **Analyses**

48  
49 We performed probabilistic analyses to estimate means and 95% CI of total costs, QALYs, and  
50 incremental cost-effectiveness ratios (ICERs) to reflect the underlying parameter uncertainty.  
51  
52 Additionally, the time to the diagnosis of IBD among IBD patients was calculated. A total of  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 5,000 Monte Carlo simulations were generated from the parameter probability distributions. The  
4  
5 base-case results were presented in a cost-effectiveness plane (Supplementary file) and as the  
6  
7 cost-effectiveness acceptability curve, which demonstrates the probability of the FC testing  
8  
9 strategy being cost-effective compared to the standard care across a range of willingness-to-pay  
10  
11 thresholds.  
12  
13

14  
15  
16  
17 To explore the sensitivity of results to specific parameter uncertainty, alternative assumptions  
18  
19 and sources of data, we also conducted a series of scenario analyses. 1) IBD prevalence was  
20  
21 varied from 5% to 20% in 5% increments. 2) FC testing accuracy was changed using an  
22  
23 alternative data source. The sensitivity and specificity for repeating FC testing among the first  
24  
25 FC testing  $\geq 100\mu\text{g/g}$  in Turvill *et al*<sup>12</sup> were used in the model. 3) The sensitivity and specificity  
26  
27 of the primary care practice in Waugh *et al*<sup>7</sup> was used. 4) We increased the proportion of patients  
28  
29 with abnormal blood test for whom an endoscopy was ordered in the initial gastroenterologist  
30  
31 consultation from 83% to 100%. 5) We changed the proportion of non-IBD patients with  
32  
33 symptoms after further intensive management by GPs that needed further investigation by  
34  
35 specialist and endoscopy from 5% (same as Waugh *et al*<sup>7</sup> and Whitehead and Hutton.<sup>16</sup>) to 30%  
36  
37 with 5% increments. 6) Different FC test costs and an increase or decrease in other costs by 20%  
38  
39 were implemented. 7) We changed the source of utility decrement estimates from Stark *et al*<sup>30</sup> to  
40  
41 that of Gregor *et al*<sup>32</sup> and Poole *et al*.<sup>33</sup> 8) Time taken to the first follow-up by GP and time taken  
42  
43 to follow-up by a specialist were changed from 1 month to 4 months with 1-month increments.  
44  
45  
46  
47  
48  
49 9) We applied our model to a patient population without gastrointestinal alarm symptoms  
50  
51 described by Walker *et al*.<sup>11</sup>  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Patient and public involvement

Patients and/or public were not involved in our study. A hypothetical cohort of adult patients has been simulated.

## RESULTS

### Base case

For the base case, the probabilistic analysis based on 5,000 Monte Carlo simulations showed that the FC testing strategy was about \$21 more expensive on average than the standard practice using blood test (\$295.12 vs. \$273.93) but yielded a slightly higher QALY (0.751 vs. 0.750, respectively) (Table 2). Thus, the ICER was \$20,323.35 per QALY gained. The time to diagnosis for IBD patients was 39.96 days (95% CI: 16.34-65.29) shorter under the FC testing strategy (192.39 days (95% CI: 143.10-239.74) than standard practice (232.36 days (95% CI: 186.02-277.92)). There was an 81.3% probability that the FC testing strategy was cost-effective at the willingness-to-pay threshold of \$50,000/QALY (Figure 4).

### Scenario analyses

Our analyses showed that the cost-effectiveness of FC testing strategy was sensitive to the prevalence of IBD among the patients presenting with gastrointestinal symptoms in primary care, the FC cost, and the value of utility decrements (Table 2). When the prevalence was increased to 20%, the probability of the FC testing strategy being cost-effective would increase to 96.7% at the threshold of \$50,000/QALY. The probability of FC testing being cost effective became 96.5% when using the sensitivity and specificity estimates for repeating FC testing strategy in Turvill *et al.* The maximum price at which the FC testing strategy would still be cost-effective

1  
2  
3 was about \$70. At \$70, the probability of FC testing being cost-effective was 47.4% at the  
4  
5 willingness-to-pay threshold of \$50,000/QALY. When applying a much lower utility monthly  
6  
7 decrement especially for CD (from 0.023 to 0.006 for CD and from 0.017 to 0.014 for UC), the  
8  
9 probability of FC testing strategy was 68.6% at the threshold of \$50,000/QALY.  
10  
11  
12  
13

## 14 **DISCUSSION**

15  
16 Based on cost-effectiveness models built in previous studies,<sup>7,16-18</sup> current practice guidelines in  
17  
18 Canada,<sup>19</sup> and clinical expertise from gastroenterologists, we constructed a decision analytic  
19  
20 model to evaluate the cost-effectiveness of adding FC testing to current practice compared with  
21  
22 the current practice of blood test only in the diagnosis of adult IBD patients in the Canadian  
23  
24 primary care setting. To our knowledge, this is the first cost-effectiveness analysis of FC testing  
25  
26 in primary care in Canada. Our base-case analysis suggested that the FC test was cost-effective.  
27  
28 Probabilistic analysis showed that at a willingness-to-pay threshold of \$50,000 per QALY, there  
29  
30 was an 81.3% chance of the FC testing strategy being cost-effective. Scenario analysis  
31  
32 demonstrated that the cost-effectiveness was most sensitive towards prevalence of IBD, monthly  
33  
34 utility decrement of IBD, and cost of FC test.  
35  
36  
37  
38  
39  
40  
41

42 A 6.8% prevalence of IBD was applied in our base case analysis. This estimate was based on a  
43  
44 prospective UK primary care cohort of patients aged between 18 and 46 years old.<sup>11</sup> The  
45  
46 prevalence was very similar to the one used in the cost-effectiveness analysis conducted by  
47  
48 Waugh *et al.*<sup>7</sup> Among our model population (aged 19-64 years old), the prevalence would likely  
49  
50 be higher. Unfortunately, Canadian estimates were not found in published literature. Thus, we  
51  
52 conducted scenario analysis by varying the prevalence from 5% to 20%. Although the cost-  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 effectiveness of the FC testing strategy was highly sensitive to the prevalence of IBD in the adult  
4 patient population presented in the primary care setting, our study has shown it is still cost-  
5  
6 effective when the prevalence is as low as 5%.  
7  
8  
9

10  
11  
12 The ICER of the FC testing strategy compared with blood testing increased when the monthly  
13 utility decrement for IBD was lower. This finding is consistent with the assumption made in the  
14 calculation of QALYs for IBD patients. A delay in diagnosis would cause patients to reach a  
15 lower utility value before diagnosis. Therefore, a higher utility decrement for IBD increased the  
16 difference in QALYs gained between the two strategies and caused a decrease in ICER and vice  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

We used the current FC test cost, \$40, in our base case, which was consistent with the cost used  
in previous cost-effectiveness analyses conducted in the UK and US.<sup>7,18</sup> When the cost of FC  
testing was under \$70, the FC testing strategy had the potential to be cost-effective. The wider  
implementation of FC testing across Canada may drive the cost down. Laboratory-based FC  
testing has been shown to be cost-effective when conducted in batches.<sup>7,10</sup>

One of the strengths of our study is that we used the FC testing accuracy in primary care<sup>11</sup>  
instead of the secondary care setting. The test accuracy in the secondary care setting was found  
to be higher than that of primary care setting. According to the most recent meta-analysis  
conducted by Waugh *et al*,<sup>7</sup> all of studies included were for secondary setting and the  
synthesized sensitivity (0.93) and specificity (0.94) of FC testing at the 50µg/g cut-off were both  
higher than the estimates (0.86 and 0.90) for the 100µg/g cut-off we used for the primary care

1  
2  
3 setting. However, the sensitivity and specificity values of CRP/ESR in our study were derived  
4  
5 from secondary care sources<sup>20-22</sup> and thus might differ in primary care setting.  
6  
7

8  
9  
10 Additionally, we estimated the benefit of using FC testing in primary care in terms of reducing  
11  
12 the time to IBD diagnosis (by about 40 days). The average times to IBD diagnosis among IBD  
13  
14 patients were 192.4 days with FC testing and 232.4 days for standard practice. The time to  
15  
16 diagnosis under the standard practice was reasonably consistent with a Canadian study that  
17  
18 reported the mean time to diagnosis for CD and UC to be 255.5 and 202.3 days, respectively.<sup>34</sup>  
19  
20 Delayed diagnosis is a common problem in IBD. A study involving 1,591 IBD patients from the  
21  
22 Swiss IBD cohort reported a diagnostic delay of 9 and 4 months for CD and UC.<sup>35</sup> The delay was  
23  
24 due to similarities in symptoms among patients with mild IBD and those with IBS. A literature  
25  
26 review on natural history studies of CD reported that at time of diagnosis, one third of patients  
27  
28 already had intestinal complications such as ileitis, colitis, or ileocolitis.<sup>36</sup> In UC, an early  
29  
30 diagnosis and identification of patients with a high risk of developing complicated disease, is  
31  
32 crucial for choosing appropriate treatment and prevention of colectomies.<sup>37</sup> The FC testing  
33  
34 strategy has the potential to speed up diagnosis and reduce the wait time for a specialist and  
35  
36 endoscopy by avoiding the unnecessary referrals.  
37  
38  
39  
40  
41  
42  
43

44 Our study has several limitations. Firstly, there was a lack of data for certain parameter inputs of  
45  
46 the model. For example, costs and utility decrements of complications associated with  
47  
48 colonoscopy such as bleeding and perforation could not be identified and were therefore not  
49  
50 considered in this analysis. In Canada, the pooled rates of colonoscopy-related bleeding,  
51  
52 perforation, and mortality were 1.64/1000, 0.85/1000, and 0.074/1000, respectively.<sup>38</sup> While the  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 rates of complications associated with colonoscopy may be low, the impact on the overall costs  
4 and outcomes may be significant if the time horizon of the analysis was longer, especially when  
5 deaths occur. As the number of colonoscopies were expected to be reduced by FC testing, we  
6 took a more conservative approach by not considering the impact of the complications associated  
7 with colonoscopies. Data on the utility decrement of IBD due to delayed diagnosis was also  
8 unavailable. Therefore, we adopted the approach used in Waugh *et al*,<sup>7</sup> assuming the annual  
9 utility decrement of IBD due to delayed diagnosis as the difference between active disease and  
10 remission of UC. While our CEA was limited to costs from a health sector perspective,  
11 considering costs from a societal perspective, e.g., productivity losses due to colonoscopy, would  
12 further make FC testing more cost effective.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27

28 Secondly, we did not consider a longer time horizon. In long term, because of the earlier  
29 diagnosis, we expect FC to generate more benefits, e.g., by avoiding mortality/risk resulting from  
30 reduced unnecessary colonoscopies or bowel perforations/surgeries. Therefore, we expect our  
31 study to provide a relatively conservative cost-effectiveness estimate for FC. Nevertheless,  
32 further research on the long-term impact of early diagnosis of IBD and IBS is needed to validate  
33 this claim. Adopting a long-term horizon would likely produce more favourable results for FC  
34 and hence our finding that FC is cost-effective should hold in the long-run.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

47 Thirdly, the model assumed that FC would be used as a single test applying a fixed cut-off of  
48 100µg/g. Alternative two-stage testing strategies may also be used. Turvill *et al*, for example,  
49 recently evaluated such a retesting FC strategy, using a cut-off of 100µg/g and conducting a  
50 repeat FC testing for patients with an initial test above this cut-off.<sup>12</sup> They found this retesting  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 FC strategy to be cost-saving in a UK primary care setting, due to saving 100-150 unnecessary  
4 colonoscopies and 140-190 gastroenterology outpatient appointments compared to CRP/ESR  
5 testing alone. The utility of the second FC test is that it can cut out a high proportion of false  
6 positive test results, resulting in overall cost-savings. The results of our scenario analysis using  
7 the sensitivity and specificity estimates from Turvill *et al* indicate a higher cost-effectiveness of  
8 FC using the retesting strategy (a 96.5% probability of being cost-effective compared to  
9 CRP/ESR testing alone) versus the single testing base-case strategy (81.3%). The future research  
10 should focus on these kinds of confirmatory testing strategies.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23

24 Additionally, our modelling assumed 100% patient uptake for every diagnostic test, blood test,  
25 FC test, and endoscopy. Given the invasive nature and set of complications associated with  
26 colonoscopies, patients may refuse this diagnostic test. The FC test may also not be widely  
27 accepted, with a variable uptake rate between primary and secondary care. Some patients might  
28 decline to produce a sample of feces for their GP, but may possibly be willing to do so for a  
29 gastroenterologist if the alternative is colonoscopy. Recently, a home-based FC kit has been  
30 made available, allowing patients to measure the concentration of FC directly using a rapid  
31 immunochromatographic assay captured by a smartphone's camera. The availability of this kit  
32 may increase the uptake and patient adherence of FC testing.<sup>39</sup>  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

47 It is worth noting that FC test accuracy might differ by populations with different age or in  
48 different settings. We used test sensitivity and specificity values from Walker *et al*,<sup>11</sup> which  
49 focused on young adults between 18 and 46 years old in the UK and might not be applicable to  
50 our model population aged 19-64 years old. In addition, different FC tests produced by different  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 manufacturers and using different platforms, can produce significantly different test results (i.e.  
4 between-method bias).<sup>7</sup> This means that the sensitivity and specificity values adopted in our  
5 study (based on Walker *et al*<sup>11</sup> using a specific ELISA test), may not hold for different  
6 laboratories with different pre-analytical and analytical operating procedures and/or using  
7 different test kits/methods. This is potentially a significant issue for home-based FC kits since  
8 the benefits of increased uptake of testing may be negated by issues with test imprecision and  
9 bias.

10  
11  
12 Future research can be conducted to estimate the cost-effectiveness of FC test for distinguishing  
13 between IBD and non-IBD in the paediatrics population when the important model parameters  
14 are available. Furthermore, there has also been growing interest in the use of FC test in a few  
15 areas of IBD management. For example, FC test might be used to monitor disease progression,  
16 predict relapse and monitor response to treatment.<sup>40</sup> As such, an economic model which links the  
17 diagnostic outcomes of this analysis to the management of IBD in terms of treatment and  
18 monitoring can be considered in the future.

19  
20  
21 In conclusion, using FC at the 100µg/g cut-off in primary care in the diagnosis of IBD can be a  
22 cost-effective strategy and can speed up IBD diagnosis in adults who present with  
23 gastrointestinal symptoms in Canada.

**Author Statement:**

WZ and GR designed the study. All authors contributed to the cost-effectiveness model: CHW initiated the model, MC, TM and GR contributed their expertise in the model building and parameter determination, and WZ modified and finalized the model. WZ and CHW drafted the manuscript and all authors significantly contributed to and reviewed the final manuscript. All authors agree to be accountable for all aspects of the work.

**Funding:** This work was supported by the Future Leaders in Inflammatory Bowel Disease (FLIBD) Grant.

**Competing interests:** None declared.

**Ethics approval:** Not applicable. A hypothetical cohort of adult patients has been simulated.

**Data sharing statement:** There is no additional unpublished data from the study.

**Open access:** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

## REFERENCES

1. Irvine EJ. Quality of life of patients with ulcerative colitis: past, present, and future. *Inflamm. Bowel Dis.* 2008;14:554–565.
2. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. *Lancet Lond. Engl.* 2018;390:2769–2778.
3. Rocchi A, Benchimol EI, Bernstein CN, et al. Inflammatory bowel disease: a Canadian burden of illness review. *Can. J. Gastroenterol. J. Can. Gastroenterol.* 2012;26:811–817.
4. Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. *Clin. Epidemiol.* 2014;6:71–80.
5. Walsham NE, Sherwood RA. Fecal calprotectin in inflammatory bowel disease. *Clin. Exp. Gastroenterol.* 2016;9:21–29.
6. Jellema P, Windt D a. WM van der, Schellevis FG, et al. Systematic review: accuracy of symptom-based criteria for diagnosis of irritable bowel syndrome in primary care. *Aliment. Pharmacol. Ther.* 2009;30:695–706.
7. Waugh N, Cummins E, Royle P, et al. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation. *Health Technol. Assess. Winch. Engl.* 2013;17:xv–xix, 1–211.
8. Rhee PF van, Vijver EV de, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. *BMJ.* 2010;341:c3369.
9. Rosenfeld G, Greenup A-J, Round A, et al. FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease. *World J. Gastroenterol.* 2016;22:8211–8218.

- 1  
2  
3 10. NICE. Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel |  
4 Guidance and guidelines. Available at: <https://www.nice.org.uk/guidance/dg11> [Accessed  
5  
6 January 18, 2018].  
7  
8  
9  
10 11. Walker GJ, Moore L, Heerasing N, et al. Faecal calprotectin effectively excludes  
11  
12 inflammatory bowel disease in 789 symptomatic young adults with/without alarm symptoms: a  
13  
14 prospective UK primary care cohort study. *Aliment. Pharmacol. Ther.* 2018;47:1103–1116.  
15  
16  
17 12. Turvill J, Turnock D, Holmes H, et al. Evaluation of the clinical and cost-effectiveness of  
18  
19 the York Faecal Calprotectin Care Pathway. *Frontline Gastroenterol.* 2018;9:285–294.  
20  
21  
22 13. NHS England. Faecal Calprotectin in Primary Care as a Decision Diagnostic for  
23  
24 Inflammatory Bowel Disease and Irritable Bowel Syndrome. Available at: [https://www.pcc-](https://www.pcc-cic.org.uk/sites/default/files/articles/attachments/fcp_consensus_paper_2018_0.pdf)  
25  
26 [cic.org.uk/sites/default/files/articles/attachments/fcp\\_consensus\\_paper\\_2018\\_0.pdf](https://www.pcc-cic.org.uk/sites/default/files/articles/attachments/fcp_consensus_paper_2018_0.pdf) [Accessed  
27  
28 December 9, 2018].  
29  
30  
31 14. GIS. Fecal Calprotectin Test. *Gastrointest. Soc.* Available at:  
32  
33 <https://www.badgut.org/information-centre/a-z-digestive-topics/fecal-calprotectin-test/>  
34  
35 [Accessed January 18, 2018].  
36  
37  
38 15. Turvill J. Local Primary Care Guidelines: Use of Faecal Calprotectin in the Assessment  
39  
40 of Patients with Lower Gastrointestinal Symptoms. 2014. Available at:  
41  
42 [https://www.nice.org.uk/guidance/dg11/resources/primary-care-guidelines--york-teaching-](https://www.nice.org.uk/guidance/dg11/resources/primary-care-guidelines--york-teaching-hospital-pdf-4535195223)  
43  
44 [hospital-pdf-4535195223](https://www.nice.org.uk/guidance/dg11/resources/primary-care-guidelines--york-teaching-hospital-pdf-4535195223).  
45  
46  
47 16. Whitehead S, Hutton J. *Economic report: Value of calprotectin in screening out irritable*  
48  
49 *bowel syndrome*. York, UK: Centre for Evidence-based Purchasing; 2010.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 17. Dubinsky MC, Johanson JF, Seidman EG, et al. Suspected inflammatory bowel disease--  
4 the clinical and economic impact of competing diagnostic strategies. *Am. J. Gastroenterol.*  
5  
6 2002;97:2333–2342.  
7  
8  
9  
10 18. Yang Z, Clark N, Park KT. Effectiveness and cost-effectiveness of measuring fecal  
11 calprotectin in diagnosis of inflammatory bowel disease in adults and children. *Clin.*  
12  
13 *Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc.* 2014;12:253-262.e2.  
14  
15  
16  
17 19. Canadian Association of Gastroenterology. Enhanced primary care pathway: IBS. 2016.  
18 Available at: [https://www.cag-](https://www.cag-acg.org/images/publications/IBS_Enhanced_Primary_Care_Pathway_July_2016.pdf)  
19  
20 [acg.org/images/publications/IBS\\_Enhanced\\_Primary\\_Care\\_Pathway\\_July\\_2016.pdf](https://www.cag-acg.org/images/publications/IBS_Enhanced_Primary_Care_Pathway_July_2016.pdf).  
21  
22  
23  
24 20. Kaiser T, Langhorst J, Wittkowski H, et al. Faecal S100A12 as a non-invasive marker  
25 distinguishing inflammatory bowel disease from irritable bowel syndrome. *Gut.* 2007;56:1706–  
26  
27 1713.  
28  
29  
30  
31 21. Poullis AP, Zar S, Sundaram KK, et al. A new, highly sensitive assay for C-reactive  
32 protein can aid the differentiation of inflammatory bowel disorders from constipation- and  
33  
34 diarrhoea-predominant functional bowel disorders. *Eur. J. Gastroenterol. Hepatol.* 2002;14:409–  
35  
36 412.  
37  
38  
39  
40 22. Shine B, Berghouse L, Jones JE, et al. C-reactive protein as an aid in the differentiation  
41 of functional and inflammatory bowel disorders. *Clin. Chim. Acta Int. J. Clin. Chem.*  
42  
43 1985;148:105–109.  
44  
45  
46  
47 23. Pavlidis P, Chedgy FJ, Tibble JA. Diagnostic accuracy and clinical application of faecal  
48 calprotectin in adult patients presenting with gastrointestinal symptoms in primary care. *Scand.*  
49  
50 *J. Gastroenterol.* 2013;48:1048–1054.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 24. Thompson WG, Heaton KW, Smyth GT, et al. Irritable bowel syndrome in general  
4 practice: prevalence, characteristics, and referral. *Gut*. 2000;46:78–82.  
5  
6  
7  
8 25. Kok L, Elias SG, Witteman BJM, et al. Diagnostic accuracy of point-of-care fecal  
9 calprotectin and immunochemical occult blood tests for diagnosis of organic bowel disease in  
10 primary care: the Cost-Effectiveness of a Decision Rule for Abdominal Complaints in Primary  
11 Care (CEDAR) study. *Clin. Chem*. 2012;58:989–998.  
12  
13  
14  
15 26. British Columbia Ministry of Health. MEDICAL SERVICES COMMISSION  
16 PAYMENT SCHEDULE. 2017. Available at:  
17  
18  
19 <https://www2.gov.bc.ca/assets/gov/health/practitioner-pro/medical-services-plan/msc-payment->  
20  
21 [schedule-july-2017.pdf](https://www2.gov.bc.ca/assets/gov/health/practitioner-pro/medical-services-plan/msc-payment-schedule-july-2017.pdf).  
22  
23  
24  
25  
26 27. Sharara N, Adam V, Crott R, et al. The costs of colonoscopy in a Canadian hospital using  
27 a microcosting approach. *Can. J. Gastroenterol*. 2008;22:565–570.  
28  
29  
30  
31 28. Canadian Institute for Health Information. National Health Expenditure Trends. 2018.  
32 Available at: <https://www.cihi.ca/en/national-health-expenditure-trends> [Accessed January 23,  
33 2018].  
34  
35  
36  
37 29. Spiegel B, Harris L, Lucak S, et al. Developing valid and reliable health utilities in  
38 irritable bowel syndrome: results from the IBS PROOF Cohort. *Am. J. Gastroenterol*.  
39 2009;104:1984–1991.  
40  
41  
42  
43  
44 30. Stark RG, Reitmeir P, Leidl R, et al. Validity, reliability, and responsiveness of the EQ-  
45 5D in inflammatory bowel disease in Germany. *Inflamm. Bowel Dis*. 2010;16:42–51.  
46  
47  
48  
49 31. Leddin D, Armstrong D, Borgaonkar M, et al. The 2012 SAGE wait times program:  
50 Survey of Access to GastroEnterology in Canada. *Can. J. Gastroenterol*. 2013;27:83–89.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



- 1  
2  
3 32. Gregor JC, McDonald JW, Klar N, et al. An evaluation of utility measurement in Crohn's  
4 disease. *Inflamm. Bowel Dis.* 1997;3:265–276.  
5  
6  
7  
8 33. Poole CD, Connolly MP, Nielsen SK, et al. A comparison of physician-rated disease  
9 severity and patient reported outcomes in mild to moderately active ulcerative colitis. *J. Crohns*  
10 *Colitis.* 2010;4:275–282.  
11  
12  
13  
14 34. Benchimol EI, Manuel DG, Mojaverian N, et al. Health Services Utilization, Specialist  
15 Care, and Time to Diagnosis with Inflammatory Bowel Disease in Immigrants to Ontario,  
16 Canada: A Population-Based Cohort Study. *Inflamm. Bowel Dis.* 2016;22:2482–2490.  
17  
18  
19  
20 35. Vavricka SR, Spigaglia SM, Rogler G, et al. Systematic evaluation of risk factors for  
21 diagnostic delay in inflammatory bowel disease. *Inflamm. Bowel Dis.* 2012;18:496–505.  
22  
23  
24 36. Peyrin-Biroulet L, Loftus EV, Colombel J-F, et al. The natural history of adult Crohn's  
25 disease in population-based cohorts. *Am. J. Gastroenterol.* 2010;105:289–297.  
26  
27  
28  
29 37. Monstad I, Hovde Ø, Solberg IC, et al. Clinical course and prognosis in ulcerative colitis:  
30 results from population-based and observational studies. *Ann. Gastroenterol. Q. Publ. Hell. Soc.*  
31 *Gastroenterol.* 2014;27:95–104.  
32  
33  
34  
35 38. Rabeneck L, Paszat LF, Hilsden RJ, et al. Bleeding and perforation after outpatient  
36 colonoscopy and their risk factors in usual clinical practice. *Gastroenterology.* 2008;135:1899–  
37 1906, 1906.e1.  
38  
39  
40  
41 39. Bello C, Roseth A, Guardiola J, et al. Usability of a home-based test for the measurement  
42 of fecal calprotectin in asymptomatic IBD patients. *Dig. Liver Dis. Off. J. Ital. Soc.*  
43 *Gastroenterol. Ital. Assoc. Study Liver.* 2017;49:991–996.  
44  
45  
46  
47 40. Ikhtaire S, Shajib MS, Reinisch W, et al. Fecal calprotectin: its scope and utility in the  
48 management of inflammatory bowel disease. *J. Gastroenterol.* 2016;51:434–446.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1. Model input parameters**

| Parameter  | Estimate | Distribution                 | Distribution parameters                    | Data source  |
|--|----------|------------------------------|--|--|
| IBD prevalence, %  | 6.8      | Beta                         | Alpha = 50<br>Beta = 689                   | Walker et al. <sup>11</sup>  |
| UC proportion, %   | 44.6     | Fixed                        |  | Rocchi et al. <sup>3</sup>   |
| <b>Test accuracy</b>   |          |                              |  |  |
| <b>Sensitivity</b>   |          |                              |  |  |
| Blood test   | 0.649    | Normal, logit transformation | Logit estimate = 0.613<br>Logit SE = 0.199 | Meta-analysis based on a systematic review of three studies <sup>6,20-22</sup> |
| FC test, at 100µg/g cut-off  | 0.860    | Beta                         | Alpha = 43<br>Beta = 7                     | Walker et al. <sup>11</sup>  |
| <b>Specificity</b>   |          |                              |  |  |
| Blood test   | 0.866    | Normal, logit transformation | Logit estimate = 1.867<br>Logit SE = 0.196 | Meta-analysis based on a systematic review of three studies <sup>6,20-22</sup> |
| FC test, at 100µg/g cut-off  | 0.901    | Beta                         | Alpha = 621<br>Beta = 68                   | Walker et al. <sup>11</sup>  |
| <b>Model probabilities, %</b>  |          |                              |  |  |
| Proportion of patients with abnormal blood test with endoscopy ordered in the initial gastroenterologist consultation                              | 88.3     | Beta                         | Alpha = 7.520<br>Beta = 0.993              | Expert opinion   |
| Proportion of non-IBD patients with persistent symptoms after the initial management by GPs  | 47.0     | Log-normal                   | 95% CI: 33-57                              | Waugh et al. <sup>7</sup>  |
| Proportion of non-IBD patients with symptoms after further intensive management by GPs that need further investigation by specialist and endoscopy | 15.0     | Fixed                        |  | Expert opinion   |
| <b>Cost estimates (\$)</b>   |          |                              |  |  |
| FC test  | 40.00    | Fixed                        |  | Local clinic cost, Waugh et al. <sup>7</sup> and Yang et al. <sup>18</sup>     |
| Initial GP visit   | 68.64    | Fixed                        |  | BC MSC payment schedule <sup>26</sup>  |
| Follow-up GP visit   | 30.92    | Fixed                        |  | BC MSC payment schedule <sup>26</sup>  |
| Initial gastroenterologist consultation  | 160.25   | Fixed                        |  | BC MSC payment schedule <sup>26</sup>  |

| Parameter  | Estimate | Distribution | Distribution parameters  | Data source                           |
|--|----------|--------------|--|---------------------------------------|
| Follow-up gastroenterologist consultation  | 97.39    | Fixed        |  | BC MSC payment schedule <sup>26</sup> |
| Surgical pathology   | 85.52    | Fixed        |  | BC MSC payment schedule <sup>26</sup> |
| Colonoscopy, with biopsy   | 427.70   | Fixed        |  | Sharara et al. <sup>27</sup>          |
| <b>Utilities</b>   |          |              |  |                                       |
| <b>Non-IBD</b>   |          |              |  |                                       |
| a) With adequately controlled symptoms   | 0.78     | Beta         | Alpha = 5.367<br>Beta = 1.514  | Spiegel et al. <sup>29</sup>          |
| b) With persistent symptoms  | 0.73     |              | Calculated from a/c  | Spiegel et al. <sup>29</sup>          |
| c) Fixed ratio for utility of adequately controlled over persistent symptoms                   |          | Fixed        | 1.068  |                                       |
| Weighted IBS utility   | 0.76     |              | Calculated from a), b) and Proportion of non-IBD patients with persistent symptoms above |                                       |
| <b>IBD</b>   |          |              |  |                                       |
| Active UC  | 0.71     | Beta         | Alpha = 3.802<br>Beta = 1.553  | Stark et al. <sup>30</sup>            |
| Active CD  | 0.61     | Beta         | Alpha = 1.116<br>Beta = 0.713  | Stark et al. <sup>30</sup>            |
| Monthly utility decrement for UC   | 0.017    | Beta         | Alpha = 1.601<br>Beta = 94.443   | Stark et al. <sup>30</sup>            |
| Monthly utility decrement for CD   | 0.023    | Beta         | Alpha = 1.647<br>Beta = 68.958   | Stark et al. <sup>30</sup>            |
| <b>Wait time</b>   |          |              |  |                                       |
| Time taken to undergo blood test and/or FC test after presenting with symptoms in primary care | 7 days   | Fixed        |  | Expert opinion                        |
| Time taken to obtain results of blood test and FC test   | 7 days   | Fixed        |  | Expert opinion                        |
| Time taken to follow-up by GP first time   | 3 months | Fixed        |  | Expert opinion                        |
| Time taken to follow-up by GP second time  | 4 weeks  | Fixed        |  | Expert opinion                        |
| Time taken to a specialist consultation for IBD patients                                       | 86.50    | Normal       | SE=17.602  | Leddin et al. <sup>31</sup>           |
| Time taken to a specialist consultation for non-IBD patients                                   | 122.00   | Normal       | SE=9.694   | Leddin et al. <sup>31</sup>           |
| Time taken to endoscopy after seeing a specialist  | 63.50    | Normal       | SE=18.622  | Leddin et al. <sup>31</sup>           |

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

| <b>Parameter</b>                        | <b>Estimate</b> | <b>Distribution</b> | <b>Distribution parameters</b> | <b>Data source</b> |
|---|-----------------|---------------------|--------------------------------|--------------------|
| Time taken to follow-up by a specialist | 3 months        | Fixed               |                                | Expert opinion     |

IBD: inflammatory bowel disease; UC: ulcerative colitis; CD: Crohn’s disease; FC: fecal calprotectin; GP: general practitioner; IBS: irritable bowel syndrome; SE: standard error; MSC: Medical Services Commission

For peer review only

Table 2. Results of base-case analysis and scenario analyses

| Scenario   | FC testing strategy       |                        | Standard practice (blood test) |                        | Incremental Cost         | Incremental QALY        | ICER (\$/QALY) | Probability of FC being cost-effective* |
|--|---------------------------|------------------------|--------------------------------|------------------------|--------------------------|-------------------------|----------------|---|
|  | Cost, \$                  | QALY                   | Cost, \$                       | QALY                   |                          |                         |                |   |
| <b>Base-case</b>   | 295.12<br>(274.49,317.53) | 0.751<br>(0.431,0.939) | 273.93<br>(245.40,306.05)      | 0.750<br>(0.430,0.938) | 21.19 (-<br>7.50,46.57)  | 0.001<br>(0.0003,0.002) | 20,323.35      | 81.3%                                   |
| <b>Scenario Analyses</b>   |                           |                        |                                |                        |                          |                         |                |   |
| <b>IBD prevalence, %</b>   |                           |                        |                                |                        |                          |                         |                |   |
| 5  | 286.17<br>(268.43,306.09) | 0.757<br>(0.427,0.943) | 264.65<br>(238.41,294.96)      | 0.756<br>(0.426,0.942) | 21.52 (-<br>7.75,46.72)  | 0.001<br>(0.0002,0.002) | 24,440.81      | 75.5%                                   |
| 10   | 312.60<br>(295.98,331.11) | 0.743<br>(0.434,0.928) | 291.21<br>(267.12,319.28)      | 0.742<br>(0.433,0.927) | 21.39 (-<br>5.67,45.80)  | 0.001<br>(0.0004,0.003) | 15,594.08      | 89.3%                                   |
| 15   | 339.26<br>(323.00,357.86) | 0.740<br>(0.448,0.916) | 318.14<br>(294.04,345.63)      | 0.738<br>(0.447,0.915) | 21.12 (-<br>5.02,43.94)  | 0.002<br>(0.0004,0.005) | 11,515.23      | 93.8%                                   |
| 20   | 365.81<br>(350.40,383.68) | 0.728<br>(0.442,0.907) | 344.93<br>(322.74,371.08)      | 0.725<br>(0.440,0.904) | 20.88 (-<br>3.94,41.96)  | 0.002<br>(0.0006,0.006) | 8,843.74       | 96.7%                                   |
| <b>FC test accuracy (Turvill et al.<sup>12</sup>)</b>  |                           |                        |                                |                        |                          |                         |                |   |
| Sensitivity=0.94 (95% CI:<br>0.85-0.98)  | 285.36<br>(265.56,306.98) | 0.755<br>(0.431,0.939) | 274.16<br>(245.10,306.04)      | 0.754<br>(0.430,0.937) | 11.21 (-<br>16.20,35.83) | 0.001<br>(0.0005,0.003) | 8,012.69       | 96.5%                                   |
| Specificity=0.92 (95% CI<br>0.90-0.94)   |                           |                        |                                |                        |                          |                         |                |   |
| <b>Primary care practice accuracy (Waugh et al.<sup>7</sup>)</b>   |                           |                        |                                |                        |                          |                         |                |   |
| Sensitivity=1 (7/7)  | 295.55                    | 0.753                  | 312.85                         | 0.752                  | -17.30 (-                | 0.001 (-                | N/A            | 93.6%                                   |
| Specificity=0.79 (82/104)  | (275.41,317.36)           | (0.446,0.938)          | (270.56,359.49)                | (0.445,0.937)          | 62.90,22.76)             | 0.0001,0.002)           |                |   |
| <b>Proportion of patients with abnormal blood test with endoscopy ordered in the initial gastroenterologist consultation, %</b>                      |                           |                        |                                |                        |                          |                         |                |   |
| 100  | 295.38<br>(274.60,317.32) | 0.751<br>(0.430,0.938) | 276.23<br>(248.77,307.54)      | 0.750<br>(0.429,0.937) | 19.15 (-<br>10.31,44.69) | 0.001<br>(0.0002,0.002) | 22,007.50      | 76.9%                                   |
| <b>Proportion of non-IBD patients with symptoms after further intensive management by GPs that need investigation by specialist and endoscopy, %</b> |                           |                        |                                |                        |                          |                         |                |   |
| 5  | 268.69<br>(251.37,286.92) | 0.754<br>(0.444,0.940) | 248.96<br>(222.27,278.72)      | 0.753<br>(0.444,0.939) | 19.73 (-<br>10.67,46.48) | 0.001<br>(0.0003,0.003) | 17,988.04      | 83.5%                                   |
| 10   | 281.84<br>(263.26,301.20) | 0.754<br>(0.447,0.938) | 261.12<br>(234.23,290.74)      | 0.753<br>(0.446,0.937) | 20.72 (-<br>8.35,46.16)  | 0.001<br>(0.0002,0.002) | 19,504.34      | 82.4%                                   |
| 20   | 308.68<br>(286.39,332.03) | 0.751<br>(0.426,0.938) | 286.82<br>(257.72,318.88)      | 0.750<br>(0.426,0.938) | 21.85 (-<br>5.70,45.83)  | 0.001<br>(0.0002,0.002) | 21,405.41      | 81.2%                                   |
| 25   | 322.23<br>(297.17,350.17) | 0.749<br>(0.423,0.937) | 300.26<br>(268.29,334.99)      | 0.748<br>(0.422,0.936) | 21.97 (-<br>5.25,45.94)  | 0.001<br>(0.0003,0.002) | 22,040.22      | 79.5%                                   |

| Scenario   | FC testing strategy       |                        | Standard practice<br>(blood test) |                        | Incremental<br>Cost      | Incremental<br>QALY     | ICER<br>(\$/QALY) | Probability of<br>FC being<br>cost-effective* |
|--|---------------------------|------------------------|-----------------------------------|------------------------|--------------------------|-------------------------|-------------------|---|
|  | Cost, \$                  | QALY                   | Cost, \$                          | QALY                   |                          |                         |                   |   |
| 30   | 335.85<br>(308.40,366.80) | 0.750<br>(0.432,0.934) | 313.02<br>(280.31,348.54)         | 0.749<br>(0.431,0.933) | 22.84 (-<br>3.46,45.44)  | 0.001<br>(0.0002,0.002) | 23,221.90         | 78.8%   |
| <b>Cost of FC, \$</b>  |                           |                        |                                   |                        |                          |                         |                   |   |
| 20   | 275.24<br>(254.13,297.02) | 0.755<br>(0.446,0.940) | 273.98<br>(246.12,304.75)         | 0.754<br>(0.445,0.939) | 1.26 (-<br>27.32,25.62)  | 0.001<br>(0.0002,0.002) | 1,206.34          | 94.9%   |
| 30   | 285.21<br>(264.91,307.09) | 0.753<br>(0.436,0.940) | 274.13<br>(246.69,306.58)         | 0.752<br>(0.435,0.939) | 11.08 (-<br>17.29,36.28) | 0.001<br>(0.0003,0.002) | 10,567.51         | 89.8%   |
| 50   | 305.42<br>(284.54,327.76) | 0.751<br>(0.428,0.941) | 274.12<br>(246.34,305.69)         | 0.750<br>(0.428,0.940) | 31.29<br>(2.93,55.78)    | 0.001<br>(0.0003,0.002) | 29,789.72         | 71.7%   |
| 60   | 315.60<br>(295.76,337.54) | 0.751<br>(0.430,0.936) | 274.19<br>(246.49,305.45)         | 0.750<br>(0.430,0.936) | 41.40<br>(13.49,66.07)   | 0.001<br>(0.0002,0.002) | 39,243.50         | 59.8%   |
| 70   | 325.29<br>(305.29,347.98) | 0.753<br>(0.428,0.938) | 274.15<br>(246.63,305.86)         | 0.751<br>(0.427,0.936) | 51.14<br>(22.70,75.99)   | 0.001<br>(0.0002,0.002) | 48,712.48         | 47.4%   |
| <b>All cost estimates except FC test cost, \$</b>  |                           |                        |                                   |                        |                          |                         |                   |   |
| +20%   | 346.68<br>(321.97,372.92) | 0.752<br>(0.430,0.940) | 329.42<br>(295.89,367.82)         | 0.751<br>(0.429,0.939) | 17.26 (-<br>16.39,48.03) | 0.001<br>(0.0003,0.002) | 16,191.86         | 83.4%   |
| -20%   | 244.18<br>(227.92,262.28) | 0.752<br>(0.433,0.936) | 219.14<br>(196.94,244.50)         | 0.751<br>(0.432,0.935) | 25.04<br>(2.13,44.91)    | 0.001<br>(0.0003,0.003) | 23,509.13         | 79.8%   |
| <b>Utility decrement</b>   |                           |                        |                                   |                        |                          |                         |                   |   |
| CD = 0.006 (Gregor et al. <sup>32</sup> )  | 295.11                    | 0.755                  | 274.24                            | 0.755                  | 20.87 (-                 | 0.001                   | 30,136.89         | 68.6%   |
| UC = 0.014 (Poole et al. <sup>33</sup> )   | (274.59,316.66)           | (0.427,0.941)          | (246.79,304.96)                   | (0.427,0.940)          | 6.50,45.47)              | (0.0002,0.001)          |                   |   |
| <b>Time taken to follow-up by GP first time</b>  |                           |                        |                                   |                        |                          |                         |                   |   |
| 1 month  | 294.97<br>(274.80,316.36) | 0.756<br>(0.422,0.945) | 274.09<br>(245.92,306.40)         | 0.755<br>(0.421,0.944) | 20.89 (-<br>8.13,46.10)  | 0.001<br>(0.0002,0.002) | 18,830.57         | 81.9%   |
| 2 months   | 295.36<br>(274.91,317.69) | 0.758<br>(0.437,0.943) | 274.07<br>(246.25,306.46)         | 0.757<br>(0.436,0.942) | 21.29 (-<br>7.90,45.83)  | 0.001<br>(0.0002,0.002) | 19,650.08         | 81.7%   |
| 4 months   | 295.28<br>(275.08,317.76) | 0.749<br>(0.442,0.940) | 274.03<br>(245.76,304.35)         | 0.748<br>(0.441,0.939) | 21.25 (-<br>6.75,45.57)  | 0.001<br>(0.0002,0.002) | 21,451.73         | 80.8%   |
| <b>Time taken to follow-up by a specialist</b>   |                           |                        |                                   |                        |                          |                         |                   |   |
| 1 month  | 295.47<br>(275.10,317.87) | 0.747<br>(0.425,0.937) | 274.37<br>(246.13,305.91)         | 0.746<br>(0.424,0.936) | 21.10 (-<br>7.54,46.45)  | 0.001<br>(0.0002,0.002) | 23,213.73         | 76.1%   |
| 2 months   | 295.35<br>(275.19,318.36) | 0.757<br>(0.435,0.939) | 274.19<br>(247.23,305.55)         | 0.756<br>(0.434,0.937) | 21.16 (-<br>7.75,45.96)  | 0.001<br>(0.0002,0.002) | 21,587.69         | 79.6%   |
| 4 months   | 295.49<br>(274.69,317.09) | 0.751<br>(0.430,0.940) | 274.42<br>(246.23,305.94)         | 0.750<br>(0.429,0.939) | 21.07 (-<br>7.51,46.49)  | 0.001<br>(0.0003,0.003) | 18,991.77         | 83.4%   |
| <b>Patient population without gastrointestinal alarm symptoms (Walker et al.<sup>11</sup>)</b> |                           |                        |                                   |                        |                          |                         |                   |   |

| Scenario   | FC testing strategy |               | Standard practice (blood test) |               | Incremental Cost | Incremental QALY | ICER (\$/QALY) | Probability of FC being cost-effective* |
|--|---------------------|---------------|--------------------------------|---------------|------------------|------------------|----------------|---|
|  | Cost, \$            | QALY          | Cost, \$                       | QALY          |                  |                  |                |   |
| Prevalence = 4% (18/447)   | 276.29              | 0.760         | 258.90                         | 0.760         | 17.40 (-         | 0.001            | 21,608.85      | 75.6%                                   |
| Sensitivity = 0.84 (15/18)   | (253.94,299.86)     | (0.429,0.948) | (230.11,291.19)                | (0.429,0.947) | 13.70,44.78)     | (0.0002,0.002)   |                |   |
| Specificity = 0.91 (390/429)   |                     |               |                                |               |                  |                  |                |   |
| 95% confidence intervals (CI) in brackets  |                     |               |                                |               |                  |                  |                |   |
| IBD: inflammatory bowel disease; FC: fecal calprotectin; GP: general practitioner; CD: Crohn's disease; UC: ulcerative colitis; QALY: quality-adjusted life year; ICER: incremental cost-effectiveness ratio |                     |               |                                |               |                  |                  |                |   |
| *at \$50,000/QALY threshold  |                     |               |                                |               |                  |                  |                |   |

For peer review only

1  
2  
3 **Figure 1. Overview of the model structure for standard practice using blood test**  
4

5 IBD: inflammatory bowel disease; GP: general practitioner  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



1  
2  
3 **Figure 2. Overview of the model structure for fecal calprotectin testing strategy**  
4

5 FC: fecal calprotectin IBD: inflammatory bowel disease; GP: general practitioner  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1  
2  
3 **Figure 3. Overview of the decision branch for normal blood test or negative fecal**  
4  
5 **calprotectin test results**  
6

7  
8 FC: fecal calprotectin IBD: inflammatory bowel disease; GP: general practitioner  
9

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1  
2  
3 **Figure 4. Cost-effectiveness acceptability curve**  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1

279x361mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 2

215x279mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 3

279x361mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 4

279x361mm (300 x 300 DPI)

## Supplementary File

### Meta-analysis for sensitivity and specificity of blood test

Jellema et al. conducted a high quality systematic review that summarized the evidence on the performance of different diagnostic tests including the blood tests (C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)) in patients with abdominal symptoms.<sup>1</sup> They identified four studies that investigated the diagnostic performance of CRP or ESR with different diagnostic cut-off points. The gastroenterologists (Drs. Rosenfeld and Chavannes) in our study selected the studies and the cut-off points that are most relevant to the clinical practice.

**Table 1. Diagnostic performance of studies with test cut-offs of CRP  $\geq 5\text{mg/l}$  and ESR  $\geq 15\text{mm/h}$**


| Study                                    | True Positives | False Positives | True Negatives | False Negatives |
|--|----------------|-----------------|----------------|-----------------|
| Kaiser <i>et al</i> , 2007 <sup>2</sup>  | 29             | 5               | 19             | 21              |
| Poullis <i>et al</i> , 2002 <sup>3</sup> | 11             | 16              | 143            | 9               |
| Shine <i>et al</i> , 1985 <sup>4</sup>   | 32             | 9               | 32             | 9               |

The numbers were directly obtained from Jellema et al.<sup>1</sup>

Subsequently, we have attempted to model these data using a bivariate analysis to take account of the correlation between the sensitivity and specificity based on Reitsma et al.<sup>5</sup> (model specification shown on page 988). However, the estimated covariance matrix was not full rank and might be unreliable, possibly due to our small sample size (only 3 studies). Therefore, we estimated the sensitivity and specificity independently (i.e., without accounting for the correlation between the sensitivity and specificity). The logit estimates for sensitivity and specificity were 0.613 (SE=0.199) and 1.867 (0.196), respectively.



### Cost-effectiveness plane for our base case



### References

1. Jellema P, Windt D a. WM van der, Schellevis FG, et al. Systematic review: accuracy of symptom-based criteria for diagnosis of irritable bowel syndrome in primary care. *Aliment. Pharmacol. Ther.* 2009;30:695–706.
2. Kaiser T, Langhorst J, Wittkowski H, et al. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. *Gut.* 2007;56:1706–1713.
3. Poullis AP, Zar S, Sundaram KK, et al. A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation- and

1  
2  
3 diarrhoea-predominant functional bowel disorders. *Eur J Gastroenterol Hepatol.*  
4  
5 2002;14:409–412.  
6

7  
8 4. Shine B, Berghouse L, Jones JE, et al. C-reactive protein as an aid in the differentiation of  
9  
10 functional and inflammatory bowel disorders. *Clin. Chim. Acta.* 1985;148:105–109.  
11

12  
13 5. Reitsma JB, Glas AS, Rutjes AWS, et al. Bivariate analysis of sensitivity and specificity  
14  
15 produces informative summary measures in diagnostic reviews. *J Clin Epidemiol.*  
16  
17 2005;58:982–990.  
18

19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

# Reporting checklist for economic evaluation of health interventions

Based on the CHEERS guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the CHEERS reporting guidelines, and cite them as:

Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.

|                           |                    | Reporting Item   | Page Number |
|---------------------------|--------------------|--|-------------|
| Title                     | <a href="#">#1</a> | Identify the study as an economic evaluation or use more specific terms such as “cost-effectiveness analysis”, and describe the interventions compared.                                | P1          |
| Abstract                  | <a href="#">#2</a> | Provide a structured summary of objectives, perspective, setting, methods (including study design and inputs), results (including base case and uncertainty analyses), and conclusions | P2-P3       |
| Background and objectives | <a href="#">#3</a> | Provide an explicit statement of the broader context for the study. Present the study question and its relevance for health policy or practice decisions                               | P5-P6       |

|    |                      |                      |   |                           |
|----|----------------------|----------------------|---|---------------------------|
| 1  | Target population    | <a href="#">#4</a>   | Describe characteristics of the base case           | Last paragraph            |
| 2  | and subgroups        |                      | population and subgroups analysed, including        | on P7                     |
| 3  |                      |                      | why they were chosen.                               |                           |
| 4  |                      |                      |   |                           |
| 5  |                      |                      |   |                           |
| 6  | Setting and location | <a href="#">#5</a>   | State relevant aspects of the system(s) in which    | P6-P7                     |
| 7  |                      |                      | the decision(s) need(s) to be made.                 |                           |
| 8  |                      |                      |   |                           |
| 9  |                      |                      |   |                           |
| 10 | Study perspective    | <a href="#">#6</a>   | Describe the perspective of the study and relate    | P6                        |
| 11 |                      |                      | this to the costs being evaluated.                  |                           |
| 12 |                      |                      |   |                           |
| 13 |                      |                      |   |                           |
| 14 | Comparators          | <a href="#">#7</a>   | Describe the interventions or strategies being      | P7                        |
| 15 |                      |                      | compared and state why they were chosen.            |                           |
| 16 |                      |                      |   |                           |
| 17 |                      |                      |   |                           |
| 18 | Time horizon         | <a href="#">#8</a>   | State the time horizon(s) over which costs and      | 2 <sup>nd</sup> paragraph |
| 19 |                      |                      | consequences are being evaluated and say why        | on P8                     |
| 20 |                      |                      | appropriate.  |                           |
| 21 |                      |                      |   |                           |
| 22 |                      |                      |   |                           |
| 23 | Discount rate        | <a href="#">#9</a>   | Report the choice of discount rate(s) used for      | N/A, 2 <sup>nd</sup>      |
| 24 |                      |                      | costs and outcomes and say why appropriate          | paragraph on              |
| 25 |                      |                      |   | P8                        |
| 26 |                      |                      |   |                           |
| 27 |                      |                      |   |                           |
| 28 | Choice of health     | <a href="#">#10</a>  | Describe what outcomes were used as the             | P7-P8                     |
| 29 | outcomes             |                      | measure(s) of benefit in the evaluation and their   |                           |
| 30 |                      |                      | relevance for the type of analysis performed        |                           |
| 31 |                      |                      |   |                           |
| 32 |                      |                      |   |                           |
| 33 |                      |                      |   |                           |
| 34 | Measurement of       | <a href="#">#11a</a> | Single study-based estimates: Describe fully the    | P9-P10                    |
| 35 | effectiveness        |                      | design features of the single effectiveness study   |                           |
| 36 |                      |                      | and why the single study was a sufficient source    |                           |
| 37 |                      |                      | of clinical effectiveness data                      |                           |
| 38 |                      |                      |   |                           |
| 39 |                      |                      |   |                           |
| 40 |                      |                      |   |                           |
| 41 | Measurement of       | <a href="#">#11b</a> | Synthesis-based estimates: Describe fully the       | P9-P10 and                |
| 42 | effectiveness        |                      | methods used for identification of included studies | supplementary             |
| 43 |                      |                      | and synthesis of clinical effectiveness data        | file                      |
| 44 |                      |                      |   |                           |
| 45 |                      |                      |   |                           |
| 46 | Measurement and      | <a href="#">#12</a>  | If applicable, describe the population and methods  | P11-P12                   |
| 47 | valuation of         |                      | used to elicit preferences for outcomes.            |                           |
| 48 | preference based     |                      |   |                           |
| 49 | outcomes             |                      |   |                           |
| 50 |                      |                      |   |                           |
| 51 |                      |                      |   |                           |
| 52 |                      |                      |   |                           |
| 53 |                      | <a href="#">#13a</a> | Single study-based economic evaluation:             | N/A                       |
| 54 |                      |                      | Describe approaches used to estimate resource       |                           |
| 55 |                      |                      | use associated with the alternative interventions.  |                           |
| 56 |                      |                      | Describe primary or secondary research methods      |                           |
| 57 |                      |                      | for valuing each resource item in terms of its unit |                           |
| 58 |                      |                      |   |                           |
| 59 |                      |                      |   |                           |
| 60 |                      |                      |   |                           |

|    |                       |  |             |
|----|-----------------------|--|-------------|
| 1  |                       | cost. Describe any adjustments made to                                 |             |
| 2  |                       | approximate to opportunity costs                                       |             |
| 3  |                       |  |             |
| 4  | Estimating resources  | <a href="#">#13b</a> Model-based economic evaluation: Describe         | P11         |
| 5  | and costs             | approaches and data sources used to estimate                           |             |
| 6  |                       | resource use associated with model health states.                      |             |
| 7  |                       | Describe primary or secondary research methods                         |             |
| 8  |                       | for valuing each resource item in terms of its unit                    |             |
| 9  |                       | cost. Describe any adjustments made to                                 |             |
| 10 |                       | approximate to opportunity costs.                                      |             |
| 11 |                       |  |             |
| 12 |                       |  |             |
| 13 |                       |  |             |
| 14 |                       |  |             |
| 15 | Currency, price date, | <a href="#">#14</a> Report the dates of the estimated resource         | P11         |
| 16 | and conversion        | quantities and unit costs. Describe methods for                        |             |
| 17 |                       | adjusting estimated unit costs to the year of                          |             |
| 18 |                       | reported costs if necessary. Describe methods for                      |             |
| 19 |                       | converting costs into a common currency base                           |             |
| 20 |                       | and the exchange rate.   |             |
| 21 |                       |  |             |
| 22 |                       |  |             |
| 23 |                       |  |             |
| 24 |                       |  |             |
| 25 | Choice of model       | <a href="#">#15</a> Describe and give reasons for the specific type of | P7-P9 and   |
| 26 |                       | decision analytical model used. Providing a figure                     | Figures 1-3 |
| 27 |                       | to show model structure is strongly                                    |             |
| 28 |                       | recommended.   |             |
| 29 |                       |  |             |
| 30 |                       |  |             |
| 31 |                       |  |             |
| 32 | Assumptions           | <a href="#">#16</a> Describe all structural or other assumptions       | P7-P13      |
| 33 |                       | underpinning the decision-analytical model.                            |             |
| 34 |                       |  |             |
| 35 |                       |  |             |
| 36 | Analytical methods    | <a href="#">#17</a> Describe all analytical methods supporting the     | P12-P13     |
| 37 |                       | evaluation. This could include methods for dealing                     |             |
| 38 |                       | with skewed, missing, or censored data;                                |             |
| 39 |                       | extrapolation methods; methods for pooling data;                       |             |
| 40 |                       | approaches to validate or make adjustments                             |             |
| 41 |                       | (such as half cycle corrections) to a model; and                       |             |
| 42 |                       | methods for handling population heterogeneity                          |             |
| 43 |                       | and uncertainty.   |             |
| 44 |                       |  |             |
| 45 |                       |  |             |
| 46 |                       |  |             |
| 47 |                       |  |             |
| 48 | Study parameters      | <a href="#">#18</a> Report the values, ranges, references, and, if     | Table 1     |
| 49 |                       | used, probability distributions for all parameters.                    |             |
| 50 |                       | Report reasons or sources for distributions used                       |             |
| 51 |                       | to represent uncertainty where appropriate.                            |             |
| 52 |                       | Providing a table to show the input values is                          |             |
| 53 |                       | strongly recommended.  |             |
| 54 |                       |  |             |
| 55 |                       |  |             |
| 56 |                       |  |             |
| 57 |                       |  |             |
| 58 |                       |  |             |
| 59 |                       |  |             |
| 60 |                       |  |             |

|    |                       |                      |   |                 |
|----|-----------------------|----------------------|---|-----------------|
| 1  | Incremental costs     | <a href="#">#19</a>  | For each intervention, report mean values for the     | P14 and Table 2 |
| 2  | and outcomes          |                      | main categories of estimated costs and outcomes       |                 |
| 3  |                       |                      | of interest, as well as mean differences between      |                 |
| 4  |                       |                      | the comparator groups. If applicable, report          |                 |
| 5  |                       |                      | incremental cost-effectiveness ratios.                |                 |
| 6  |                       |                      |   |                 |
| 7  |                       |                      |   |                 |
| 8  |                       |                      |   |                 |
| 9  | Characterising        | <a href="#">#20a</a> | Single study-based economic evaluation:               | N/A             |
| 10 | uncertainty           |                      | Describe the effects of sampling uncertainty for      |                 |
| 11 |                       |                      | the estimated incremental cost and incremental        |                 |
| 12 |                       |                      | effectiveness parameters, together with the           |                 |
| 13 |                       |                      | impact of methodological assumptions (such as         |                 |
| 14 |                       |                      | discount rate, study perspective).                    |                 |
| 15 |                       |                      |   |                 |
| 16 |                       |                      |   |                 |
| 17 |                       |                      |   |                 |
| 18 |                       |                      |   |                 |
| 19 |                       | <a href="#">#20b</a> | Model-based economic evaluation: Describe the         | P13-P15         |
| 20 |                       |                      | effects on the results of uncertainty for all input   |                 |
| 21 |                       |                      | parameters, and uncertainty related to the            |                 |
| 22 |                       |                      | structure of the model and assumptions.               |                 |
| 23 |                       |                      |   |                 |
| 24 |                       |                      |   |                 |
| 25 |                       |                      |   |                 |
| 26 | Characterising        | <a href="#">#21</a>  | If applicable, report differences in costs,           | N/A             |
| 27 | heterogeneity         |                      | outcomes, or cost effectiveness that can be           |                 |
| 28 |                       |                      | explained by variations between subgroups of          |                 |
| 29 |                       |                      | patients with different baseline characteristics or   |                 |
| 30 |                       |                      | other observed variability in effects that are not    |                 |
| 31 |                       |                      | reducible by more information.                        |                 |
| 32 |                       |                      |   |                 |
| 33 |                       |                      |   |                 |
| 34 |                       |                      |   |                 |
| 35 |                       |                      |   |                 |
| 36 | Study findings,       | <a href="#">#22</a>  | Summarise key study findings and describe how         | P15-P20         |
| 37 | limitations,          |                      | they support the conclusions reached. Discuss         |                 |
| 38 | generalisability, and |                      | limitations and the generalisability of the findings  |                 |
| 39 | current knowledge     |                      | and how the findings fit with current knowledge.      |                 |
| 40 |                       |                      |   |                 |
| 41 |                       |                      |   |                 |
| 42 | Source of funding     | <a href="#">#23</a>  | Describe how the study was funded and the role        | P21             |
| 43 |                       |                      | of the funder in the identification, design, conduct, |                 |
| 44 |                       |                      | and reporting of the analysis. Describe other non-    |                 |
| 45 |                       |                      | monetary sources of support                           |                 |
| 46 |                       |                      |   |                 |
| 47 |                       |                      |   |                 |
| 48 |                       |                      |   |                 |
| 49 | Conflict of interest  | <a href="#">#24</a>  | Describe any potential for conflict of interest of    | P21             |
| 50 |                       |                      | study contributors in accordance with journal         |                 |
| 51 |                       |                      | policy. In the absence of a journal policy, we        |                 |
| 52 |                       |                      | recommend authors comply with International           |                 |
| 53 |                       |                      | Committee of Medical Journal Editors                  |                 |
| 54 |                       |                      | recommendations                                       |                 |
| 55 |                       |                      |   |                 |
| 56 |                       |                      |   |                 |
| 57 |                       |                      |   |                 |
| 58 |                       |                      |   |                 |
| 59 |                       |                      |   |                 |
| 60 |                       |                      |   |                 |

1 The CHEERS checklist is distributed under the terms of the Creative Commons Attribution License  
2 CC-BY-NC. This checklist can be completed online using <https://www.goodreports.org/>, a tool made  
3 by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only